Affiliation Index: A

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
A
Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls
Ana-Maria Orbai1, Hong Fang1, Joan T. Merrill2, Graciela S. Alarcón3, Caroline Gordon4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Birmingham, Birmingham, United Kingdom, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

Type-1 Interferon Does Not Directly Impair Endothelial Cell Function in Vitro:  Implications for Cardiovascular Models of Systemic Lupus Erythematosus
John A. Reynolds1, David W. Ray1, Terence O'Neill1, M. Yvonne Alexander1 and Ian N. Bruce2, 1The University of Manchester, Manchester, United Kingdom, 2A, Manchester, United Kingdom

A Prospective Study of Seizures in Systemic Lupus Erythematosus
John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge Sanchez-Guerrero6, Juanita Romero-Diaz7, Daniel Wallace8, Ann Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman13, M. Petri14, Paul R. Fortin15, Dafna D. Gladman16, Ian N. Bruce17, Kristjan Steinsson18, M.A. Dooley19, Munther A. Khamashta20, Graciela S. Alarcon21, Barri J. Fessler21, Rosalind Ramsey-Goldman22 and Susan Manzi23, 1Dalhousie University, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9Montreal General Hospital, Montreal, QC, 10McGill UHC/RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London, United Kingdom, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15Toronto Western Hospital, Toronto, ON, 16Toronto Western Hospital, University of Toronto, Toronto, ON, 17A, Manchester, United Kingdom, 18Landspital Univ Hospital, Reykjavik, Iceland, 19University of North Carolina at Chapel Hill, Chapel Hill, NC, 20Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 21University of Alabama at Birmingham, Birmingham, AL, 22Northwestern University Feinberg School of Medicine, Chicago, IL, 23Allegheny Singer Research Institute, Pittsburgh, PA

Predictors of Seizures in Systemic Lupus Erythematosus
John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge Sanchez-Guerrero6, Juanita Romero-Diaz7, Daniel Wallace8, Ann E. Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman13, M. Petri14, Paul R. Fortin15, Dafna D. Gladman16, Ian N. Bruce17, Kristjan Steinsson18, M.A. Dooley19, Munther A. Khamashta20, Graciela S. Alarcon21, Barri J. Fessler21, Rosalind Ramsey-Goldman22 and Susan Manzi23, 1Dalhousie University and Capital Health, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9Research Institute of the McGill Univ. Health, Montreal, QC, 10McGill UHC/RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London, United Kingdom, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15Toronto Western Hospital, Toronto, ON, 16Toronto Western Hospital, University of Toronto, Toronto, ON, 17A, Manchester, United Kingdom, 18Landspital Univ Hospital, Reykjavik, Iceland, 19University of North Carolina at Chapel Hill, Chapel Hill, NC, 20Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 21University of Alabama at Birmingham, Birmingham, AL, 22Northwestern University Feinberg School of Medicine, Chicago, IL, 23Allegheny Singer Research Institute, Pittsburgh, PA

Longitudinal Assessment of SLE Disease Activity: BILAG-2004, SLEDAI-2000 or Both?
Chee-Seng Yee1, Caroline Gordon1, David A. Isenberg2, Bridget Griffiths3, Lee- Suan Teh4, Ian N. Bruce5, Yasmeen Ahmad6, Anisur Rahman2, Athiveeraramapandian Prabu1, Mohammed Akil7, Neil J. McHugh8, Christopher Edwards9, DP. D'Cruz10, Munther A. Khamashta11 and Vernon Farewell12, 1University of Birmingham, Birmingham, United Kingdom, 2University College London, London, United Kingdom, 3Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 4Royal Blackburn Hospital, Blackburn, United Kingdom, 5A, Manchester, United Kingdom, 6The Department of Rheumatology, Betsi Cadwaladr University Health Board (West), Llandudno, LL30 1LB, UK, Wales, United Kingdom, 7Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, 8Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 9Southhampton General Hospital, Southampton, United Kingdom, 10St. Thomas' Hospital, London, United Kingdom, 11Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 12MRC Biostatistics Unit, Cambridge, United Kingdom

The BILAG-2004 Systems Tally - a Novel Way of Analysing the BILAG-2004 Scores
Chee-Seng Yee1, Caroline Gordon1, David A. Isenberg2, Bridget Griffiths3, Lee- Suan Teh4, Ian N. Bruce5, Yasmeen Ahmad6, Anisur Rahman2, Athiveeraramapandian Prabu1, Mohammed Akil7, Neil J. McHugh8, Christopher Edwards9, DP. D'Cruz10, Munther A. Khamashta11 and Vernon Farewell12, 1University of Birmingham, Birmingham, United Kingdom, 2University College London, London, United Kingdom, 3Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 4Royal Blackburn Hospital, Blackburn, United Kingdom, 5A, Manchester, United Kingdom, 6The Department of Rheumatology, Betsi Cadwaladr University Health Board (West), Llandudno, LL30 1LB, UK, Wales, United Kingdom, 7Sheffield Center Rheumatic Dis, Sheffield South Yorkshire, United Kingdom, 8Royal National Hospital, Bath, United Kingdom, 9University of Southampton, Southampton, United Kingdom, 10St. Thomas' Hospital, London, United Kingdom, 11Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 12MRC Biostatistics Unit, Cambridge, United Kingdom

Anti-C1q Antibody in Systemic Lupus Erythematosus
Ana-Maria Orbai1, Gunnar K. Sturfelt2, Ola Nived3, Hong Fang1, Graciela S. Alarcón4, Caroline Gordon5, Joan T. Merrill6, Paul R. Fortin7, Ian N. Bruce8, David A. Isenberg9, Daniel J. Wallace10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University Hospital Lund, Lund, Sweden, 3University Hospital, Lund, Sweden, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Birmingham, Birmingham, United Kingdom, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Toronto Western Hospital, Toronto, ON, 8A, Manchester, United Kingdom, 9University College London, London, United Kingdom, 10Cedars-Sinai/UCLA, Los Angeles, CA, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus.  Clinical and Immunologic Associations
Ana-Maria Orbai1, Hong Fang1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

Serum Cystatin C Is Affected by Inflammation and Renal Dysfunction in Patients with Systemic Lupus Erythematosus
Christine LY Chew1, Awal Al-M Husain1, Philip Pemberton2, Sahena Haque1, Allen Yates2 and Ian N. Bruce3, 1University of Manchester, Manchester, United Kingdom, 2Manchester Royal Infirmary, Manchester, United Kingdom, 3A, Manchester, United Kingdom

The Association Between Clinical and Lifestyle Factors and the Development of Inflammatory Polyarthritis and Rheumatoid Arthritis. Results From the European Prospective Investigation of Cancer (Norfolk) Study and the Norfolk Arthritis Register
Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Diane K. Bunn3, Mark Lunt1, Nick Warehan2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce4, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3University of East Anglia, Norwich, United Kingdom, 4A, Manchester, United Kingdom

Higher Fruit and Fructose Consumption Is Associated with a Reduced Risk of Inflammatory Polyarthritis and Rheumatoid Arthritis in Men. Results From the European Prospective Investigation of Cancer (Norfolk) and the Norfolk Arthritis Register
Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Marleen Lentjes3, Diane K. Bunn4, Mark Lunt1, Nick Wareham2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce5, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3Cambridge, United Kingdom, 4University of East Anglia, Norwich, United Kingdom, 5A, Manchester, United Kingdom

Panel Discussion and Questions
Ian N. Bruce, A, Manchester, United Kingdom, Peter E. Lipsky, University of Texas Southwestern Medical Center at Dallas, Charlottesville, VA, Ronald F. van Vollenhoven, The Karolinska Institute, Stockholm, Sweden and Joan T. Merrill, Oklahoma Medical Research Foundation, Oklahoma City, OK
A. S. L. Desenzano del Garda
Epidemiologic Results of Early Rheumatologic Evaluations in a Cohort of Psoriatic Patients Complaining of Musculo-Skeletal Symptoms
Gabriele De Marco1, Angelo Cattaneo2, Carlo Carrera2, Simona Tavecchio3, Massimo Ricci4, Claudio Fracchiolla5 and Antonio Marchesoni6, 1Istituto Ortopedico Gaetano Pini, Milano, Italy, 2Fondazione I. R. C. C. S. Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy, 3Universita' delgli Studi di Milano, Milano, Italy, 4Universita' degli Studi di Milano, Milano, Italy, 5A. S. L. Desenzano del Garda, Desenzano del Garda, Italy, 6Rheumatology Unit, Ospedale G Pini, Milano, Italy
A.I. DuPont Hospital for Children
IL-10 Mainly Derived From Activated Hepatic T-Cells Suppresses Toll-Like Receptor 9-Mediated Macrophage Activation Syndrome Independent of Effects on the Pathogenic IL-12/Interferon-γ Axis
Scott W. Canna1, Michele E. Paessler1, Portia Kreiger2, Katharine Slade1, Sheila Rao1 and Edward M. Behrens1, 1Childrens Hospital of Philadelphia, Philadelphia, PA, 2A.I. DuPont Hospital for Children, Wilmington, DE

Interferon-γ and Toll-Like Receptor 9 Collaborate to Cause Both Leukopenia and Anemia In a Murine Model of Macrophage Activation Syndrome by Two Distinct Mechanisms
Katharine Slade1, Scott Canna1, Portia Kreiger2 and Edward M. Behrens1, 1Childrens Hospital of Philadelphia, Philadelphia, PA, 2A.I. DuPont Hospital for Children, Wilmington, DE
A2PG
Pharmacokinetic-Pharmacodynamic Modeling of Ozoralizumab (ATN-103), a Novel Humanized Nanobody Tumor Necrosis Factor Inhibitor for Rheumatoid Arthritis
Chandrasekhar Udata1, Arnab Mukherjee2, Matt Hutmacher3, Mark Peterson1, Kai-Hsin Liao1, Tina Checchio2, Kathy Shields4, Xu Meng1 and Gail Comer4, 1Pfizer, San Diego, CA, 2Pfizer, Groton, CT, 3A2PG, Ann Arbor, MI, 4Pfizer, Collegeville, PA
Aalborg Hospital
Adalimumab Added to Methotrexate and Intra-Articular Glucocorticoid Increases Remission Rates At One Year In Early, DMARD-Naïve Patients with Rheumatoid Arthritis - An Investigator-Initiated Randomized, Controlled, Double-Blinded Study
Kim Hørslev-Petersen1, Merete L. Hetland2, Peter Junker3, Jan Pødenphant4, Torkell Ellingsen5, Palle Ahlqvist6, Hanne M. Lindegaard3, Asta Linauskas7, Annette Schlemmer8, Mette Y. Dam9, Ib Hansen10, Hans Chr Horn6, Anette Jørgensen9, Sophie B. Krintel2, Johnny Raun1, Christian G. Ammitzbøll9, Julia Johansen2, Mikkel Østergaard11 and Kristian Stengaard-Pedersen9, 1University of Southern Denmark, Graasten, Denmark, 2Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Odense University Hospital, Odense C, Denmark, 4Copenhagen University at Gentofte,, Hellerup, Denmark, 5University Hospital, Silkeborg, Denmark, 6Vejle Hospital,, Vejle, Denmark, 7Vendsyssel Hospital, Hjørring, Denmark, 8Aalborg Hospital, Aalborg, Denmark, 9Arhus University Hospital, Aarhus, Denmark, 10Viborg Hospital, Viborg, Denmark, 11Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Aalborg University
Pressure Pain Threshold and Knee Pain in Osteoarthritis: The Multicenter Osteoarthritis Study
Tuhina Neogi1, Jingbo Niu1, Lars Arendt-Nielsen2, Joachim Scholz3, Laura Frey-Law4, Clifford Woolf5, Yuqing Zhang1, Larry Bradley6, Michael C. Nevitt7 and David T. Felson1, 1Boston University School of Medicine, Boston, MA, 2Aalborg University, Aalborg, Denmark, 3Columbia University, New York, NY, 4University of Iowa, Iowa City, IA, 5Children's Hospital, Boston, MA, 6University of Alabama, Birmingham, AL, 7University of California-San Francisco, San Francisco, CA

Everyday Life and Rheumatoid Arthritis - Implications for Patient Education
Tine Mechlenborg Kristiansen1, Jette Primdahl1, Rasmus Antoft2 and Kim Hørslev-Petersen1, 1University of Southern Denmark, Graasten, Denmark, 2Aalborg University, Aalborg, Denmark
Aarhus University Hospital
Novel Mutation of the LPIN2 Gene in Majeed Syndrome. Response to IL-1 Inhibition
Troels Herlin1, Mette Bjerre2, Bente Fiirgaard1, Gitte Kerndrup3, Henrik Hasle1 and Polly J. Ferguson4, 1Aarhus University Hospital, Aarhus N, Denmark, 2Aarhus University Hospital, Aarhus C, Denmark, 3Vejle Hospital, Denmark, 4University of Iowa Carver College of Medicine, Iowa City, IA

Early Versus Delayed Retreatment with Rituximab (RTX) in Relation to Long Term Clinical Response – Data From the CERERRA Collaboration
Elisabeth Lie1, Katerina Chatzidionysiou2, Evgeny L. Nasonov3, Galina Lukina3, Karel Pavelka4, Dan C. Nordström5, Matija Tomsic6, Cem Gabay7, Ioan Ancuta8, Piet LC van Riel9, Juan J. Gomez-Reino10, João E. Fonseca11, Merete L. Hetland12, Ulrik Tarp13, Ronald F. van Vollenhoven2 and Tore K. Kvien1, 1Diakonhjemmet Hospital, Oslo, Norway, 2Karolinska Institute, Stockholm, Sweden, 3Institute of Rheumatology, Moscow, Russia, 41Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 5ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 6University Medical Centre Ljubjana, Ljubljana, Slovenia, 7Geneva University Hospitals, for the SCQM registry, Geneva, Switzerland, 8Cantacuzino Hospital, Bucharest, Romania, 9Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Hospital Clinico Universitario, Santiago, Spain, 11Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal, 12Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 13Aarhus University Hospital, Aarhus, Denmark

Short- and Long-Term Effect of Unguided, Intra-Articular Injections with Betamethasone In Early Rheumatoid Arthritis. Impact of Joint Area, Repeated Injections, MRI Findings, Anti-CCP, IgM-RF and CRP
Merete L. Hetland1, Mikkel Østergaard2, Bo J. Ejbjerg3, Søren Jacobsen4, Kristian Stengaard-Pedersen5, Peter Junker6, Tine Lottenburger6, Ib Hansen7, Lis Smedegaard Andersen8, Ulrik Tarp9, Anders Svendsen10, Jens Kristian Pedersen6, Henrik Skjødt11, Torkell Ellingsen12, Hanne M. Lindegaard6 and Kim Hørslev-Petersen13, 1Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 2Copenhagen University Hospital in Glostrup, Glostrup, Denmark, 3Hospital at Slagelse, Slagelse, Denmark, 4Copenhagen University Hospital, Copenhagen, Denmark, 5Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, 6Odense University Hospital, Odense C, Denmark, 7Viborg Hospital, Viborg, Denmark, 8Denmark, 9Aarhus University Hospital, Aarhus, Denmark, 10Odense, Denmark, 11Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 12University Hospital, Silkeborg, Denmark, 13University of Southern Denmark, Graasten, Denmark

Efficacy of Different Doses of Rituximab for the Treatment of RA: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LC van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Lisbon Medical Academic Medical Center on behalf of Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain

Seropositivity and Response to RTX: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LCM Van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4DANBIO, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Hosp Santa Maria, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain

Characterization of Long-Term Responders to First Treatment Course of Rituximab (RTX) – Results From the CERERRA Collaboration
Elisabeth Lie1, Katerina Chatzidionysiou2, Evgeny L. Nasonov3, Galina Lukina3, Karel Pavelka4, Dan C. Nordström5, Matija Tomsic6, Cem Gabay7, Ioan Ancuta8, Piet LC van Riel9, Juan J. Gomez-Reino10, João E. Fonseca11, Merete L. Hetland12, Ulrik Tarp13, Tore K. Kvien1 and Ronald F. van Vollenhoven2, 1Diakonhjemmet Hospital, Oslo, Norway, 2Karolinska Institute, Stockholm, Sweden, 3Institute of Rheumatology, Moscow, Russia, 41Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 5ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 6University Medical Centre Ljubjana, Ljubljana, Slovenia, 7University Hospitals of Geneva, on behalf of the SCQM registry, Geneva, Switzerland, 8Cantacuzino Hospital, Bucharest, Romania, 9Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 10Hospital Clinico Universitario, Santiago, Spain, 11Lisbon Academic Medical Center, on behalf of Rheumatic Diseases Portuguese Register (Reuma.pt), Lisbon, Portugal, 12Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 13Aarhus University Hospital, Aarhus, Denmark
Abacus International
Systematic Review and Network Meta-Analysis of Combination Therapy for Methotrexate-Experienced, Rheumatoid Arthritis Patients: Analysis of American College of Rheumatology Criteria Scores 20, 50 and 70
Michelle E. Orme1, Iain Fotheringham2, Stephen A. Mitchell2, Dean Spurden3 and Alex Bird3, 1ICERA consutling, United Kingdom, 2Abacus International, United Kingdom, 3Pfizer Ltd, Surrey, United Kingdom
Abbott
Analysis of Genetic Influence of HLA-DRB1, IL4R, and FcγRIIb on Radiographic Responses to Methotrexate Monotherapy or Adalimumab Plus Methotrexate Through 26 Weeks in Patients with Early Rheumatoid Arthritis
Alla Skapenko1, Josef Smolen2, Arthur Kavanaugh3, Sourav Santra4, Hartmut Kupper5, Theresa Peterson4 and Hendrik Schulze-Koops1, 1University of Munich, Munich, Germany, 2Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 3University of California San Diego, La Jolla, CA, 4Abbott, Abbott Park, IL, 5Abbott, Ludwigshafen, Germany

Long-Term Efficacy and Safety of Adalimumab for up to 6 Years in Patients with Juvenile Idiopathic Arthritis
Daniel J. Lovell1, Nicolino Ruperto2, Andreas Reiff3, Lawrence K. Jung3, Gloria Higgins3, Isabelle Koné-Paut2, Olcay Y. Jones3, Melissa J. McIlraith4, Nupun Andhivarothai5, Hartmut Kupper6, Edward H. Giannini3, Theresa Peterson5 and Alberto Martini2, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2PRINTO-IRCCS, Genova, Italy, 3PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 4Abbott, Rungis, France, 5Abbott, Abbott Park, IL, 6Abbott, Ludwigshafen, Germany

Clinical and Radiographic Implications of Time to Treatment Response in Early Rheumatoid Arthritis Patients with Baseline Levels of Disease Activity Reflective of a Clinical Practice Setting
Edward Keystone1, Michael E. Weinblatt2, Boulos Haraoui3, Benoit Guerette4, Neelufar Mozaffarian5, Shufang Liu5, Benjamin Wolfe5 and Arthur Kavanaugh6, 1University of Toronto, Toronto, ON, 2Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Institut de Rhumatologie, Montreal, QC, 4Abbott, Rungis, France, 5Abbott, Abbott Park, IL, 6University of California San Diego, San Diego, CA

Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
Ferdinand C. Breedveld1, Edward Keystone2, Désirée van der Heijde3, Robert Landewe4, Josef Smolen5, Benoit Guerette6, Melissa McIlraith6, Hartmut Kupper7, Shufang Liu8, Benjamin Wolfe8 and Arthur Kavanaugh9, 1Leiden Univ Medical Ctr, Leiden, Netherlands, 2University of Toronto, Toronto, ON, 3Leiden University Medical Center, Leiden, Netherlands, 4Academic Medical Center, Amsterdam, Netherlands, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Abbott, Rungis, France, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8Abbott, Abbott Park, IL, 9University of California San Diego, San Diego, CA

Treating Rheumatoid Arthritis to Target: Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate, Methotrexate Alone, or Methotrexate Plus Subsequent Adalimumab
Josef Smolen1, Roy M. Fleischmann2, Paul Emery3, Ronald F. van Vollenhoven4, Benoit Guerette5, Sourav Santra6, Hartmut Kupper7, Laura Redden6, Benjamin Wolfe6 and Arthur Kavanaugh8, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2MCRC, University of Texas, Dallas, TX, 3Chapel Allerton Hospital, Leeds, United Kingdom, 4The Karolinska Institute, Stockholm, Sweden, 5Abbott, Rungis, France, 6Abbott, Abbott Park, IL, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8University of California San Diego, San Diego, CA

Withdrawal of Adalimumab in Early Rheumatoid Arthritis Patients Who Attained Stable Low Disease Activity with Adalimumab Plus Methotrexate: Results of a Phase 4, Double-Blind, Placebo-Controlled Trial
Arthur Kavanaugh1, Paul Emery2, Roy Fleischmann3, Ronald F. van Vollenhoven4, Karel Pavelka5, Patrick Durez6, Benoit Guerette7, Sourav Santra8, Laura Redden8, Hartmut Kupper9, Theresa Peterson8 and Josef Smolen10, 1University of California San Diego, La Jolla, CA, 2Chapel Allerton Hospital, Leeds, United Kingdom, 3University of Texas Southwestern Medical Center, Dallas, TX, 4The Karolinska Institute, Stockholm, Sweden, 51Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6Université Catholique de Louvain, Brussels, Belgium, 7Abbott, Rungis, France, 8Abbott, Abbott Park, IL, 9Abbott, Ludwigshafen, Germany, 10Medical University of Vienna and Hietzing Hospital, Vienna, Austria

Combination Therapy with Adalimumab+Methotrexate Significantly Improved Work Ability, Physical Function, Fatigue, and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis: Results From a 26-Week Analysis
Paul Emery1, Arthur F. Kavanaugh2, Josef Smolen3, Mary A. Cifaldi4, Leonardo Chaves4, Benoit Guerette5, Vipin Arora4 and Ronald F. van Vollenhoven6, 1Chapel Allerton Hospital, Leeds, United Kingdom, 2University of California San Diego, San Diego, CA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Abbott Laboratories, Abbott Park, IL, 5Abbott, Rungis, France, 6The Karolinska Institute, Stockholm, Sweden

Safety and Effectiveness of Adalimumab in Patients with Rheumatoid Arthritis During More Than 5 Years of Therapy Observed in a Phase 3b and Post-Marketing Observational Study
Gerd-Rüdiger Burmester1, Marco Matucci-Cerinic2, Xavier Mariette3, Francisco Navarro-Blasco4, Uemit Oezer5, Sonja Kary5, Kristina Unnebrink5, Theresa Peterson6 and Hartmut Kupper5, 1Charité - University Medicine, Berlin, Germany, 2Univ Florence, Firenze, Italy, 3Université Paris-Sud Hôpital Bicêtre, Le Kremlin Bicêtre, France, 4Universitario de Elche, Alicante, Spain, 5Abbott, Ludwigshafen, Germany, 6Abbott, Abbott Park, IL

Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
Edward Keystone1, Désirée van der Heijde2, Michael E. Weinblatt3, Neelufar Mozaffarian4, Benoit Guerette5, Hartmut Kupper6, Shufang Liu4, Benjamin Wolfe4 and Arthur Kavanaugh7, 1University of Toronto, Toronto, ON, 2Leiden University Medical Center, Leiden, Netherlands, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Abbott, Abbott Park, IL, 5Abbott, Rungis, France, 6Abbott GmbH & Co KG, Ludwigshafen, Germany, 7University of California San Diego, San Diego, CA
Abbott GmBH & Co KG
Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results
Désirée van der Heijde1, Maxime A. Breban2, Dale G. Halter3, Gino DiVittorio4, Johan Bratt5, Fabrizio Cantini6, Sonja Kary7, L. Steven Brown8, Hartmut Kupper7, Tracy F. Nicholson9 and Philip J. Mease10, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hopital Ambroise Pare, Boulogne, France, 3Houston, TX, 4Mobile, AL, 5Karolinska Univ Hosp Huddinge, Stockholm, Sweden, 6Stabilimento Ospedaliero Misericordia, Prato, Italy, 7Abbott GmBH & Co KG, Ludwigshafen, Germany, 8Abbott Laboratories, Abbott Park, IL, 9Abbott Laboratories, 10Seattle Rheumatology Associate, Seattle, WA

Baseline Levels of the Inflammatory Biomarker C-Reactive Protein Are Significantly Correlated with Magnetic Resonance Imaging Measures of Synovitis At Baseline and After 26 Weeks of Treatment in Patients with Early Rheumatoid Arthritis
Charles G. Peterfy, Spire Sciences LLC, Kentfield, CA, Boulos Haraoui, Institut de Rhumatologie, Montreal, QC, Arthur Kavanaugh, University of California San Diego, San Diego, CA, Josef S. Smolen, Krankenhaus Lainz, Vienna, Austria, Sourav Santra, Abbott GmBH & Co KG, Abbott Park, IL, Hartmut Kupper, Abbott GmBH & Co KG, Ludwigshafen, Germany, Tracy F. Nicholson, Abbott Laboratories and Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom
Abbott GmbH & Co KG
Differences in Comorbidities Related to Rheumatoid Arthritis and Psoriatic-Arthritis: Data From Large Prospectiv Observational Studies
Frank Behrens1, Diamant Thaci2, Hanns-Martin Lorenz3, Brigitte Krummel-Lorenz4, Lothar Meier5, Holger Gnann6, Gerd Greger7, Bianca Wittig7 and Harald Burkhardt1, 1CIRI/Rheumatology, J.W. Goethe University, Frankfurt/Main, Germany, 2Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, 3Medizinische Klinik und Poliklinik, Universität, Heidelberg, Germany, 4CIRI/Endokrinologikum, Frankfurt/Main, Germany, 5CIRI/Rheumatologische Schwerpunktpraxis, Hofheim, Germany, 6Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, 7Abbott GmbH & Co KG, Wiesbaden, Germany

Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
Ferdinand C. Breedveld1, Edward Keystone2, Désirée van der Heijde3, Robert Landewe4, Josef Smolen5, Benoit Guerette6, Melissa McIlraith6, Hartmut Kupper7, Shufang Liu8, Benjamin Wolfe8 and Arthur Kavanaugh9, 1Leiden Univ Medical Ctr, Leiden, Netherlands, 2University of Toronto, Toronto, ON, 3Leiden University Medical Center, Leiden, Netherlands, 4Academic Medical Center, Amsterdam, Netherlands, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Abbott, Rungis, France, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8Abbott, Abbott Park, IL, 9University of California San Diego, San Diego, CA

Treating Rheumatoid Arthritis to Target: Outcomes and Predictors in Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate, Methotrexate Alone, or Methotrexate Plus Subsequent Adalimumab
Josef Smolen1, Roy M. Fleischmann2, Paul Emery3, Ronald F. van Vollenhoven4, Benoit Guerette5, Sourav Santra6, Hartmut Kupper7, Laura Redden6, Benjamin Wolfe6 and Arthur Kavanaugh8, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2MCRC, University of Texas, Dallas, TX, 3Chapel Allerton Hospital, Leeds, United Kingdom, 4The Karolinska Institute, Stockholm, Sweden, 5Abbott, Rungis, France, 6Abbott, Abbott Park, IL, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8University of California San Diego, San Diego, CA

Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
Edward Keystone1, Désirée van der Heijde2, Michael E. Weinblatt3, Neelufar Mozaffarian4, Benoit Guerette5, Hartmut Kupper6, Shufang Liu4, Benjamin Wolfe4 and Arthur Kavanaugh7, 1University of Toronto, Toronto, ON, 2Leiden University Medical Center, Leiden, Netherlands, 3Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Abbott, Abbott Park, IL, 5Abbott, Rungis, France, 6Abbott GmbH & Co KG, Ludwigshafen, Germany, 7University of California San Diego, San Diego, CA
Abbott Laboratories
Factors Associated with Work Status and Missed Work Days in Patients with Rheumatoid Arthritis
Leslie R. Harrold1, Mary A. Cifaldi2, Ying Shan1, George Reed1, Katherine C. Saunders3, Joel M. Kremer4 and Jeffrey D. Greenberg5, 1UMass Medical School, Worcester, MA, 2Abbott Laboratories, Abbott Park, IL, 3CORRONA, Inc., Southborough, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5New York University School of Medicine, New York, NY

Impact of Juvenile Idiopathic Arthritis on Parents’ Work Absences
Rafia Rasu1, Stephanie E. Kirbach2, Oscar Hayes2, Walter A. Bawa1 and Mary A. Cifaldi2, 1University of Missouri-Kansas City, Kansas City, 2Abbott Laboratories, Abbott Park, IL

Sustained Improvement of Spinal Mobility, Physical Function, and Quality of Life in Patients with Ankylosing Spondylitis: 5-Year Results
Désirée van der Heijde1, Maxime A. Breban2, Dale G. Halter3, Gino DiVittorio4, Johan Bratt5, Fabrizio Cantini6, Sonja Kary7, L. Steven Brown8, Hartmut Kupper7, Tracy F. Nicholson9 and Philip J. Mease10, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Hopital Ambroise Pare, Boulogne, France, 3Houston, TX, 4Mobile, AL, 5Karolinska Univ Hosp Huddinge, Stockholm, Sweden, 6Stabilimento Ospedaliero Misericordia, Prato, Italy, 7Abbott GmBH & Co KG, Ludwigshafen, Germany, 8Abbott Laboratories, Abbott Park, IL, 9Abbott Laboratories, 10Seattle Rheumatology Associate, Seattle, WA

Costs and Absences Associated with Rheumatoid Arthritis On Work Productivity: A Comparison Between Employees with and without Rheumatoid Arthritis In a United States Population
Nathan L. Kleinman1, Richard A. Brook2, Stephanie E. Kirbach3 and Mary A. Cifaldi3, 1HCMS Group, Cheyenne, WY, 2The JeSTARx Group, Newfoundland, NJ, 3Abbott Laboratories, Abbott Park, IL

Effect of Adalimumab on Function, Health-Related Quality of Life, Work Productivity, and Daily Activities in Patients with Non-Radiographic Axial Spondyloarthritis
Walter P. Maksymowych1, Philip J. Mease2, Sumati Rao3, Aileen Pangan3, L. Steven Brown3, Vipin Arora3 and Mary A. Cifaldi3, 1University of Alberta, Edmonton, AB, 2Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, 3Abbott Laboratories, Abbott Park, IL

Validation of the Patient Acceptable Work State: Establishing Thresholds for Patient-Reported Outcomes in a Longitudinal, Observational Study in Patients with Ankylosing Spondylitis
Walter P. Maksymowych1, Sumati Rao2, Annelies Boonen3, Naijun Chen4 and Mary A. Cifaldi2, 1University of Alberta, Edmonton, AB, 2Abbott Laboratories, Abbott Park, IL, 3University Hospital Maastricht, Maastricht, Netherlands, 4Abbott Laboratories, Abbott Park, Illinois, Abbott Park, IL

Baseline Levels of the Inflammatory Biomarker C-Reactive Protein Are Significantly Correlated with Magnetic Resonance Imaging Measures of Synovitis At Baseline and After 26 Weeks of Treatment in Patients with Early Rheumatoid Arthritis
Charles G. Peterfy, Spire Sciences LLC, Kentfield, CA, Boulos Haraoui, Institut de Rhumatologie, Montreal, QC, Arthur Kavanaugh, University of California San Diego, San Diego, CA, Josef S. Smolen, Krankenhaus Lainz, Vienna, Austria, Sourav Santra, Abbott GmBH & Co KG, Abbott Park, IL, Hartmut Kupper, Abbott GmBH & Co KG, Ludwigshafen, Germany, Tracy F. Nicholson, Abbott Laboratories and Paul Emery, Chapel Allerton Hospital, Leeds, United Kingdom

IL-1beta Inhibits TNF-Mediated Differentiation of Human Osteoclast Precursors Grown in Presence of Fibroblast-Like Synoviocytes
Bohdan P. Harvey, Farhan A. Syed and Zehra Kaymakcalan, Abbott Laboratories, Worcester, MA

Combination Therapy with Adalimumab+Methotrexate Significantly Improved Work Ability, Physical Function, Fatigue, and Other Patient-Reported Outcomes in Early Rheumatoid Arthritis: Results From a 26-Week Analysis
Paul Emery1, Arthur F. Kavanaugh2, Josef Smolen3, Mary A. Cifaldi4, Leonardo Chaves4, Benoit Guerette5, Vipin Arora4 and Ronald F. van Vollenhoven6, 1Chapel Allerton Hospital, Leeds, United Kingdom, 2University of California San Diego, San Diego, CA, 3Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 4Abbott Laboratories, Abbott Park, IL, 5Abbott, Rungis, France, 6The Karolinska Institute, Stockholm, Sweden

Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis – Results From a Phase 3 Study
Joachim Sieper1, Désirée van der Heijde2, Maxime Dougados3, Philip J. Mease4, L. Steven Brown5, Tracy F. Nicholson6 and Aileen Pangan5, 1Charité Universitätsmedizin, Berlin, Germany, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Paris-Descartes University, Cochin Hospital, Paris, France, 4Seattle Rheumatology Associate, Seattle, WA, 5Abbott Laboratories, Abbott Park, IL, 6Abbott Laboratories
Abbott Laboratories, Abbott Park, Illinois
Validation of the Patient Acceptable Work State: Establishing Thresholds for Patient-Reported Outcomes in a Longitudinal, Observational Study in Patients with Ankylosing Spondylitis
Walter P. Maksymowych1, Sumati Rao2, Annelies Boonen3, Naijun Chen4 and Mary A. Cifaldi2, 1University of Alberta, Edmonton, AB, 2Abbott Laboratories, Abbott Park, IL, 3University Hospital Maastricht, Maastricht, Netherlands, 4Abbott Laboratories, Abbott Park, Illinois, Abbott Park, IL
ABC Medical Center and Tufts University
Anatomical Basis of Rheumatologic Examination: Upper Extremity and Cervical Region
Pablo Villaseñor-Ovies1, Joseph Biundo2, Juan J. Canoso3, Simon Carette4, Francisco J. de Toro-Santos5, Cristina Hernández-Díaz1, Robert A. Kalish6, Dennis McGonagle7, Miguel A. Saavedra-Salinas8 and José E. Navarro-Zarza9, 1Instituto Nacional de Rehabilitación, Mexico City, Mexico, 2Luisiana State Univesity, USA, Metairie, LA, 3ABC Medical Center and Tufts University, Mexico City, Mexico, 4Toronto Western Hospital, Toronto, ON, 5Complejo Hospitalario Universitario Juan Canalejo, Universidad de la Coruña, La Coruña, Spain, 6Tufts Medical Center, Boston, MA, 7University of Leeds and Leeds Teaching Hospitals, Leeds, United Kingdom, 8Centro Médico Nacional, México, Mexico, 9Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico

Knowledge of Clinical Anatomy by Rheumatology Fellows and Rheumatologists in Latin America
José E. Navarro-Zarza1, Cristina Hernández-Díaz2, Miguel A. Saavedra-Salinas3, Robert A. Kalish4, Juan J. Canoso5 and Pablo Villaseñor-Ovies2, 1Mexican Taskforce for the Advancement of Clinical Anatomy, Mexico, Mexico, 2Instituto Nacional de Rehabilitación, Mexico City, Mexico, 3Centro Médico Nacional, México, Mexico, 4Tufts Medical Center, Boston, MA, 5ABC Medical Center and Tufts University, Mexico City, Mexico
ABC Medical Ctr
Development and Initial Validation of a chronic Damage Index in Patients with Antiphospholipid Syndrome
Mary-Carmen Amigo, ABC Medical Ctr, Mexico City, Mexico, Leonor A. Barile, Hospital Especialidades CMN, Mexico City, Mexico, Alberto Barragan, México, Mexico, Gisela Espinosa-Cuervo, Research Unit, Mexican College of Rheumatology, Mexico, Mexico, Mavis Goycochea, Instituto Mexicano del Seguro Social and Research Unit, Mexican College of Rheumatology, Mexico City, Mexico, Laura Aline Martinez-Martinez, Intituto Nacional de Cardiologia, Mexico, Mexico, Gabriela Medina, Seris/Zachila s/n La Raza, Mexico City, Mexico, Angelica Vargas, Instituto Nac de Cardiologia, Mexico City, Mexico and Luis J. Jara-Quezada, Hospital de Especialidades Centro Médico La Raza, IMSS, Mexico City, Mexico
Abington Memorial Hospital
Ultrasound Guided Hip Joint Injection, Its Safety and Efficacy
Srijana Pandit1, Charles H. Pritchard2, Elana Eisner2 and Mary Naglak1, 1Abington Memorial Hospital, Abington, PA, 2Rheumatic Disease Associates, Willow Grove, PA
Ablynx nv
Superior Efficacy of Ozoralizumab, An Anti-Human TNF Nanobody in a Transgenic Mouse Model of Polyarthritis
Martin Hegen1, Els Beirnaert2, Guy Hermans2, Peter Casteels2, Marina Shen1, Julie Lee1, Lori Fitz1, Nilufer Seth1, Yulia Vugmeyster1, Christopher Wrocklage1, Kyri Dunussi-Joannopoulos1, Cheryl L. Nickerson-Nutter1 and Mary Collins1, 1Pfizer, Cambridge, MA, 2Ablynx nv, Zwijnaarde, Belgium
Abott
HM-018, An Oral Small Molecule JAK Inhibitor, Ameliorates Experimental Autoimmune Encephalomyelitis (EAE) in Mice
Yu Cai1, Wuzhong Shen1, Qianqian Dong1, Zhipeng Wu1, Xiaoning Yang1, Ping Ren1, Youjun Yu1, Hongxia Shen1, Jia Li1, Jian Wang1, Yang Sai1, James Yan1, Wei Deng1, Jianguo Ji2, Weiguo Su1 and Haoran Zhao1, 1Hutchison Medipharma Limited, Shanghai, China, 2Abott, Shanghai, China

A Novel, Highly Selective Syk Kinase Inhibitor Significantly Ameliorates the Severity of Arthritis in Rodents
Zhong Cui Sun1, Yu Cai1, Yan Qiu1, Lei Fang1, Xiaoming Dai1, Zhipeng Wu1, Ping Ren1, Jianlin He1, Changwu Lu1, Yongjuan Yu1, Jian Wang1, Yang Sai1, James Yan1, Jia Li1, Wei Deng1, Weihan Zhang1, Jianguo Ji2, Weiguo Su1 and Haoran Zhao1, 1Hutchison Medipharma Limited, Shanghai, China, 2Abott, Shanghai, China
Abstract Medical Int'l
Results of a Randomized Controlled Study of Adalimumab for Steroid Sparing in Patients with Giant-Cell Arteritis
Xavier Mariette, Université Paris-Sud, Le Kremlin Bicetre, France, Gabriel Baron, Epidemiology, Paris, France, Eric Hachulla, Internal Medicine, Lille CEDEX, France, Michel DeBandt, Abstract Medical Int'l, Boulogne, France, C. Larroche, Hospital University Bobigny, France, Xavier Puéchal, Le Mans General Hospital, Le Mans, France, Francois Maurier, Division of internal Medicine, CHR Metz, Metz, Metz, France, B. de Wazieres, CHU de Nimes, Nimes, France, T. Quemeneur, CHR de Valenciennes, Valenciennes, France and Philippe Ravaud, Hopital Hotel Dieu, Paris Descartes University, Paris, France
Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH
Differences in Comorbidities Related to Rheumatoid Arthritis and Psoriatic-Arthritis: Data From Large Prospectiv Observational Studies
Frank Behrens1, Diamant Thaci2, Hanns-Martin Lorenz3, Brigitte Krummel-Lorenz4, Lothar Meier5, Holger Gnann6, Gerd Greger7, Bianca Wittig7 and Harald Burkhardt1, 1CIRI/Rheumatology, J.W. Goethe University, Frankfurt/Main, Germany, 2Klinik für Dermatologie, Venerologie und Allergologie, J.W. Goethe University, Frankfurt/Main, Germany, 3Medizinische Klinik und Poliklinik, Universität, Heidelberg, Germany, 4CIRI/Endokrinologikum, Frankfurt/Main, Germany, 5CIRI/Rheumatologische Schwerpunktpraxis, Hofheim, Germany, 6Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, 7Abbott GmbH & Co KG, Wiesbaden, Germany
Academic Medical Center
Serum 14-3-3η: A Rheumatoid Arthritis Biomarker
Walter P. Maksymowych, University of Alberta, Edmonton, AB, Robert Landewe, Academic Medical Center, Amsterdam, Netherlands, Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Paul-Peter Tak, Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands and Anthony Marotta, Augurex Life Sciences Corp, North Vancouver, BC

Extracellular 14-3-3η: An Early RA Pathogenic Factor
Anthony Marotta, Augurex Life Sciences Corp, North Vancouver, BC, Vivian Bykerk, Brigham and Women's Hospital, Boston, MA, Katherine A. Siminovitch, Mount Sinai Hospital, Toronto, ON, Maarten Boers, VU University Medical Center, Amsterdam, Netherlands, Robert Landewe, Academic Medical Center, Amsterdam, Netherlands, Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Paul-Peter Tak, Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands, M. C. Genovese, Stanford University Medical Center, Palo Alto, CA, Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA and Walter P. Maksymowych, University of Alberta, Edmonton, AB

Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
Ferdinand C. Breedveld1, Edward Keystone2, Désirée van der Heijde3, Robert Landewe4, Josef Smolen5, Benoit Guerette6, Melissa McIlraith6, Hartmut Kupper7, Shufang Liu8, Benjamin Wolfe8 and Arthur Kavanaugh9, 1Leiden Univ Medical Ctr, Leiden, Netherlands, 2University of Toronto, Toronto, ON, 3Leiden University Medical Center, Leiden, Netherlands, 4Academic Medical Center, Amsterdam, Netherlands, 5Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 6Abbott, Rungis, France, 7Abbott GmbH & Co KG, Ludwigshafen, Germany, 8Abbott, Abbott Park, IL, 9University of California San Diego, San Diego, CA

Golimumab Use and Sustained Clinical Response in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-Tumor Necrosis Factor Alpha Agents
Josef Smolen1, Jonathan Kay2, Robert Landewe3, Eric L. Matteson4, Norman B. Gaylis5, J. Wollenhaupt6, Frederick T. Murphy7, O. Zamani8, Yiying Zhou9, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2University of Massachusetts Medical School, Worcester, MA, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Rochester, MN, 5Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6Eilbeck Hospital, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Rheumazentrum Favoriten, Wien, Austria, 9Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA

Where is the Inflammation: The Synovium and Lymph Nodes in Pre- Rheumatoid Arthritis
Danielle Marie Gerlag, Academic Medical Center, Amsterdam, Netherlands
Academic Medical Center (AMC) / Emma Children's Hospital
The Reliability of a New Juvenile Arthritis MRI Scoring System for the Knee; JAMRIS
Robert Hemke1, Marion A.J. Van Rossum2, Mira van Veenendaal2, J. Merlijn van den Berg2, Koert M. Dolman3, Taco W. Kuijpers2 and Mario Maas4, 1Academic Medical Center (AMC) / Emma Children's Hospital, Amsterdam, Netherlands, 2Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 3St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

Non-Invasive MRI by Omitting Intravenous Contrast Injection; Does It Change the Radiologic Assessment of Knee Joint Pathologies in JIA?
Robert Hemke1, Taco W. Kuijpers2, Mira van Veenendaal2, J. Merlijn van den Berg2, Koert M. Dolman3, Marion A. J. van Rossum2 and Mario Maas4, 1Academic Medical Center (AMC) / Emma Children's Hospital, Amsterdam, Netherlands, 2Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 3St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4Department of Radiology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Academic Medical Center / University of Amsterdam
The 2010 ACR/EULAR Classification Criteria for Rheumatoid Arthritis: Earlier Diagnosis At the Expense of Increased Heterogeneity
Maria J. H. de Hair1, K. A. Lehmann1, Marleen G. H. van de Sande1, Karen Maijer1, Danielle M. Gerlag1 and Paul P. Tak2, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands

Expression Levels of the Nicotinic Acetylcholine alpha7 Receptor on Monocytes and Synovial Tissue of Rheumatoid Arthritis Patients
Frieda. A. Koopman, Maria J. H. de Hair, Danielle M. Gerlag, Paul P. Tak and Margriet Vervoordeldonk, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

Spondyloarthritis: A Clinical Comparison Between Men and Women
Jacqueline E. Paramarta, Leen E. De Rycke, Carmen A. Ambarus, Paul P. Tak and Dominique L. Baeten, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

Synovial Inflammation and Expression of Mediators of Pain in Preclinical Rheumatoid Arthritis Subjects with Arthralgia
Maria J. H. de Hair1, Patrick Leclerc2, Britt N. Sotthewes1, Marleen G. H. van de Sande1, Tamara H. Ramwadhdoebe1, Christiaan van der Leij3, Wouter Bos4, Mario Maas1, Dirkjan van Schaardenburg5, Danielle M. Gerlag1, Marina Korotkova2, Per Johan Jakobsson6 and Paul P. Tak7, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Karolinska Institute, Stockholm, Sweden, 3Academic Medical Center / University of Amsterdam, 4Reade, Amsterdam, Netherlands, 5Jan van Breemen Research Institute / Reade, Amsterdam, Netherlands, 6Rheumatology Unit, Karolinska Institutet; Karolinska University hospital, Stockholm, Sweden, 7Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands

The Value of Positron Emission Tomography – Computed tomography in Patients with Large Vessel Vasculitis
Man Wai Tang, Danielle Marie Gerlag, A. Elisabeth Hak, Berthe L.F. van Eck-Smit and Paul-Peter Tak, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands

Innate Immune Stimulation Triggers Early-Onset Spondyloarthritis in HLA-B27/Human beta2 Microglobulin Transgenic Rats
Leonie M. van Duivenvoorde1, Gleb M. Slobodin2, Nimman Satumtira2, Martha L. Dorris2, Paul P. Tak3, Dominique L. Baeten1 and Joel D. Taurog2, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2UT Southwestern Medical Center, Dallas, TX, 3Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands

Safety and Biodistribution of An Adeno-Associated Virus Vector, AAV5 hIFN beta (ART-I02), Delivered Via Intra-Articular Injection to Rhesus Monkeys with Collagen-Induced Arthritis
Caroline J. Aalbers1, L. Bevaart1, K. de Cortie1, M.P.M. Vierboom2, J.F. Wright3, Paul P. Tak4 and Margriet Vervoordeldonk5, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Biomedical Primate Research Centre, Rijswijk, Netherlands, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands, 5Arthrogen B.V, Amsterdan, Netherlands

Simultaneous but Spatially Distinct Occurrence of Inflammation, Tissue Destruction and Osteoproliferation in the HLA-B27/Human beta2 Microglobulin Transgenic Rat Model of Spondyloarthritis
Leonie M. van Duivenvoorde1, Martha L. Dorris2, Nimman Satumtira2, Paul P. Tak1, Joel D. Taurog2 and Dominique L. Baeten1, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2UT Southwestern Medical Center, Dallas, TX
Academic Medical Center at the University of Amsterdam
How Inflammation Impacts Endothelial Function as Primary Target for Cardiovascular Diseases
Kees Hovingh, Academic Medical Center at the University of Amsterdam , Amsterdam, Netherlands
Academic Medical Center, University of Amsterdam
Health Related Quality of Life and Psychosocial Developmental Trajectory in Young Female Beneficiaries with Juvenile Idiopathic Arthritis
Lotte Haverman1, Eefje J.A. Verhoof1, Heleen Maurice-Stam1, Hugo S.A. Heymans1, D. Gerlag2, Marion A. J. Van Rossum1 and Martha A. Grootenhuis1, 1Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, 2Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients Under Biological Therapies in Daily Practice – Results From the Portuguese Register Reuma.Pt
Sofia Ramiro1, Pedro Machado2, Raquel Roque3, Helena Santos4, Joaquim Polido-Pereira5, Daniela Peixoto6, Cátia Duarte7, Fernando Pimentel-Santos8, Cândida Silva4, J. E. Fonseca5, Filipa Teixeira6, Andrea Marques7, Filipe Araújo8, Jaime C. Branco8, José Pereira Da-Silva7, José Costa6, Jose A. Pereira Da Silva9, Luis Cunha Miranda4, J. Canas da Silva3, Helena Canhão5, A.M. Van Tubergen10, Desirée van der Heijde11, Robert Landewé12 and MJ Santos3, 1Hospital Garcia de Orta, Almada, Portugal and Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2Hospitais da Universidade de Coimbra, Coimbra, Portugal and Leiden University Medical Center, Leiden, Netherlands, 3Hospital Garcia de Orta, Almada, Portugal, 4Instituto Português de Reumatologia, Lisboa, Portugal, 5Instituto de Medicina Molecular, Faculdade de Medicina da Universidade de Lisboa and Rheumatology Department, Centro Hospitalar de Lisboa Norte, EPE, Hospital de Santa Maria, Lisboa, Portugal, 6Centro Hospitalar do Alto Minho, Hospital de Ponte de Lima, Ponte de Lima, Portugal, 7Hospitais da Universidade de Coimbra, Coimbra, Portugal, 8Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, 9Centro Hospitalar de Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal, 10Maastricht University Medical Center, Maastricht, Netherlands, 11Leiden University Medical Center, Leiden, Netherlands, 12Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging
Xenofon Baraliakos1, J. Braun1, D. D. Laurent2, D. Baeten3, D. van der Heijde4, J. Sieper5, Paul Emery6, I. McInnes7, J. van Laar8, R. Landewe9, P. Wordsworth10, J. Wollenhaupt11, H. Kellner12, A. M. Wright13, S. Gsteiger13 and W. Hueber2, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Novartis Institutes for BioMedical Research, Basel, Switzerland, 3Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4Leiden University Medical Center, Leiden, Netherlands, 5Charite Campus Benjamin Franklin, Berlin, Germany, 6Chapel Allerton Hospital, Leeds, United Kingdom, 7University of Glasgow, Glasgow, United Kingdom, 8Newcastle University, Newcastle upon Tyne, United Kingdom, 9Maastricht University Medical Center, Maastricht, Netherlands, 10Nuffield Orthopaedic Centre, Oxford, United Kingdom, 11Eilbeck Hospital, Hamburg, Germany, 12Centre for Inflammatory Joint Diseases, Munich, Germany, 13Novartis Pharma AG, Basel, Switzerland
Academic Medical Center/University of Amsterdam
Serum Biomarkers to Predict Clinical Response in Proof-of-Concept Trials in Spondyloarthritis
Maureen C. Turina, Nataliya Yeremenko, Jacqueline Paramarta, Bernard Vandooren, Paul-Peter Tak, Leen E. De Rycke and Dominique L. Baeten, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

Identification of Robust and Disease-Specific Stromal Alterations in Spondyloarthritis Synovitis
Nataliya Yeremenko1, Gemma M. M. Rigter1, Iris Simon2, Juan D. Cañete3, Paul P. Tak1 and Dominique L. Baeten1, 1Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Agendia BV, Amsterdam, Netherlands, 3Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain

Patient Tolerability of Arthroscopic Synovial Biopsy Compared to MRI
Maria J. H. de Hair, Marleen G. H. van de Sande, Mario Maas, Danielle M. Gerlag and Paul P. Tak, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Academic Medical Centre
Outward Carotid Arterial Wall Remodelling in Rheumatoid Arthritis: A Case-Control Study
Alper M. van Sijl1, Katja van der Hurk2, Mike J.L. Peters3, Vokko P. van Halm4, Giel Nijpels2, Coen D.A. Stehouwer5, Yvo M. Smulders3, A.E. Voskuyl6, Jacqueline M. Dekker2 and Michael T. Nurmohamed7, 1Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 2EMGO institute, VU university medical centre, Amsterdam, Netherlands, 3VU University medical center, Amsterdam, Netherlands, 4Academic Medical Centre, Amsterdam, Netherlands, 5Maastricht University, Maastricht, Netherlands, 6VU Medical Center, Amsterdam, Netherlands, 7Reade, Centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands
Academic Rheumatology Group, D
ILAR: Past, Present and Future
Luis R. Espinoza, LSU Medical Center, New Orleans, LA, Adewale O. Adebajo, Academic Rheumatology Group, D, Sheffield, United Kingdom and Mark Andrejeski, Executive Vice President, American College of Rheumatology, Atlanta, GA
Actelion France
Evaluation of the Impact of Recurrent Ischemic Digital Ulcers on Hand Disability in Patients with Systemic Sclerosis (ECLIPSE). Report of the Cohort At the Time of Inclusion
Luc Mouthon, Hopital Cochin, Paris, France, Patrick Carpentier, CHU Grenoble, Grenoble, France, Catherine Lok, Amiens Hospital, France, Eve Puzenat, Besançon, Besançon, France, Pierre Clerson, Orgametrie, Roubaix, Virginie Gressin, Actelion France, Paris, France and Marie-Aleth Richard, Marseille, Paris, France
Actelion Pharmaceuticals Ltd
Development and Content Validity of the Hand Disability in Systemic Sclerosis—Digital Ulcers (HDISS-DU) Scale
Dinesh Khanna1, Serge Poiraudeau2, Heather Gelhorn3, Elke Hunsche4, Kelly Papadakis4, Loic Perchenet4, Maria Stoeckl Mattera5, Margaret Vernon5 and Luc Mouthon2, 1University of Michigan, Ann Arbor, MI, 2Hopital Cochin, Paris, France, 3United BioSource Corporation, Golden, CO, 4Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 5United BioSource Corporation, Bethseda, Bethesda, US., MD
Addenbrookexs Hospital University of Cambridge
Optimal Definition for the Duration of Sustained Remission in ANCA-Associated Vasculitis
Gunnar Tomasson1, Michael Walsh2, Thomas F. Hiemstra3, Maarten Boers4, Peter A. Merkel1 and EUVAS Investigators5, 1Boston University School of Medicine, Boston, MA, 2McMaster University, Hamilton, 3Addenbrookexs Hospital University of Cambridge, Cambridge, United Kingdom, 4VU University Medical Center, Amsterdam, Netherlands, 5Cambridge, United Kingdom
Additional Professor Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow
Identification of Immunogenic HLA-B*27:05 Restricted Peptides of Salmonella Outer Membrane Protein (OMP) in Patients with Reactive Arthritis and Undifferentiated Spondyloarthropathy
Ramnath Misra1, Amit Singh1 and Amita Aggarwal2, 1Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 2Additional Professor Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Lucknow, India
Adelaide and Meath Hospital
Correlation of Vascular Endothelial Growth Factor and Interleukin-6 Levels with Power Doppler Ultrasound of Synovial Joints in Early Inflammatory Arthritis
Joanne Kitchen, Adelaide and Meath Hospital, Dublin, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland

Power Doppler Ultrasound Findings and Serum Levels of Pro- and Anti-Inflammatory Cytokines in Normal Joints
Joanne Kitchen, Adelaide and Meath Hospital, Dublin, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland
Adelaide and Meath Hospital Inc National Children's Hospital
Development of a Care Pathway for Inflammatory Arthritis
Shona P. Lee, Adelaide and Meath Hospital Inc National Children's Hospital, Dublin 24, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland
Adelaide, Meath hospital Dublin (incorporating the National Children's hospital)
Correlation of Vascular Endothelial Growth Factor and Interleukin-6 Levels with Power Doppler Ultrasound of Synovial Joints in Early Inflammatory Arthritis
Joanne Kitchen, Adelaide and Meath Hospital, Dublin, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland

Power Doppler Ultrasound Findings and Serum Levels of Pro- and Anti-Inflammatory Cytokines in Normal Joints
Joanne Kitchen, Adelaide and Meath Hospital, Dublin, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland

HLA Associations Reveal Genetic Heterogeneity in Psoriatic Arthritis and in the Psoriasis Phenotype
Robert Winchester1, Gregory Minevich1, Valeria Steshenko1, Brian Kirby2, David Kane3, David A. Greenberg4 and Oliver M. FitzGerald2, 1Columbia University, New York, NY, 2St. Vincent's University Hospital, Dublin, Ireland, 3Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland, 4Mailman School of Public Health Columbia University, New York City, NY

The Effectiveness of Exercise with and without Manual Therapy for Hip Osteoarthritis: A Multi-Centre Randomised Controlled Trial
Helen P. French1, Tara Cusack2, Aisling Brennan3, Aoife Caffrey4, Vanessa Cuddy5, Martina Fitzpatrick4, Oliver M. FitzGerald6, Clare Gilsenan5, David Kane3, Paul G. O'Connell5, Breon White7 and G M. McCarthy7, 1Royal College of Surgeons in Ireland, Dublin 2, Ireland, 2University College Dublin, Dublin, Ireland, 3Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland, 4St. Vincent's University Hospital, Dublin 4, Ireland, 5Beaumont Hospital, Dublin 9, Ireland, 6St. Vincent's University Hospital, Dublin, Ireland, 7Mater Misericordiae University Hospital, Dublin 7, Ireland

Development of a Care Pathway for Inflammatory Arthritis
Shona P. Lee, Adelaide and Meath Hospital Inc National Children's Hospital, Dublin 24, Ireland and David Kane, Adelaide, Meath hospital Dublin (incorporating the National Children's hospital), Dublin 24, Ireland
Admiraal de Ruyter hospital
Combination of Disease-Modifying Antirheumatic Drugsprohibits the Need of Early Initiation of Biologicals, Independent of Glucocorticosteroids. A clinical trial to Investigate Different Induction Therapies in Early Rheumatoid Arthritis
P.H.P. de Jong1, Johanna Hazes2, P.J. Barendregt3, A.M. Huisman4, D. van Zeben4, P.A. van der Lubbe5, A.H. Gerards5, M.H. de Jager6, P.B. de Sonnaville7, B.A. Grillet8, Jolanda J. Luime9 and A.E.A.M. Weel3, 1University Medical Center, Rotterdam, Netherlands, 2Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Vlietland Hospital, Schiedam, Netherlands, 6Albert Schweitzer Hospital, Dordrecht, Netherlands, 7Admiraal de Ruyter hospital, Goes, 8Zorgsaam hospital, Terneuzen, Netherlands, 9Erasmus MC - University Medical Center, Rotterdam, Netherlands
Admiraal de Ruyter Hospital
Remission Induction Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid and Undifferentiated Arthritis
K.V.C. Wevers-de Boer1, L. Heimans1, K. Visser1, H.K. Ronday2, T.H.E. Molenaar3, P.E.H. Seys4, C. Bijkerk5, M.L. Westedt6, W. De Beus7, P.B. de Sonnaville8, T. Huizinga1 and C.F. Allaart1, 1Leiden University Medical Center, Leiden, Netherlands, 2Haga Hospital, The Hague, Netherlands, 3Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, Netherlands, 5Reinier de Graaf Gasthuis, Delft, Netherlands, 6Bronovo Hospital, The Hague, Netherlands, 7MCH, The Hague, Netherlands, 8Admiraal de Ruyter Hospital, Goes
Adolfo Lutz Institute
Antimalarials: A Window of Opportunity to Improve the Influenza A/H1N1 Vaccine Response in Lupus Patients Under Immunosuppressive Agents
Eduardo F. Borba1, Carla G.S. Saad1, Sandra G. Pasoto1, Ana L. G. Calich1, Nadia E. Aikawa1, Ana C. M. Ribeiro2, Julio C. B. Moraes2, Elaine P. Leon1, Luciana P.C. Seguro1, Lissiane K. N. Guedes1, Clovis A. Silva1, Celio Goncalves2, Ricardo Fuller3, Suzimara A. Oliveira1, Maria A. Ishida4, Alexander R. Precioso5 and Eloisa Bonfa6, 1University of Sao Paulo, Sao Paulo, Brazil, 2Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3University of Sao Paulo, São Paulo, Brazil, 4Adolfo Lutz Institute, Sao Paulo, Brazil, 5Butantan Institute, Sao Paulo, Brazil, 6Faculdade de Medicina da Universidade de São Paulo (FMUSP), Sao Paulo, Brazil

Influenza H1N1 Vaccination in Mixed Connective Tissue Disease: Effectiveness and Safety Independent of Disease or Therapy
Renata Miossi1, Ricardo Fuller1, Julio C. B. Moraes1, Ana Cristina Medeiros1, Carla G.S. Saad1, Nadia E. Aikawa1, Joao Miraglia2, Maria A. Ishida3, M.Teresa C. Caleiro1 and Eloisa Bonfa1, 1University of Sao Paulo, Sao Paulo, Brazil, 2Fundação Butantan, São Paulo, Brazil, 3Adolfo Lutz Institute, Sao Paulo, Brazil

Influenza A H1N1/2009 Vaccine in Rheumatic Disease Patients Under Anti-TNF Therapy:  Safety and Response
Ivan L.A. França1, Ana C. M. Ribeiro1, Nadia E. Aikawa1, Carla G.S. Saad1, Ana L. G. Calich1, Julio C. B. Moraes1, Ieda Laurindo1, Joao Miraglia2, Maria A. Ishida3, Eloisa Bonfa1 and Clovis Silva1, 1Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Fundação Butantan, São Paulo, Brazil, 3Adolfo Lutz Institute, Sao Paulo, Brazil
Advanced Clinical Research
Rilonacept for Gout Flare Prevention in Patients on Uric Acid-Lowering Therapy: Results of a Double-Blind, Placebo-Controlled, Phase 3, International Safety Study
John S. Sundy1, H. Ralph Schumacher2, Judith Kirstein3, Essack Mitha4, Steven P. Weinstein5, Jian Wang5, Shirletta King-Davis5 and Robert R. Evans5, 1Duke University Medical Center, Durham, NC, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Advanced Clinical Research, West Jordan, UT, 4Newtown Clinical Research, Johannesburg, Gauteng, South Africa, 5Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER)
Conception, Family Size and Miscarriages in Fibromyalgia Patients
Robert S. Katz1, Sharon M. Ferbert2, Patricia Kuenzi1, Jessica L. Polyak3 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3Rheumatology Associates, Chicago, IL

Fibromyalgia and Parental Medical Histories of Depression and Alcoholism
Robert S. Katz1, Ben J. Small2, Sharon M. Ferbert3, Patricia Kuenzi1 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2Rush University Medical School, Chicago, IL, 3Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL

Family Stress in Childhood of Patients with Fibromyalgia
Robert S. Katz1, Sharon M. Ferbert2, Ben J. Small3 and Susan Shott1, 1Rush University Medical Center, Chicago, IL, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3Rush University Medical School, Chicago, IL

Childhood Social Ostracism in Fibromyalgia
Afton L. Hassett1, Sharon M. Ferbert2, Susan Shott3 and Robert S. Katz3, 1University of Michigan Medical School, Ann Arbor, MI, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3Rush University Medical Center, Chicago, IL

Psychiatric Disorders in Fibromyalgia Patients, Results  Patient Survey
Robert S. Katz1, Sharon M. Ferbert2, Alexandra Small3, Susan Shott1 and Patricia Kuenzi1, 1Rush University Medical Center, Chicago, IL, 2Advocates for Funding Fibromyalgia Treatment, Education and Research(AFFTER), Libertyville, IL, 3University of Illinois Medical School
Affiliated Drum Tower Hospital of Nanjing University Medical School
Effects of OAZ In Regulating B-Cell Proliferation by Mesenchymal Stem Cells From Patients with Systemic Lupus Erythematosus
Xuebing Feng1, Yan Liu1, Nan Che1, Dandan Wang1, Betty P. Tsao2 and Lingyun Sun1, 1Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, 2UCLA School of Medicine, Los Angeles, CA
Agency for Healthcare Research and Quality
The Government’s Agenda for Comparative Effectiveness Research: What Does It Mean for Policy and Funding?
Carolyn M. Clancy, Agency for Healthcare Research and Quality, Rockville, MD
Agendia BV
Identification of Robust and Disease-Specific Stromal Alterations in Spondyloarthritis Synovitis
Nataliya Yeremenko1, Gemma M. M. Rigter1, Iris Simon2, Juan D. Cañete3, Paul P. Tak1 and Dominique L. Baeten1, 1Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Agendia BV, Amsterdam, Netherlands, 3Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
Aging and Inflammation Research Lab, INIBIC-CHU A Coruña
Age-Related Mitochondrial Dysfunction Sensitizes Human Synoviocytes to Inflammatory Response
M. Noa Valcárcel-Ares1, Romina R. Riveiro-Naveira1, Carlos Vaamonde-García1, Laura Hermida-Carballo1, Francisco J. Blanco2 and Maria J. López-Armada1, 1Aging and Inflammation Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain, 2Osteoarticular and Aging Research Lab, INIBIC-CHU A Coruña, A Coruña, Spain
Aichi Medical University
Serodiagnosis of Mycobacterium Avium-Complex Pulmonary Disease with An Enzyme Immunoassay Kit That Detects Anti-Glycopeptidolipid Core Antigen IgA Antibodies In Patients with Rheumatoid Arthritis
Shogo Banno1, Maiko Watanabe2, Kanesige Sasaki2, Taio Naniwa2 and Yoshihito Hayami2, 1Aichi Medical University, Aichi-prefecture, Japan, 2Nagoya City University, Nagoya city, Japan
Ain Shams University
Imaging As An Outcome Measure in Early Inflammatory Arthritis: Monitoring Disease Activity and Patients’ Response to Therapy Using Ultrasonography
Yasser M. El Miedany1, Maha El Gaafary2, Deborah Palmer1 and Sally Youssef2, 1Darent Valley Hospital, Dartford, United Kingdom, 2Ain Shams University, Cairo, Egypt

Patient Reported Outcome Measures: Its Impact on Disease Activity and Adherence to Therapy in Inflammatory Arthritis
Yasser M. El Miedany1, Deborah Palmer1 and Maha El Gaafary2, 1Darent Valley Hospital, Dartford, United Kingdom, 2Ain Shams University, Cairo, Egypt
Ajou University School of Med
Treatment of Chemotherapy-Related Arthropathy with Disease Modifying Antirheumatic Drugs: Results of An Open-Labeled Multicenter Pilot Study
Hyoun Ah Kim1, Hyo-Jin Choi2, Hanjoo Baek2, Mie Jin Lim3, Won Park3, Jisoo Lee4, Sung Jae Choi5, Bo Young Yoon6, Sang Tae Choi7, Jung-Soo Song7, Sung Soo Kim8 and Chang-Hee Suh1, 1Ajou University School of Med, Suwon, South Korea, 2Gachon University Gil Hospital, Incheon, South Korea, 3Center for Rheumatism, Inha University Hospital, Incheon, South Korea, 4Ewha Womans University Mokdong Hospital, Seoul, South Korea, 5Korea University Medical Center, Ansan, South Korea, 6Inje University Ilsan Paik Hospital, Goyang, South Korea, 7Chung-Ang University College of Medicine, Seoul, South Korea, 8Ulsan Univ Med Sch Gangneung, Gangneung
Ajou University School of Medicine
Expression and Function of the NALP3 Inflammasome in Behçet’s Disease
En Hyung Kim1, Jae Young Shin2, Mi-Jin Park2, Sun Park2 and Eun-So Lee2, 1Kwan Dong University, Cheil General Hospital and Women's Healthcare Center, Seoul, South Korea, 2Ajou University School of Medicine, Suwon, South Korea
Al Biraa Arthritis Center
Increased Awareness of Arthritis May Result in Earlier Diagnosis of Rheumatoid Arthritis
Sara Zafar1, Humeira M. Badsha2, Ayman Mofti2, Arlene Delosantos2, Janice Altares2, Gerald Matudio2 and Kok Ooi Kong3, 1University of Edinburgh, Edinburgh, United Kingdom, 2Al Biraa Arthritis Center, Dubai, United Arab Emirates, 3Tan Tong Seck Hospital, Singapre, Singapore
Albany Medical College
Sustained Inhibition of Structural Damage in Patients with Rheumatoid Arthritis and An Inadequate Response to Tumor Necrosis Factor Inhibitors Prior to Rituximab Treatment: 5-Year Data From the REFLEX Study
Edward Keystone1, Stanley B. Cohen2, Paul Emery3, Joel M. Kremer4, Maxime Dougados5, James E. Loveless6, Carol Chung7, Patricia B. Lehane8 and Helen Tyrrell8, 1University of Toronto, Toronto, ON, 2Metroplex Clinical Research Center, Dallas, TX, 3Chapel Allerton Hospital, Leeds, United Kingdom, 4Albany Medical College, Albany, NY, 5Rene Descartes University, Paris, France, 6St. Luke's Rheumatology, Boise, ID, 7Genentech, Inc., South San Francisco, CA, 8Roche Products Limited, Welwyn Garden City, United Kingdom
Albany Medical College and The Center for Rheumatology
Factors Associated with Work Status and Missed Work Days in Patients with Rheumatoid Arthritis
Leslie R. Harrold1, Mary A. Cifaldi2, Ying Shan1, George Reed1, Katherine C. Saunders3, Joel M. Kremer4 and Jeffrey D. Greenberg5, 1UMass Medical School, Worcester, MA, 2Abbott Laboratories, Abbott Park, IL, 3CORRONA, Inc., Southborough, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5New York University School of Medicine, New York, NY

Factors Associated with Relapse of Remission in Rheumatoid Arthritis
Leslie R. Harrold1, George Reed1, David H. Collier2, Grace S. Park2, Hong Chang3, Andrew S. Koenig4, Katherine C. Saunders5, Debra J. Zack6, Joel M. Kremer7 and Jeffrey D. Greenberg8, 1UMass Medical School, Worcester, MA, 2Amgen Inc., Thousand Oaks, CA, 3Tufts Medical Center, Boston, MA, 4Pfizer Inc., Collegeville, PA, 5CORRONA, Inc., Southborough, MA, 6Amgen Inc, Thousand Oaks, CA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8New York University School of Medicine, New York, NY

Combinations of Anti-Citrullinated Peptide Antibodies with Rheumatoid Factor Isotypes Reveal An Attribute Associated with Disease Activity in Rheumatoid Arthritis Patients Treated with Methotrexate
Thierry Dervieux, Exagen Diagnostics, Albuquerque, NM, Cole Harris, Exagen Diagnostics and Joel M. Kremer, Albany Medical College and The Center for Rheumatology, Albany, NY

Epistasis in Folate Mediated One Carbon Metabolism Contributes to High Disease Activity in Two Cohorts of Rheumatoid Arthritis Patients Receiving Long Term Methotrexate Therapy
Thierry Dervieux1, J. M. Kremer2, Rebecca Roberts3 and Lisa K. Stamp3, 1Exagen Diagnostics, Albuquerque, NM, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3University of Otago, Christchurch, Christchurch, New Zealand

Tocilizumab Monotherapy and Tocilizumab Plus Disease-Modifying Antirheumatic Drugs in a US Rheumatoid Arthritis Population with Inadequate Response to Anti-Tumor Necrosis Factor Agents
Michael E. Weinblatt1, Joel M. Kremer2, John J. Cush3, William Rigby4, Lichen Teng5, Natasha Singh5, Raymond L. Malamet6 and Mark C. Genovese7, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Baylor Research Institute, Dallas, TX, 4Dartmouth Medical School, Lebanon, NH, 5Roche, Nutley, NJ, 6Genentech, South San Francisco, CA, 7Stanford University, Palo Alto, CA

Trend of Tumor Necrosis Factor Inhibitors Use Among Patients with Rheumatoid Arthritis: Analysis From the Consortium of Rheumatology Researchers of North America Registry
Pim Jetanalin1, Susan P. Messing2, Kimberly Kaukeinen2, Joel M. Kremer3 and Susan J. Lee1, 1University of California San Diego, La Jolla, CA, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3Albany Medical College and The Center for Rheumatology, Albany, NY

Gene-Gene Interactions in Folate Pathway Contribute to Methotrexate Adverse Events in Rheumatoid Arthritis
Thierry Dervieux1, Judith Wessels2, J. M. Kremer3, Tom W.J. Huizinga2 and Henk-Jan Guchelaar2, 1Exagen Diagnostics, Albuquerque, NM, 2Leiden University Medical Center, Leiden, Netherlands, 3Albany Medical College and The Center for Rheumatology, Albany, NY

Patterns of Interaction Between Genetic and Non-Genetic Attributes and Methotrexate Efficacy in Rheumatoid Arthritis
Thierry Dervieux1, Judith Wessels2, J. M. Kremer3, Leonid Padyukov4, Maria Seddighzadeh4, Saedis Saevarsdottir4, R.F. van Vollenhoven4, Lars Klareskog4, T. Huizinga2 and Henk-Jan Guchelaar2, 1Exagen Diagnostics, Albuquerque, NM, 2Leiden University Medical Center, Leiden, Netherlands, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 4Karolinska Institutet, Stockholm, Sweden

Risk for Herpes Zoster in Patients with Rheumatoid and Psoriatic Arthritis
Dimitrios A. Pappas1, George Reed2, Michele M. Hooper3, Ying Shan2, Bojena Bitman4, Jeffrey D. Greenberg5, Deborah Wenkert3, Jie Zhang6, Joel M. Kremer7 and Jeffrey R. Curtis6, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMass Medical School, Worcester, MA, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA, 5New York University School of Medicine, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7Albany Medical College and The Center for Rheumatology, Albany, NY

A Profile of Rheumatoid Arthritis Patients Treated with Tocilizumab in a United States Registry Population
Dimitrios A. Pappas1, Alan Rathbun2, George Reed3, Joel M. Kremer4, Isidro Villanueva5, Jenny Devenport6, Sarika Ogale6, Ani John6 and Jeffrey D. Greenberg7, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMASS Medical School, Worcester, MA, 3UMass Medical School, Worcester, MA, 4Albany Medical College and The Center for Rheumatology, Albany, NY, 5Viregen Macarena Hospital, Sevilla, Spain, 6Genentech, South San Francisco, CA, 7New York University School of Medicine, New York, NY

Effect of Weight, Body Mass Index and Weight-Based Dosing on Persistency of Anti-TNFs in Psoriatic Arthritis
Jeffrey D. Greenberg1, Rebecca Bolce2, Ying Shan3, Katherine C. Saunders4, George Reed3, Joel M. Kremer5 and Dennis Decktor2, 1New York University School of Medicine, New York, NY, 2Janssen Services, LLC, Horsham, PA, 3UMass Medical School, Worcester, MA, 4CORRONA, Inc., Southborough, MA, 5Albany Medical College and The Center for Rheumatology, Albany, NY

Immunogenicity Is Low and Transient with Intravenous (IV) Abatacept Therapy: Results From a Large Pooled Analysis of 3985 Patients (pts) with Rheumatoid Arthritis (RA) and up to 8 Years’ Exposure
Michael E. Weinblatt1, Mark C. Genovese2, Michael H. Schiff3, Rene Westhovens4, Rieke Alten5, Ingrid Delaet6, Marleen Nys6, James Manning6 and Joel M. Kremer7, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Stanford University, Palo Alto, CA, 3Rheumatology Division, University of Colorado, Denver, CO, 4University Hospital KU Leuven, Leuven, Belgium, 5Rheumatology Schlossparkklinik, Berlin, Germany, 6Bristol-Myers Squibb, Princeton, NJ, 7Albany Medical College and The Center for Rheumatology, Albany, NY

Efficacy and Safety of Tocilizumab As Monotherapy or in Combination with Nonbiologic Disease-Modifying Antirheumatic Drugs: A 24-Week Randomized Study in a United States Population
Michael E. Weinblatt1, Joel M. Kremer2, John J. Cush3, William F. C. Rigby4, Lichen Teng5, Natasha Singh5 and Raymond L. Malamet6, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Baylor Research Institute, Dallas, TX, 4Dartmouth-Hitchcock Med Ctr, Lebanon, NH, 5Roche, Nutley, NJ, 6Genentech, South San Francisco, CA

Red Blood Cell Folate Polyglutamates Are An Important Determinant of RA Disease Activity In Patients On Methotrexate – Implications for Folic Acid Supplementation
Lisa K. Stamp1, Peter T. Chapman2, Murray Barclay1, Joel M. Kremer3 and Thierry Dervieux4, 1University of Otago, Christchurch, Christchurch, New Zealand, 2Christchurch Hospital, Christchurch, New Zealand, 3Albany Medical College and The Center for Rheumatology, Albany, NY, 43Exagen Diagnostics, Albuquerque, NM

Clinical Disease Activity and Acute Phase Reactant (APR) Levels Are Discordant Among Patients with Active Rheumatoid Arthritis (RA) and Contribute Separately to Predicting Outcome At 1 Year
Jonathan Kay, University of Massachusetts Medical School, Worcester, MA, Susan P. Messing, University of Rochester School of Medicine and Dentistry, Rochester, NY, Joel M. Kremer, Albany Medical College and The Center for Rheumatology, Albany, NY, Jeffrey D. Greenberg, New York University School of Medicine, New York, NY and Daniel E. Furst, UCLA Medical School, Los Angeles, CA

Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: a 24-Month Phase 3 Study
Désirée van der Heijde1, Y. Tanaka2, Roy Fleischmann3, Edward C. Keystone4, J. M. Kremer5, C A. F. Zerbini6, M. Cardiel7, S. B. Cohen8, P. T. Nash9, Yeong Wook Song10, D. Tegzova11, B. Wyman12, D. Gruben12, B. Benda13, G. Wallenstein12, S. H. Zwillich12, J. D. Bradley12, C. A. Connell12 and the ORAL Scan investigators14, 1Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2University of Occupational & Environmental Health, Kitakyushu, Fukuoka, Japan, 3University of Texas Southwestern Medical Center, Dallas, TX, 4Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, Mount Sinai Hospital, Toronto, ON, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6Centro Paulista de Investigação Clinica, Sao Paulo, Brazil, 7Institute of Rheumatology, Prague, Czech Republic, 8Metroplex Clinical Research Centre, Dallas, TX, 9University of Queensland, Brisbane, Australia, 10Seoul National University Hospital, Seoul, South Korea, 11Institute Of Rheumatology, Prague, Czech Republic, 12Pfizer Inc., Groton, CT, 13Pfizer Inc., Collegeville, PA, 14Groton

Comparative Effectiveness of Abatacept Versus Subsequent Anti-TNF Agents Among Rheumatoid Arthritis Patients with Previous Anti-TNF Exposure
Leslie R. Harrold1, George Reed1, Jeffrey R. Curtis2, Daniel H. Solomon3, Marc Hochberg4, Alina U. Onofrei1, Joel M. Kremer5 and Jeffrey D. Greenberg6, 1UMass Medical School, Worcester, MA, 2Univ of Alabama-Birmingham, Birmingham, AL, 3Brigham and Women's Hospital, Boston, MA, 4University of Maryland School of Medicine, Baltimore, MD, 5Albany Medical College and The Center for Rheumatology, Albany, NY, 6New York University School of Medicine, New York, NY

Tofacitinib (CP-690,550) in Combination with Traditional Disease-Modifying Anti-Rheumatic Drugs: Phase 3 Study Patient-Reported Outcomes in Patients with Active Rheumatoid Arthritis and An Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs
V. Strand1, J. M. Kremer2, Z. G. Li3, S. Hall4, Roy M. Fleischmann5, M. C. Genovese6, E. Martin-Mola7, J. Isaacs8, D. Gruben9, G. Wallenstein9, S. Krishnaswami9, S. H. Zwillich9, T. Koncz10, R. Riese9, J. D. Bradley9 and the ORAL Sync investigators11, 1Stanford University, Palo Alto, CA, 2Albany Medical College and The Center for Rheumatology, Albany, NY, 3Peking University People's Hospital, Peking, China, 4Melbourne Rheumatology, Melbourne, Australia, 5MCRC, University of Texas, Dallas, TX, 6Stanford University Medical Center, Palo Alto, CA, 7Hospital Universitario La Paz, Madrid, Spain, 8University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, 9Pfizer Inc., Groton, CT, 10Pfizer Inc., New York, NY, 11Groton

N-3 Fatty Acids in Rheumatic Diseases and the Intersection with Cardiovascular Morbidity
Joel M. Kremer, Albany Medical College and The Center for Rheumatology, Albany, NY
Albert Einstein Coll of Med
Inverse Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone Observed in the General Population but Not Among Rheumatoid Arthritis Patients
Anna R. Broder1, Amy Skversky2, Michal L. Melamed3, Jonathan N. Tobin4, John A. Hardin5 and Chaim Putterman3, 1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine/CDN Network, New York, NY, 5Albert Einstein Coll of Med, Bronx, NY
Albert Einstein College of Med
TWEAK/Fn14 Pathway Blockade Attenuates Renal Disease In Autoantibody-Induced Nephritis
Yumin Xia1, Sean Campbell1, Leal Herlitz2, Jennifer S. Michaelson3, Linda C. Burkly3 and Chaim Putterman4, 1Albert Einstein College of Med, Bronx, NY, 2Columbia Presbyterian Medical Center, 3Biogen Idec, Cambridge, MA, 4Albert Einstein College of Medicine, Bronx, NY

Deficiency of the TWEAK Receptor Fn14 Is Protective In the MRL-Lpr/Lpr Mouse Model of Lupus Nephritis
Yumin Xia1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

Dispensability of APRIL to Development of Systemic Lupus Erythematosus (SLE) In SLE-Prone NZM 2328 Mice
Chaim O. Jacob1, Shunhua Guo1, Noam Jacob1, Rahul Pawar2, Chaim Putterman3, William J. Quinn III4, Michael P. Cancro4, Thi-Sau Migone5 and William Stohl1, 1University of Southern California Keck School of Medicine, Los Angeles, CA, 2Albert Einstein College of Med, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4University of Pennsylvania School of Medicine, Philadelphia, PA, 5Human Genome Sciences, Rockville, MD

Fn14 Deficiency Ameliorates Neuropsychiatric Disease In MRL-Lpr/Lpr Lupus Prone Mice
Jing Wen1, Yumin Xia1, Jennifer S. Michaelson2, Linda C. Burkly2, Maria Gulinello1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

The Contribution of Cell Bound Complement Activation Products to the Diagnosis of Systemic Lupus Erythematosus
Kenneth C. Kalunian, UCSD School of Medicine, La Jolla, CA, W. Chatham, UAB Arthritis Clinical Intervention Program, Birmingham, AL, Elena M. Massarotti, Brigham and Women's Hospital, Boston, MA, Cole Harris, Exagen Diagnostics, R.A. Furie, North Shore-LIJ Health System, Lake Success, NY, Jill P. Buyon, NYU School of Medicine, New York, NY, Eliza F. Chakravarty, Stanford University, Palo Alto, CA, Emily C. Somers, University of Michigan, Ann Arbor, MI, Puja Chitkara, SDAMC, San Diego, CA, Rachel L. Gross, Albert Einstein College of Medicine, New York, NY, Kyriakos A. Kirou, Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY, Joyce Reyes-Thomas, Albert Einstein College of Med, Bronx, NY, Rosalind Ramsey-Goldman, Northwestern University Feinberg School of Medicine, Chicago, IL, Christine Hsieh, University of Chicago, Chicago, IL, Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Thierry Dervieux, Exagen Diagnostics, Albuquerque, NM and A. Weinstein, Washington Hospital Center, Washington, DC

TWEAKing Cutaneous Manifestations In MRL-Lpr/Lpr Lupus Prone mice  
Yumin Xia1, Karin Blecher1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2, Adam Friedman1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

Ethical Issues in Rheumatology: A Survey of the American College of Rheumatology Membership
C. Ronald MacKenzie, Hosp for Special Surgery, New York, NY, Michele Meltzer, Jefferson Universtiy, Philadelphia, PA and Elizabeth A. Kitsis, Albert Einstein College of Med, Bronx, NY

Albert Einstein College of Medicine
High Antiphospholipid Antibody Levels May Reflect Chronic Endothelial Damage in Non-Autoimmune-Associated Thrombosis
Anna R. Broder1, Jonathan N. Tobin2, Jacob H. Rand3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine/CDN Network, New York, NY, 3Montefiore Medical Center, Bronx, NY

Is Sunlight Exposure and Vitamin D Intake Associated with Rheumatoid Arthritis?
Nicole C. Wright1, Brian T. Walitt2, Jeffery R. Curtis1, Mary Pettinger3, Christine G. Parks4, Anneclaire J. De Roos3, Jean Wactawksi-Wende5, Rachel Mackey6, Rebecca D. Jackson7, Michal L. Melamed8 and Barbara V. Howard9, 1University of Alabama at Birmingham, Birmingham, AL, 2Washington Hospital Center, Washington, DC, 3Fred Hutchinson Cancer Research Center, WA, 4NIH/NIEHS, Research Triangle Park, NC, 5University of Buffalo, Buffalo, NY, 6University of Pittsburgh, Pittsburgh, PA, 7Ohio State University, Columbus, OH, 8Albert Einstein College of Medicine, Bronx, NY, 9Medstar Research Institute, Washington, DC

The Risk of Malignancy in a Large Cohort of Patients with Psoriatic Arthritis
Rachel L. Gross1, Julie S. Schwartzman-Morris1, Michael Krathen2, George Reed3, Hong Chang2, Katherine C. Saunders4, Mark C. Fisher5, Chaim Putterman1, Philip J. Mease6, Alice B. Gottlieb2 and Anna R. Broder1, 1Albert Einstein College of Medicine, Bronx, NY, 2Tufts Medical Center, Boston, MA, 3University of Massachusetts, Worcester, MA, 4CORRONA, Inc., Southborough, MA, 5Massachusetts General Hospital, Boston, MA, 6Seattle Rheumatology Associate, Seattle, WA

TWEAK/Fn14 Pathway Blockade Attenuates Renal Disease In Autoantibody-Induced Nephritis
Yumin Xia1, Sean Campbell1, Leal Herlitz2, Jennifer S. Michaelson3, Linda C. Burkly3 and Chaim Putterman4, 1Albert Einstein College of Med, Bronx, NY, 2Columbia Presbyterian Medical Center, 3Biogen Idec, Cambridge, MA, 4Albert Einstein College of Medicine, Bronx, NY

Deficiency of the TWEAK Receptor Fn14 Is Protective In the MRL-Lpr/Lpr Mouse Model of Lupus Nephritis
Yumin Xia1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

Dispensability of APRIL to Development of Systemic Lupus Erythematosus (SLE) In SLE-Prone NZM 2328 Mice
Chaim O. Jacob1, Shunhua Guo1, Noam Jacob1, Rahul Pawar2, Chaim Putterman3, William J. Quinn III4, Michael P. Cancro4, Thi-Sau Migone5 and William Stohl1, 1University of Southern California Keck School of Medicine, Los Angeles, CA, 2Albert Einstein College of Med, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4University of Pennsylvania School of Medicine, Philadelphia, PA, 5Human Genome Sciences, Rockville, MD

Fn14 Deficiency Ameliorates Neuropsychiatric Disease In MRL-Lpr/Lpr Lupus Prone Mice
Jing Wen1, Yumin Xia1, Jennifer S. Michaelson2, Linda C. Burkly2, Maria Gulinello1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

The Contribution of Cell Bound Complement Activation Products to the Diagnosis of Systemic Lupus Erythematosus
Kenneth C. Kalunian, UCSD School of Medicine, La Jolla, CA, W. Chatham, UAB Arthritis Clinical Intervention Program, Birmingham, AL, Elena M. Massarotti, Brigham and Women's Hospital, Boston, MA, Cole Harris, Exagen Diagnostics, R.A. Furie, North Shore-LIJ Health System, Lake Success, NY, Jill P. Buyon, NYU School of Medicine, New York, NY, Eliza F. Chakravarty, Stanford University, Palo Alto, CA, Emily C. Somers, University of Michigan, Ann Arbor, MI, Puja Chitkara, SDAMC, San Diego, CA, Rachel L. Gross, Albert Einstein College of Medicine, New York, NY, Kyriakos A. Kirou, Mary Kirkland Center for Lupus Care, Hospital for Special Surgery, New York, NY, Joyce Reyes-Thomas, Albert Einstein College of Med, Bronx, NY, Rosalind Ramsey-Goldman, Northwestern University Feinberg School of Medicine, Chicago, IL, Christine Hsieh, University of Chicago, Chicago, IL, Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY, Thierry Dervieux, Exagen Diagnostics, Albuquerque, NM and A. Weinstein, Washington Hospital Center, Washington, DC

Higher Education Level is Associated with Decreased Compliance in an Urban Multi-Ethnic Lupus Cohort
Rachel L. Gross, Dawn M. Wahezi, Chaim Putterman and Irene Blanco, Albert Einstein College of Medicine, Bronx, NY

Association of Androgen Receptor Gene Polymorphism with Damage in Systemic Lupus Erythematosus
Yun Deng1, Jennifer M. Grossman2, Qiong Fu1, William Martin1, Matthew Quirk1, Ornella J. Rullo3, Susan A. Boackle4, Chaim Putterman5, Jane E. Salmon6, Vasileios C. Kyttaris7, George C. Tsokos7, Erika Magdangal1, Lori Sahakian2, Weiling Chen1, Jennifer MP Woo3, Deborah K. McCurdy3, Chack-Yung Yu8, Bevra H. Hahn2, Maureen A. McMahon1 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA, 3Mattel Children's Hospital, University of California, Los Angeles, Los Angeles, CA, 4University of Colorado Denver School of Medicine, Aurora, CO, 5Albert Einstein College of Medicine, Bronx, NY, 6Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 7Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 87Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH

Inflammation May Be Associated with An Unfavorable Lipid Profile in Psoriatic Arthritis Patients in the CORRONA Registry
Asena Bahce-Altuntas1, Julie S. Schwartzman-Morris1, Nicole Jordan1, Jeffrey D. Greenberg2, Chaim Putterman1, George Reed3 and Anna R. Broder1, 1Albert Einstein College of Medicine, Bronx, NY, 2New York University School of Medicine, New York, NY, 3UMass Medical School, Worcester, MA

Syndesmophyte Formation Is Associated with Low-Grade Spine Inflammation and Disconnected From Peripheral Arthritis in Mice Immunized with Recombinant Human Aggrecan G1 Domain
Mohamed Ramez, Toni S. Forde, Elena Kudryavtseva and Vyacheslav A. Adarichev, Albert Einstein College of Medicine, Bronx, NY

Metabolic Underpinnings of Systemic Lupus Erythematosus 
Tianfu Wu1, Chun Xie1, Jie Han1, Irene Blanco2, Nancy J. Olsen3, Chaim Putterman2, Ramesh Saxena4 and Chandra Mohan4, 1University of Texas, Southwestern Medical Center at Dallas, Dallas, TX, 2Albert Einstein College of Medicine, Bronx, NY, 3Penn State MS Hershey Medical Center, Hershey, PA, 4University of Texas Southwestern Medical Center, Dallas, TX

Increased Relative Expression of the Interferon-Responsive Gene MX1 Is Present in Pregnant SLE Patients and May Distinguish Flare of SLE From Preeclampsia
Danieli Andrade1, Gloria Koo1, Patricia M. Redecha1, Kyriakos A. Kirou2, Mimi Kim3, Mary K. Crow1 and Jane E. Salmon4, 1Hospital for Special Surgery, New York, NY, 2Mary Kirkland Center for Lupus Care - Hospital for Special Surgery, New York, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

Collagen Triple Helix Repeat Containing 1 Protein Is a New Synovial Lining Biomarker Overexpressed in Antibody-Mediated Arthritis
Mohammed Talha Shekhani1, Toni S. Forde1, Anne S. Cuttler2, Volkhard Lindner2 and Vyacheslav A. Adarichev1, 1Albert Einstein College of Medicine, Bronx, NY, 2Maine Medical Center Research Institute, Scarborough, ME

Association of Serum-Based IFN-Induced Chemokine Scores with Lupus Nephritis Disease Activity
Irene Blanco1, Chaim Putterman1, Michelle Petri2 and Emily Baechler Gillespie3, 1Albert Einstein College of Medicine, Bronx, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD, 3University of Minnesota, Minneapolis, MN

Inverse Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone Observed in the General Population but Not Among Rheumatoid Arthritis Patients
Anna R. Broder1, Amy Skversky2, Michal L. Melamed3, Jonathan N. Tobin4, John A. Hardin5 and Chaim Putterman3, 1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine/CDN Network, New York, NY, 5Albert Einstein Coll of Med, Bronx, NY

Favorable Prognosis in a Large, Prospective Multicenter Study of Lupus Pregnancies
Jill P. Buyon1, Lamya Garabet2, Mimi Kim3, Emily R. Reeves2, Marta M. Guerra2, Michael D. Lockshin4, Carl A. Laskin5, Ware Branch6, Lisa R. Sammaritano2, Michelle Petri7, Joan T. Merrill8, Allen D. Sawitzke9 and Jane E. Salmon10, 1New York University School of Medicine, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Barbara Volcker Center for Women and Rheumatic Diseases: Hospital for Special Surgery, New York, NY, 5University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, 6Univ of Utah, Salt Lake City, UT, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8Oklahoma Medical Research Foundation, Oklahoma City, OK, 9University of Utah Medical Ctr, Salt Lake City, UT, 10Hospital for Special Surgery, Weill Cornell Medical College, New York, NY

TWEAKing Cutaneous Manifestations In MRL-Lpr/Lpr Lupus Prone mice  
Yumin Xia1, Karin Blecher1, Jing Wen1, Jennifer S. Michaelson2, Linda C. Burkly2, Adam Friedman1 and Chaim Putterman3, 1Albert Einstein College of Med, Bronx, NY, 2Biogen Idec, Cambridge, MA, 3Albert Einstein College of Medicine, Bronx, NY

Narrowing the Protein Tyrosine Phospahatse-22 Locus in Mice with Cartilage Proteoglycan-Induced Arthritis Explores Disease-Promoting and Disease-Suppressive Sub-Loci Neutralizing Their In Vivo Arthritis Susceptibility and Severity
Timea Besenyei1, Andras Kadar1, Beata Tryniszewska1, Vyacheslav A. Adarichev2, Katalin Mikecz1 and Tibor T. Glant1, 1Rush University Medical Center, Chicago, IL, 2Albert Einstein College of Medicine, Bronx, NY

Brucellosis-Induced Murine Arthritis and Spondylolisthesis
Elizabeth T. Lyons1, Diogo Magnani2, Toni S. Forde1, Gary Splitter2 and Vyacheslav A. Adarichev1, 1Albert Einstein College of Medicine, Bronx, NY, 2University of Wisconsin, Madison, WI

Initial Results for the LFA Collective Data Analysis Initiative (LFA CDAI): How Do Subjects From Lupus Clinical Trials Randomized to Standard of Care Respond Over Time?
Kenneth C. Kalunian1, Mimi Kim2, Leslie M. Hanrahan3, Jean-Claude P. Becker4, Sabine Bongardt5, Paul Brunetta6, David Close7, Jorn Drappa7, Richard Furie8, Bevra H. Hahn9, Matthew Linnik10, Jane E. Salmon11, Neil Solomons12 and Joan T. Merrill13, 1UCSD School of Medicine, La Jolla, CA, 2Albert Einstein College of Medicine, Bronx, NY, 3Lupus Foundation of America, Washington, DC, 4Becker Clinical Reearch Consulting LLC, New York, NY, 5UCB Biosciences, 6Genentech, So San Francisco, CA, 7MedImmune Inc., 8North Shore-LIJ Health System, Lake Success, NY, 9UCLA David Geffen School of Medicine, Los Angeles, CA, 10Lilly Research Laboratories, 11Hospital for Special Surgery, Weill Cornell Medical College, New York, NY, 12Vifor Pharma, 13Oklahoma Medical Research Foundation, Oklahoma City, OK


Higher Frequency of Metabolic Syndrome In Psoriatic Arthritis Compared with Rheumatoid Arthritis May Be Explained by High Triglycerides and Increased Rates of Obesity and Diabetes
Asena Bahce-Altuntas1, Julie S. Schwartzman-Morris1, Nicole Jordan1, Jeffrey D. Greenberg2, Chaim Putterman1, George Reed3 and Anna R. Broder1, 1Albert Einstein College of Medicine, Bronx, NY, 2NYU Hospital for Joint Diseases, New York, NY, 3UMass Medical School, Worcester, MA

Case-Based Decision Tree - Interdisciplinary Management of Chronic Low Back Pain
Douglas Schottenstein, New York Presbyterian, New York, NY and Chaim Putterman, Albert Einstein College of Medicine, Bronx, NY
Albert Einstein College of Medicine at Beth Israel Medical Center
Arthrocentesis Training Using a Knee Simulation Model
Jordan E. Brodsky, Erin P. Patton and Harry D. Fischer, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY
Albert Einstein College of Medicine/CDN Network
High Antiphospholipid Antibody Levels May Reflect Chronic Endothelial Damage in Non-Autoimmune-Associated Thrombosis
Anna R. Broder1, Jonathan N. Tobin2, Jacob H. Rand3 and Chaim Putterman1, 1Albert Einstein College of Medicine, Bronx, NY, 2Albert Einstein College of Medicine/CDN Network, New York, NY, 3Montefiore Medical Center, Bronx, NY

Inverse Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone Observed in the General Population but Not Among Rheumatoid Arthritis Patients
Anna R. Broder1, Amy Skversky2, Michal L. Melamed3, Jonathan N. Tobin4, John A. Hardin5 and Chaim Putterman3, 1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine/CDN Network, New York, NY, 5Albert Einstein Coll of Med, Bronx, NY
Albert Einstein College of Medicine/Montefiore Medical Center
Inverse Relationship Between 25-Hydroxyvitamin D and Parathyroid Hormone Observed in the General Population but Not Among Rheumatoid Arthritis Patients
Anna R. Broder1, Amy Skversky2, Michal L. Melamed3, Jonathan N. Tobin4, John A. Hardin5 and Chaim Putterman3, 1Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY, 2Montefiore Medical Center, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY, 4Albert Einstein College of Medicine/CDN Network, New York, NY, 5Albert Einstein Coll of Med, Bronx, NY
Albert Einstein Med Ctr
Symptomatic Subcutaneous Anti-Tumor Necrosis Factor-Treated Rheumatoid Arthritis Patients Improve Following An Active Switch to Golimumab: An Initial 14 Week Assessment
J. Eugene Huffstutter1, Rebecca Bolce2, Shelly P. Kafka3, Lawrence H. Brent4, Jim Wang5, Raphael J. DeHoratius2, Trev Sprabery2 and Dennis Decktor2, 1Arthritis Associates PLLC, Hixson, TN, 2Janssen Services, LLC, Horsham, PA, 3Mountain State Rheumatology, Clarksburg, WV, 4Albert Einstein Med Ctr, Philadelphia, PA, 5Johnson & Johnson Pharmaceutical Research and Development, LLC, Belle Mead
Albert Einstein Medical Center
Polyarticular Septic Arthritis: A Case Series
Rajni Kalagate1, Sherilyn T. McCollum1, Charles H. Pritchard2 and Lawrence H. Brent1, 1Albert Einstein Medical Center, Philadelphia, PA, 2Rheumatic Disease Associates, Willow Grove, PA
Albert Schweitzer Hospital
Combination of Disease-Modifying Antirheumatic Drugsprohibits the Need of Early Initiation of Biologicals, Independent of Glucocorticosteroids. A clinical trial to Investigate Different Induction Therapies in Early Rheumatoid Arthritis
P.H.P. de Jong1, Johanna Hazes2, P.J. Barendregt3, A.M. Huisman4, D. van Zeben4, P.A. van der Lubbe5, A.H. Gerards5, M.H. de Jager6, P.B. de Sonnaville7, B.A. Grillet8, Jolanda J. Luime9 and A.E.A.M. Weel3, 1University Medical Center, Rotterdam, Netherlands, 2Erasmus Medical Centre Rotterdam, Rotterdam, Netherlands, 3Maasstad Hospital, Rotterdam, Netherlands, 4Sint Franciscus Gasthuis, Rotterdam, Netherlands, 5Vlietland Hospital, Schiedam, Netherlands, 6Albert Schweitzer Hospital, Dordrecht, Netherlands, 7Admiraal de Ruyter hospital, Goes, 8Zorgsaam hospital, Terneuzen, Netherlands, 9Erasmus MC - University Medical Center, Rotterdam, Netherlands
Alberta Bone and Joint Institute and Department of Surgery, University of Calgary
Organization of Care Delivery for People with Arthritis: Models and Processes
A. M. Davis, Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, C. Cott, Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, L. Li, Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia, Vancouver, BC, M. Landry, Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, A. Jones, Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, R. Wong, Health Care and Outcomes Research, Toronto Western Research Institute, Toronto, ON, C. Frank, Alberta Bone and Joint Institute and Department of Surgery, University of Calgary, Calgary, AB, L. Bergeron, Canadian Arthritis Patient Alliance, Ottawa, ON, R. Birtwhistle, Centre for Studies in Primary Care and Family Medicine and Community Health and Epidemiology, Queen's University, Kingston, ON and E. M. Badley, Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON
Alder Hey
Investigating children's beliefs about Juvenile Arthritis: A Study Using Cognitive Interviewing
Daniela Ghio1, Wendy Thomson2, Eileen M. Baildam3, Kimme Hyrich2, Michael W. Beresford4, Carol Lydon5, Olivia Lloyd4, Gavin Cleary4, Liza J. McCann6, Childhood Arthritis Prospective Study (CAPS)7, Fiona Ulph1 and Lis Cordingley8, 1School of Psychological Sciences, University of Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Paediatric Rheumatology International Trials Organization, Genoa, Italy, 4Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 5Alder Hey, Liverpool, United Kingdom, 6Alder Hey Children's NHS Foundation Hospital, Liverpool, United Kingdom, 7Manchester, United Kingdom, 8School of Community Based Medicine, University of Manchester, Manchester, United Kingdom
Alder Hey Children's NHS Foundation Hospital
Proposal for the Development of An International Minimal Data Collection for Juvenile Dermatomyositis
Liza J. McCann, Alder Hey Children's NHS Foundation Hospital, Liverpool, United Kingdom, Clarissa A. Pilkington, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, L. Beard, UCL Institute of Child Health, London, United Kingdom, Angelo Ravelli, G. Gaslini Institute, Genova, Italy, Adam Huber, IWK Health Centre, Halifax, NS and Lucy R. Wedderburn, University College London (UCL), London, United Kingdom

Investigating children's beliefs about Juvenile Arthritis: A Study Using Cognitive Interviewing
Daniela Ghio1, Wendy Thomson2, Eileen M. Baildam3, Kimme Hyrich2, Michael W. Beresford4, Carol Lydon5, Olivia Lloyd4, Gavin Cleary4, Liza J. McCann6, Childhood Arthritis Prospective Study (CAPS)7, Fiona Ulph1 and Lis Cordingley8, 1School of Psychological Sciences, University of Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Paediatric Rheumatology International Trials Organization, Genoa, Italy, 4Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 5Alder Hey, Liverpool, United Kingdom, 6Alder Hey Children's NHS Foundation Hospital, Liverpool, United Kingdom, 7Manchester, United Kingdom, 8School of Community Based Medicine, University of Manchester, Manchester, United Kingdom
Alder Hey Children's NHS Foundation Trust
Investigating children's beliefs about Juvenile Arthritis: A Study Using Cognitive Interviewing
Daniela Ghio1, Wendy Thomson2, Eileen M. Baildam3, Kimme Hyrich2, Michael W. Beresford4, Carol Lydon5, Olivia Lloyd4, Gavin Cleary4, Liza J. McCann6, Childhood Arthritis Prospective Study (CAPS)7, Fiona Ulph1 and Lis Cordingley8, 1School of Psychological Sciences, University of Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Paediatric Rheumatology International Trials Organization, Genoa, Italy, 4Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 5Alder Hey, Liverpool, United Kingdom, 6Alder Hey Children's NHS Foundation Hospital, Liverpool, United Kingdom, 7Manchester, United Kingdom, 8School of Community Based Medicine, University of Manchester, Manchester, United Kingdom

Achieving Consensus on Quality Indicators for Pediatric Systemic Lupus Erythematosus
Joshua D. Pendl1, Matthew C. Hollander2, Shannen L. Nelson1, Xolti Morgan3, Nicolino Ruperto4, Michael W. Beresford5, Marisa Klein-Gitelman6, Marilynn G. Punaro7, Anne M. Stevens2, Tadej Avcin8, Graciela Espada9, Tsz-Leung Lee10, Yu-Lung Lau10, Jennifer L. Huggins1, Esi Morgan Dewitt1 and Hermine Brunner1, 1Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 2Seattle Children's Hospital, Seattle, WA, 3University of Cincinnati, Cincinnati, OH, 4PRINTO-IRCCS, Genova, Italy, 5Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 6Children's Memorial Hospital, Chicago, IL, 7Texas Scottish Rite Hospital, Dallas, TX, 8University Children's Hospital Ljubljana, Ljubljana, Slovenia, 9Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, 10The University of Hong Kong, Hong Kong, Hong Kong

Autoantibody Testing for Children on Biologic Therapies for Rheumatological Conditions: Results of Audit
Julie Duncan1, Jill Heath1, Eileen M. Baildam2, Gavin Cleary1, Michael W. Beresford1 and Liza J. McCann1, 1Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 2Paediatric Rheumatology International Trials Organization, Genoa, Italy

Defining Clinical Remission and Inactive Disease in Juvenile Systemic Lupus Erythematosus
Rina Mina, Cincinnati Children's Med Ctr, Cincinnati, OH, Laura E. Schanberg, Duke University Medical Center, Durham, NC, Marisa Klein-Gitelman, Children's Memorial Hospital, Chicago, IL, B. Anne Eberhard, Cohen Children's Hospital Medical Center, New Hyde Park, NY, Gloria Higgins, PRCSG, Columbus, OH, Karen Onel, University of Chicago, Chicago, IL, Nora G. Singer, MetroHealth Medical Center, Cleveland, OH, Kathleen M. O'Neil, Okla Univ Health Science Ctr, Oklahoma City, OK, Deborah M. Levy, The Hospital for Sick Children, Toronto, ON, Shannen L. Nelson, Cincinnati Children's Hospital, Cincinnati, OH, Wajeeha Yousaf, University of Cincinnati, Rubén J. Cuttica, Hospital de Pediatría Pedro de Elizalde, Buenos Aires, Argentina, Lori B. Tucker, BC Childrens Hospital, Vancouver, BC, Michael W. Beresford, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, Graciela Espada, Childrens Hosp Ricardo Gutierrez, Buenos Aires, Argentina, Angelo Ravelli, Istituto di Ricovero e Cura a Carattere Scientifico G. Gaslini, Genova, Italy, Alberto Martini, IRCCS G Gaslini, Pediatria II, Reumatologia, Genova, Italy, Edward H. Giannini, PRCSG-Cincinnati Children's Hospital Medical Center, Cincinnati, OH and Hermine Brunner, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Allegheny Singer Research Institute
Anti-beta2 Glycoprotein I IgA in Systemic Lupus Erythematosus Versus Controls
Ana-Maria Orbai1, Hong Fang1, Joan T. Merrill2, Graciela S. Alarcón3, Caroline Gordon4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3University of Alabama at Birmingham, Birmingham, AL, 4University of Birmingham, Birmingham, United Kingdom, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

A Prospective Study of Seizures in Systemic Lupus Erythematosus
John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge Sanchez-Guerrero6, Juanita Romero-Diaz7, Daniel Wallace8, Ann Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman13, M. Petri14, Paul R. Fortin15, Dafna D. Gladman16, Ian N. Bruce17, Kristjan Steinsson18, M.A. Dooley19, Munther A. Khamashta20, Graciela S. Alarcon21, Barri J. Fessler21, Rosalind Ramsey-Goldman22 and Susan Manzi23, 1Dalhousie University, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9Montreal General Hospital, Montreal, QC, 10McGill UHC/RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London, United Kingdom, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15Toronto Western Hospital, Toronto, ON, 16Toronto Western Hospital, University of Toronto, Toronto, ON, 17A, Manchester, United Kingdom, 18Landspital Univ Hospital, Reykjavik, Iceland, 19University of North Carolina at Chapel Hill, Chapel Hill, NC, 20Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 21University of Alabama at Birmingham, Birmingham, AL, 22Northwestern University Feinberg School of Medicine, Chicago, IL, 23Allegheny Singer Research Institute, Pittsburgh, PA

Predictors of Seizures in Systemic Lupus Erythematosus
John G. Hanly1, Murray B. Urowitz2, Li Su3, Caroline Gordon4, Sang-Cheol Bae5, Jorge Sanchez-Guerrero6, Juanita Romero-Diaz7, Daniel Wallace8, Ann E. Clarke9, Sasha Bernatsky10, E.M. Ginzler11, Joan T. Merrill12, David A. Isenberg13, Anisur Rahman13, M. Petri14, Paul R. Fortin15, Dafna D. Gladman16, Ian N. Bruce17, Kristjan Steinsson18, M.A. Dooley19, Munther A. Khamashta20, Graciela S. Alarcon21, Barri J. Fessler21, Rosalind Ramsey-Goldman22 and Susan Manzi23, 1Dalhousie University and Capital Health, Halifax, NS, 2Toronto Western Hospital and University of Toronto, Toronto, ON, 3MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, UK, Cambridge, United Kingdom, 4University of Birmingham, Birmingham, United Kingdom, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Mount Sinai Hospital/University Health Network, Toronto, ON, 7INCMNSZ, Mexico city, Mexico, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9Research Institute of the McGill Univ. Health, Montreal, QC, 10McGill UHC/RVH, Montreal, QC, 11SUNY-Downstate Medical Center, Brooklyn, NY, 12Oklahoma Medical Research Foundation, Oklahoma City, OK, 13University College London, London, United Kingdom, 14Johns Hopkins University School of Medicine, Baltimore, MD, 15Toronto Western Hospital, Toronto, ON, 16Toronto Western Hospital, University of Toronto, Toronto, ON, 17A, Manchester, United Kingdom, 18Landspital Univ Hospital, Reykjavik, Iceland, 19University of North Carolina at Chapel Hill, Chapel Hill, NC, 20Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 21University of Alabama at Birmingham, Birmingham, AL, 22Northwestern University Feinberg School of Medicine, Chicago, IL, 23Allegheny Singer Research Institute, Pittsburgh, PA

Post Hoc British Isles Lupus Assessment Group Index Mucocutaneous Organ Domain Item Analysis of Systemic Lupus Erythematosus Patients Treated in Phase 3 Belimumab Clinical Trials
Susan Manzi1, Dafna Gladman2, Sandra Navarra3, Jorge Sanchez-Guerrero4, David D'Cruz5, William Freimuth6, Z. John Zhong6, Greg Keenan6 and BLISS-52 and BLISS-76 Study Groups7, 1Allegheny Singer Research Institute, Pittsburgh, PA, 2Toronto Western Hospital, Toronto, ON, 3University of Santo Tomas Hospital, Manila, Philippines, 4Mount Sinai Hospital/University Health Network, Toronto, ON, 5St. Thomas' Hospital, London, United Kingdom, 6Human Genome Sciences, Inc., Rockville, MD, 7Multicenter

Anti-C1q Antibody in Systemic Lupus Erythematosus
Ana-Maria Orbai1, Gunnar K. Sturfelt2, Ola Nived3, Hong Fang1, Graciela S. Alarcón4, Caroline Gordon5, Joan T. Merrill6, Paul R. Fortin7, Ian N. Bruce8, David A. Isenberg9, Daniel J. Wallace10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University Hospital Lund, Lund, Sweden, 3University Hospital, Lund, Sweden, 4University of Alabama at Birmingham, Birmingham, AL, 5University of Birmingham, Birmingham, United Kingdom, 6Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Toronto Western Hospital, Toronto, ON, 8A, Manchester, United Kingdom, 9University College London, London, United Kingdom, 10Cedars-Sinai/UCLA, Los Angeles, CA, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

Feasibility of Implementing a Lifestyle Intervention and Its Effects on Metabolic Parameters and Adipokines in Overweight and Obese Patients with Systemic Lupus Erythematosus
Nehal Shah1, Amy D. Rickman2, Anne E. Mishler2, Nicole L. Wilson3, John M. Jakicic2, Susan Manzi4 and Amy H. Kao4, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh, PA, 3W Penn Allegheny Health System, Pittsburgh, PA, 4Allegheny Singer Research Institute, Pittsburgh, PA

Prevalence of Direct Coombs Test in Systemic Lupus Erythematosus.  Clinical and Immunologic Associations
Ana-Maria Orbai1, Hong Fang1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Laurence S. Magder22, Systemic Lupus International Collaborating Clinics (SLICC)23 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6A, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University Feinberg School of Medicine, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22University of Maryland, Baltimore, MD, 23Chicago

Derivation and Validation of Systemic Lupus International Collaborating Clinics Classification Criteria for Systemic Lupus Erythematosus
Michelle Petri1, Ana-Maria Orbai1, Graciela S. Alarcón2, Caroline Gordon3, Joan T. Merrill4, Paul R. Fortin5, Ian N. Bruce6, David A. Isenberg7, Daniel J. Wallace8, Ola Nived9, Gunnar K. Sturfelt10, Rosalind Ramsey-Goldman11, Sang-Cheol Bae12, John G. Hanly13, Jorge Sanchez-Guerrero14, Ann E. Clarke15, Cynthia Aranow16, Susan Manzi17, Murray B. Urowitz18, Dafna D. Gladman19, Kenneth C. Kalunian20, Melissa I. Costner21, Hong Fang1, Systemic Lupus International Collaborating Clinics (SLICC)22 and Laurence S. Magder23, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Birmingham, Birmingham, United Kingdom, 4Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Toronto Western Hospital, Toronto, ON, 6The University of Manchester, Manchester, United Kingdom, 7University College London, London, United Kingdom, 8Cedars-Sinai/UCLA, Los Angeles, CA, 9University Hospital, Lund, Sweden, 10University Hospital Lund, Lund, Sweden, 11Northwestern University, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Dalhousie University and Capital Health, Halifax, NS, 14Mount Sinai Hospital/University Health Network, Toronto, ON, 15Research Institute of the McGill Univ. Health, Montreal, QC, 16Feinstein Institute for Medical Research, Manhasset, NY, 17Allegheny Singer Research Institute, Pittsburgh, PA, 18Toronto Western Hospital and University of Toronto, Toronto, ON, 19Toronto Western Research Institute, University of Toronto, University Health Network, Toronto, ON, 20UCSD School of Medicine, La Jolla, CA, 21North Dallas Dermatology Assoc, Dallas, TX, 22Chicago, 23University of Maryland, Baltimore, MD

Lupus Nephritis Susceptibility Markers in PDGRFA-GSX2, SLC5A11, ID4, and HAS2-SNTB1 Regions Identified From a Meta-Analysis of Genome Wide Association Studies of Women with Systemic Lupus Erythematosus
Sharon A. Chung1, Elizabeth E. Brown2, Adrienne H. Williams3, Tushar Bhangale4, Paula S. Ramos3, Julie T. Ziegler3, Barry I. Freedman3, Robert P. Kimberly2, Timothy J. Vyse5, Peter K. Gregersen6, Chaim O. Jacob7, Marta E. Alarcon-Riquelme8, Betty P. Tsao9, John B. Harley10, Timothy W. Behrens4, M. Petri11, M. Ilyas Kamboh12, F. Yesim Demirci12, Susan Manzi13, Lindsey A. Criswell1, Kathy L. Moser14, Patrick M. Gaffney14, Robert R. Graham4 and Carl D. Langefeld3, 1University of California, San Francisco, San Francisco, CA, 2University of Alabama at Birmingham, Birmingham, AL, 3Wake Forest School of Medicine, Winston-Salem, NC, 4Genentech, Inc., South San Francisco, CA, 5King's College London, London, United Kingdom, 6Feinstein Institute for Medical Research, Manhasset, NY, 7University of Southern California, Los Angeles, CA, 8Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 9University of California, Los Angeles, Los Angeles, CA, 10Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Johns Hopkins University School of Medicine, Baltimore, MD, 12University of Pittsburgh, Pittsburgh, PA, 13Allegheny Singer Research Institute, Pittsburgh, PA, 14Oklahoma Medical Research Foundation, Oklahoma City, OK

Lifestyle Intervention for Health-Related Quality of Life in Overweight and Obese Patients with Systemic Lupus Erythematosus: A Pilot Study
Carol M. Greco1, Amy D. Rickman1, Nehal Shah1, Anne E. Mishler1, Nicole L. Wilson2, John M. Jakicic1, Susan Manzi3 and Amy H. Kao3, 1University of Pittsburgh, Pittsburgh, PA, 2W Penn Allegheny Health System, Pittsburgh, PA, 3Allegheny Singer Research Institute, Pittsburgh, PA
Almenara Hospital IPSs
The Protective Effect of Antimalarials On Thrombovascular Events In Latin American Systemic Lupus Erythematosus Patients
Guillermo J. Pons-Estel, Servicio de Enfermedades Autoinmunes, Hospital Clìnic Barcelona, Barcelona, Spain, Graciela S. Alarcón, University of Alabama at Birmingham, Birmingham, AL, Daniel Wojdyla, Universidad Nacional de Rosario, Argentina, Rosario, Argentina, Ana I. Marcos, Hospital Interzonal General de Agudos “General San Martin, La Plata, La Plata, Argentina, Alejandro J. Alvarellos, Hospital Privado, Cordoba, Argentina, Antonio A. Iglesias-Gamarra, Universidad Nacional, Bogota, Colombia, Maria H. Esteva-Spinetti, Centro Clinico San Cristobal, San Cristobal, Venezuela, Lilian Costallat, Faculdade de Ciencias Medicas, Universidade Estadual de Campinas, Campinas, Brazil, Nilzio A. Silva, Faculdade de Medicina, Universidade Federal de Goias, Goiania, Brazil, Gloria Vázquez, Universidad de Antioquia, Hospital Universitario “San Vicente de Paul”, Medellín, Colombia, Maria Loreto Massardo, Catholic University of Chile, Santiago, Chile, Marlene Guibert-Toledano, Centro de Investigaciones Médico Quirúrgicas, Habana, La Habana, Cuba, Guillermo F. Huerta-Yáñez, Hospital de Especialidades Miguel Hidalgo, Aguascalientes, Mexico, Mariano Cucho-Venegas, Almenara Hospital IPSs, Lima, Peru and Bernardo Pons-Estel, Hospital Provincial de Rosario, Rosario, Argentina
Altoona Center for Clinical Research
A Study of Tanezumab in Adults with Chronic Low Back Pain (NCT00876187)
Alan J. Kivitz1, Joseph Gimbel2, Candace Bramson3, Mary Ann Nemeth3, David Keller4, Mark T. Brown4, Christine R. West5 and Kenneth M. Verburg4, 1Altoona Center for Clinical Research, Duncansville, PA, 2Arizona Research Center, Phoenix, AZ, 3Pfizer, Groton, 4Pfizer, Groton, CT, 5Pfizer, Williamston, MI

Rilonacept Efficacy for Gout Flare Prevention in Patients with Tophi and/or Polyarticular Disease Who Initiate Uric Acid-Lowering Therapy
Robert Terkeltaub1, H. Ralph Schumacher2, Alan J. Kivitz3, Steven P. Weinstein4, Richard Wu4, Rebecca Gall4 and Robert R. Evans4, 1VA Medical Ctr, San Diego, CA, 2VA Medical Center and University of Pennsylvania, Philadelphia, PA, 3Altoona Center for Clinical Research, Duncansville, PA, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Efficacy of Canakinumab on Re-Treatment in Gouty Arthritis Patients with Limited Treatment Options: 24-Week Results From β-RELIEVED and β-RELIEVED-II Studies
R. Alten1, A. So2, Alan J. Kivitz3, T. Bardin4, M. Bloch5, A. Gimona6, A. Widmer6, G. Krammer6, N. Schlesinger7 and H. R. Schumacher8, 1Charité Teaching Hospital–Schlosspark-Klinik, Berlin, Germany, 2CHUV, Lausanne, Switzerland, 3Altoona Center for Clinical Research, Duncansville, PA, 4Hôpital Lariboisière, Paris, France, 5Holdsworth House Medical Practice, Sydney, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ, 8University of Pennsylvania and VA Medical Center, Philadelphia, PA

Assessment of Immune Responses to Pneumococcal and Influenza Vaccines in Patients with Rheumatoid Arthritis Receiving Certolizumab Pegol
Alan J. Kivitz1, Joy Schechtman2, Michele Texter3, Andreas Fichtner4 and Elliot Chartash*3, 1Altoona Center for Clinical Research, Duncansville, PA, 2SunValley Arthritis Center, Peoria, AZ, 3UCB, Smyrna, GA, 4UCB Biosciences GmBH, Monheim, Germany

Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study
Mark C. Genovese, Stanford University Medical Center, Palo Alto, CA, Alan J. Kivitz, Altoona Center for Clinical Research, Duncansville, PA, J. Abraham Simon Campos, Centro De Especialidades Médicas, Merida, Mexico, Maria Rell-Bakalarska, Rheumatology and Osteoporosis Outpatient Clinic, Warsaw, Poland, Roy M. Fleischmann, Metroplex Clinical Research Center, Dallas, TX, Martine Jasson, Sanofi, Paris, France, Allen R. Radin, Regeneron Pharmaceuticals Inc, Tarrytown, NY, Xiaohong Huang, Sanofi, Bridgewater, NJ and Tom W. J. Huizinga, Leiden University Medical Centre, Leiden, Netherlands
Altoona Ctr for Clinical Research
Improvement & Maintenance of Hemoglobin Levels Among Rheumatoid Arthritis,Psoriatic Arthritis&Ankylosing Spondylitis Patients with Anemia of Inflammation After Treatment with Golimumab:3 Year Pooled Analysis
Daniel E. Furst, UCLA, Los Angeles, CA, Tim Gathany, Johnson & Johnson Pharmaceutical Services, LLC, Horsham, PA, Jonathan Kay, University of Massachusetts Memorial Medical Center/University of Massachusetts Medical School, Worcester, MA, Mary Chester Wasko, Temple University School of Medicine, Pittsburgh, PA, Edward Keystone, University of Toronto, Toronto, ON, Arthur Kavanaugh, University of California San Diego, San Diego, CA, Atul Deodhar, Oregon Health & Science University, Portland, OR, Frederick T. Murphy, Altoona Ctr for Clinical Research, Duncansville, PA, Chenglong Han, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA and Mittie K. Doyle, Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC/University of Pennsylvania School of Medicine, Malvern/Philadelphia, PA

Golimumab Use and Sustained Clinical Response in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-Tumor Necrosis Factor Alpha Agents
Josef Smolen1, Jonathan Kay2, Robert Landewe3, Eric L. Matteson4, Norman B. Gaylis5, J. Wollenhaupt6, Frederick T. Murphy7, O. Zamani8, Yiying Zhou9, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2University of Massachusetts Medical School, Worcester, MA, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Rochester, MN, 5Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6Eilbeck Hospital, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Rheumazentrum Favoriten, Wien, Austria, 9Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA
Alysis Care Group
What Is A Realistic Treatment Target in Rheumatoid Arthritis: Remission or Minimal Disease Activity?
Yvonne M.R. de Punder1, Jaap Fransen1, Wietske Kievit1, Pieternella Houtman2, Henk Visser3, Mart A.F.J. van de Laar4 and Piet LC van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Medical Centre Leeuwarden, Leeuwarden, Netherlands, 3Alysis Care Group, Arnhem, Netherlands, 4Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands

Discontinuation of Dmards in patients with Rheumatoid Arthritis Treated with Tumor necrosis factor Blocking Agents: an Analysis in the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry
Sanne van Dartel1, Jaap Fransen1, Wietske Kievit1, Alfons den Broeder2, Henk Visser3, Andre Hartkamp4, Mart AF van de Laar5 and Piet Van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Sint Maartenskliniek, Nijmegen, Netherlands, 3Alysis Care Group, Arnhem, Netherlands, 4Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands, 5Medisch Spectrum Twente & Twente University, Enschede, Netherlands
Ambroise Paré Hospital
Distinct Rheumatological Features Induced by Aromatase Inhibitors in Breast Cancer Patients: A Prospective Multicenter Cohort Study of 138 Women with Breast Cancer
Serge Perrot1, Paul Cottu2, Xavier Decleves1, Laure Chauvenet1, Christophe Tournigand3, Jean-Yves Pierga2, Didier Bouhassira4 and Francoise Laroche3, 1Hopital Hotel Dieu, Paris, France, 2Curie Institute, Paris, France, 3Saint Antoine Hospital, Paris, France, 4Ambroise Paré Hospital, Boulogne, France

Family-Based Association Study of SPA3, a New Susceptibility Locus for Spondyloarthritis on 6p11-q11
Félicie Costantino1, Brigitte Izac1, Gilles Chiocchia2, Roula Said-Nahal3, Ariane Leboime3, Elena Zinovieva1, Diana Zelenika4, Maxime A. Breban3 and Henri-Jean Garchon1, 1Institut Cochin, Paris, France, 2Institut Cochin, 75014 Paris, France, 3Ambroise Paré Hospital, Boulogne-Billancourt, France, 4Centre National de Génotypage, Evry
Ambulant Centres f. Rheumatology
Impact of the US7 Score for Diagnosis and Prognosis of Rheumatoid Arthritis In Undifferentiated Early Arthritis
Jörg Kaufmann, Rheumatologist, Ludwigsfelde, Germany, Susanne Seel, Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany and Anne-Eve Roske, Roche Pharma AG, Grenzach-Wyhlen, Germany

Comparison of Tocilizumab and TNF Inhibitor Therapy in Rheumatoid Arthritis
Jörg Kaufmann, Rheumatologist, Ludwigsfelde, Germany, Susanne Seel, Ambulant Centres f. Rheumatology, Ludwigsfelde, Germany and Anne-Eve Roske, Roche Pharma AG, Grenzach-Wyhlen, Germany
AMC / University of Amsterdam F4-105
Role of T-cell Receptor Sequencing in Rheumatic Diseases
Niek De Vries, AMC / University of Amsterdam F4-105, Amsterdam, Netherlands
American College of Physicians
CORC Forum: Payment Reform Options
Michael S. Barr, American College of Physicians, Washington, DC
American College of Rheumatology
Quality of Care for Rheumatoid Arthritis and Osteoporosis: Results From the U.S. Medicare Physician Quality Reporting Program
Jeffrey R. Curtis1, Pradeep Sharma2, Tarun Arora3, Aseem Bharat3, Michael Morrisey, Kenneth G. Saag3, Itara Barnes5 and Elizabeth S. Delzell3, 1Univ of Alabama-Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, 3University of Alabama at Birmingham, Birmingham, AL, 4American College of Rheumatology, Atlanta, GA

Measuring Quality of Care in Juvenile Idiopathic Arthritis: The Pediatric Rheumatology Care and Outcomes Improvement Network 
Esi Morgan DeWitt, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, Timothy Beukelman, Univ of Alabama-Birmingham, Birmingham, AL, Beth S. Gottlieb, Schneider Children's Hospital, New Hyde Park, NY, Nancy Griffin, Cincinnati Children's Hospital Medical Center, Cincinnati, Yukiko Kimura, Hackensack Univ Medical Ctr, Hackensack, NJ, Itara Barnes, American College of Rheumatology, Atlanta, GA and Murray H. Passo, MUSC, Charleston, SC

Practical Auditing Guidelines and Procedures for Physician Practices
Melesia Tillman, American College of Rheumatology, Atlanta, GA

ICD-10 & HIPAA 5010 - Ready or Not…It's Coming!
Antanya Chung, American College of Rheumatology, Atlanta, GA

Bringing it All Together: Adoption, Implementation and Meaningful Use
Itara Barnes, American College of Rheumatology, Atlanta, GA

ACR Certified Rheumatology Coder Course
Antanya Chung, American College of Rheumatology, Atlanta, GA

ACR Certified Rheumatology Coder Examination
Melesia Tillman, American College of Rheumatology, Atlanta, GA
Amgen
Risk for Herpes Zoster in Patients with Rheumatoid and Psoriatic Arthritis
Dimitrios A. Pappas1, George Reed2, Michele M. Hooper3, Ying Shan2, Bojena Bitman4, Jeffrey D. Greenberg5, Deborah Wenkert3, Jie Zhang6, Joel M. Kremer7 and Jeffrey R. Curtis6, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMass Medical School, Worcester, MA, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA, 5New York University School of Medicine, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7Albany Medical College and The Center for Rheumatology, Albany, NY

Is Long-Term Etanercept Monotherapy Ever An Option in a Patient with Moderate to Severe Rheumatoid Arthritis (RA)?
Roy M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, Michael H. Schiff, Rheumatology Division, University of Colorado, Denver, CO, Deborah Wenkert, Amgen, Thousand Oaks, CA, Bojena Bitman, Amgen Inc., South San Francisco, CA, Sandeep Chaudhari, KForce Clinical Research, Tampa, FL, Jie Liu, SimulStat Incorporated, San Diego, CA, Grace S. Park, Amgen Inc., Thousand Oaks, CA and Debra J. Zack, Amgen Inc, Thousand Oaks, CA

Introduction to Biosimilars
Thomas Felix, Amgen, Thousand Oaks, CA

Rheumatologists in the Pharmaceutical Industry
Wayne H. Tsuji, Amgen, Seattle, WA
Amgen Canada Inc.
Number of Cardiovascular Risk Factors May be Associated with Higher Disease Activity Severity. Exploratory Analysis of Baseline Data from the Canadian Methotrexate and Etanercept Outcome Study: A Randomized Trial of Etanercept and Methotrexate vs Etanercept Alone in Rheumatoid Arthritis
Janet Pope, Univ of Western Ontario, London, ON, Edward Keystone, University of Toronto, Toronto, ON, Boulos Haraoui, Institut de Rhumatologie, Montreal, QC, J. Carter Thorne, Southlake Regional Health Centre, Newmarket, Newmarket, ON and Melanie Poulin-Costello, Amgen Canada Inc., Mississauga, ON
Amgen Inc
National and Regional Dosing Patterns of Tumor Necrosis Factor Blocker Therapy in Biologic-Naïve Rheumatoid Arthritis Patients in US Health Plans
Amie T. Joyce1, Shravanthi R. Gandra2, Kathy M. Fox3, Timothy W. Smith1 and Michael Pill4, 1IMS Health, Watertown, MA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4Gemini HealthCare, Westbrook, CT

Factors Associated with Relapse of Remission in Rheumatoid Arthritis
Leslie R. Harrold1, George Reed1, David H. Collier2, Grace S. Park2, Hong Chang3, Andrew S. Koenig4, Katherine C. Saunders5, Debra J. Zack6, Joel M. Kremer7 and Jeffrey D. Greenberg8, 1UMass Medical School, Worcester, MA, 2Amgen Inc., Thousand Oaks, CA, 3Tufts Medical Center, Boston, MA, 4Pfizer Inc., Collegeville, PA, 5CORRONA, Inc., Southborough, MA, 6Amgen Inc, Thousand Oaks, CA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8New York University School of Medicine, New York, NY

Costs of Tumor Necrosis Factor Blockers Per Treated Rheumatoid Arthritis Patient Using Real-World Drug Data in US Commercially-Insured Population
Vernon F. Schabert1, Shravanthi R. Gandra2, Crystal Watson2, Jason Yeaw1, Seth Goodman1, Kathy M. Fox3, Sandra Milev4 and David J. Harrison2, 1IMS Consulting Group, Alexandria, VA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4IMS Brogan, Ottawa, ON

Is Long-Term Etanercept Monotherapy Ever An Option in a Patient with Moderate to Severe Rheumatoid Arthritis (RA)?
Roy M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, Michael H. Schiff, Rheumatology Division, University of Colorado, Denver, CO, Deborah Wenkert, Amgen, Thousand Oaks, CA, Bojena Bitman, Amgen Inc., South San Francisco, CA, Sandeep Chaudhari, KForce Clinical Research, Tampa, FL, Jie Liu, SimulStat Incorporated, San Diego, CA, Grace S. Park, Amgen Inc., Thousand Oaks, CA and Debra J. Zack, Amgen Inc, Thousand Oaks, CA

Tumor Necrosis Factor Blocker Treatment Patterns After Discontinuation within the First Year of Therapy Initiation in Rheumatoid Arthritis Patients in a Real-World Managed Care Setting
Machaon Bonafede1, Crystal Watson2, Kathy M. Fox3, Nicole Princic1 and Shravanthi R. Gandra2, 1Thomson Reuters Healthcare, Cambridge, MA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD

Anti-Tumor Necrosis Factor Dose Escalation Among Biologic Naïve Rheumatoid Arthritis Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation
Machaon Bonafede1, Kathy M. Fox2, Kathleen L. Wilson1 and Shravanthi R. Gandra3, 1Thomson Reuters Healthcare, Cambridge, MA, 2Strategic Healthcare Solutions, LLC, Monkton, MD, 3Amgen Inc, Thousand Oaks, CA

Comparing Costs of Tumor Necrosis Factor Blockers Per Treated Patient for Psoriatic Arthritis Using Real-World Data in US Managed Care
Vernon F. Schabert1, Shravanthi R. Gandra2, Crystal Watson2, Seth Goodman1, Kathy M. Fox3, Jason Yeaw1, Sandra Milev4 and David J. Harrison2, 1IMS Consulting Group, Alexandria, VA, 2Amgen Inc, Thousand Oaks, CA, 3Strategic Healthcare Solutions, LLC, Monkton, MD, 4IMS Brogan, Ottawa, ON
Amgen Inc.
Factors Associated with Relapse of Remission in Rheumatoid Arthritis
Leslie R. Harrold1, George Reed1, David H. Collier2, Grace S. Park2, Hong Chang3, Andrew S. Koenig4, Katherine C. Saunders5, Debra J. Zack6, Joel M. Kremer7 and Jeffrey D. Greenberg8, 1UMass Medical School, Worcester, MA, 2Amgen Inc., Thousand Oaks, CA, 3Tufts Medical Center, Boston, MA, 4Pfizer Inc., Collegeville, PA, 5CORRONA, Inc., Southborough, MA, 6Amgen Inc, Thousand Oaks, CA, 7Albany Medical College and The Center for Rheumatology, Albany, NY, 8New York University School of Medicine, New York, NY

The Analysis of Denosumab Discontinuation and Associated Fracture Incidence in the FREEDOM Trial
Jacques P. Brown1, Jens-Erik Beck Jensen2, Chris Recknor3, Christian Roux4, Ove Tørring5, Matt Austin6, Andrea Wang6, Andreas Grauer6 and Rachel B. Wagman6, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2Hvidovre Hospital, Hvidovre, Denmark, 3United Osteoporosis Centers, Gainesville, GA, 4Paris Descartes University, Paris, France, 5Institution for Clinical Science and Education Södersjukhuset Karolinska Institutet, Stockholm, Sweden, 6Amgen Inc., Thousand Oaks, CA

Extended Safety Observations From Denosumab Administration in Postmenopausal Women From the FREEDOM and FREEDOM Extension Trials
J. P. Brown1, H. G. Bone2, R. Chapurlat3, C. Libanati4, M. L. Brandi5, E. Czerwinski6, M.-A. Krieg7, Z. Man8, D. Mellström9, S. C. Radominski10, J.-Y. Reginster11, H. Resch12, J. A. Román Ivorra13, C. Roux14, N. S. Daizadeh4, A. Grauer4, S. R. Cummings15 and S. Papapoulos16, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2Michigan Bone & Mineral Clinic, Detroit, MI, 3Hôpital Edouard Herriot, Lyon, France, 4Amgen Inc., Thousand Oaks, CA, 5University of Florence, Florence, Italy, 6Krakow Medical Center, Krakow, Poland, 7University Hospital of Lausanne, Lausanne, Switzerland, 8Centro TIEMPO, Buenos Aires, Argentina, 9Sahlgrenska University Hospital, Göteborg, Sweden, 10Universidade Federal do Paraná, Curitiba, Brazil, 11University of Liège, Liège, Belgium, 12St. Vincent Hospital, Vienna, Austria, 13Hospital Universitario La Fe, Valencia, Spain, 14Paris Descartes University, Paris, France, 15San Francisco Coordinating Center, CPMC Research Institute, San Francisco, CA, 16Leiden University Medical Center, Leiden, Netherlands

Effects of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover Over 8 Years
Michael R. McClung1, E. Michael Lewiecki2, Michael A. Bolognese3, Munro Peacock4, Richard L. Weinstein5, Beiying Ding6, M. L. Geller6, Andreas Grauer6, R.B. Wagman6 and Paul D. Miller7, 1Oregon Osteoporosis Center, Portland, OR, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 3Bethesda Health Research Center, Bethesda, MD, 4Indiana University, Indianapolis, IN, 5Diablo Clinical Research, Inc., Walnut Creek, CA, 6Amgen Inc., Thousand Oaks, CA, 7Colorado Center for Bone Research, Lakewood, CO

Transitioning to Denosumab Leads to Further Increases in BMD throughout the Skeleton in Postmenopausal Women Who Received 5 or More Years of Continuous Alendronate Therapy
Michael A. Bolognese1, Henry G. Bone2, David L. Kendler3, Maria Luisa Brandi4, Anthony Hodsman5, Philippe Orcel6, Hoi-Shen Radcliffe7, Andreas Grauer8 and Cesar Libanati8, 1Bethesda Health Research Center, Bethesda, MD, 2Michigan Bone and Mineral Clinic, Detroit, MI, 3University of British Columbia, Vancouver, BC, 4University of Florence, Florence, Italy, 5University of Western Ontario St. Joseph's Health Center, London, ON, 6Lariboisière University Hospital, Paris, France, 7Amgen Inc., Cambridge, United Kingdom, 8Amgen Inc., Thousand Oaks, CA

Risk for Herpes Zoster in Patients with Rheumatoid and Psoriatic Arthritis
Dimitrios A. Pappas1, George Reed2, Michele M. Hooper3, Ying Shan2, Bojena Bitman4, Jeffrey D. Greenberg5, Deborah Wenkert3, Jie Zhang6, Joel M. Kremer7 and Jeffrey R. Curtis6, 1Columbia University, College of Physicians & Surge, New York, NY, 2UMass Medical School, Worcester, MA, 3Amgen, Thousand Oaks, CA, 4Amgen Inc., Thousand Oaks, CA, 5New York University School of Medicine, New York, NY, 6University of Alabama at Birmingham, Birmingham, AL, 7Albany Medical College and The Center for Rheumatology, Albany, NY

Is Long-Term Etanercept Monotherapy Ever An Option in a Patient with Moderate to Severe Rheumatoid Arthritis (RA)?
Roy M. Fleischmann, University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, Michael H. Schiff, Rheumatology Division, University of Colorado, Denver, CO, Deborah Wenkert, Amgen, Thousand Oaks, CA, Bojena Bitman, Amgen Inc., South San Francisco, CA, Sandeep Chaudhari, KForce Clinical Research, Tampa, FL, Jie Liu, SimulStat Incorporated, San Diego, CA, Grace S. Park, Amgen Inc., Thousand Oaks, CA and Debra J. Zack, Amgen Inc, Thousand Oaks, CA

Denosumab Decreases Cortical Porosity in Postmenopausal Women with Low Bone Mineral Density
C. Libanati1, S. K. Boyd2, K. K. Nishiyama2, R. M. Zebaze3, D. A. Hanley2, J. R. Zanchetta4, Thierry Thomas5, S. Boutroy6, C. E. Bogado4, M. Austin1 and E. Seeman7, 1Amgen Inc., Thousand Oaks, CA, 2University of Calgary, Calgary, AB, 3University of Melbourne, Melbourne, Australia, 4Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 5INSERM U1059 and University Hospital, Saint-Étienne, France, 6INSERM U831 and Université de Lyon, Lyon, France, 7Austin and Repatriation Medical Centre, University of Melbourne, Melbourne, Australia

Six Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis:  Results From the First Three Years of the FREEDOM Extension
J.P. Brown1, H. G. Bone2, R. Chapurlat3, N. Franchimont4, M. L. Brandi5, E. Czerwinski6, M.-A. Krieg7, Z. Man8, D. Mellström9, S. C. Radominski10, J.-Y. Reginster11, H. Resch12, J. A. Román Ivorra13, C. Roux14, N. S. Daizadeh4, M. L. Geller4, S. Smith4, R.B. Wagman4, S. R. Cummings15 and S. Papapoulos16, 1CHUQ-CHUL Research Centre, Laval University, Quebec City, QC, 2Michigan Bone & Mineral Clinic, Detroit, MI, 3Hôpital Edouard Herriot, Lyon, France, 4Amgen Inc., Thousand Oaks, CA, 5University of Florence, Florence, Italy, 6Krakow Medical Center, Krakow, Poland, 7University Hospital of Lausanne, Lausanne, Switzerland, 8Centro TIEMPO, Buenos Aires, Argentina, 9Sahlgrenska University Hospital, Göteborg, Sweden, 10Universidade Federal do Paraná, Curitiba, Brazil, 11University of Liège, Liège, Belgium, 12St. Vincent Hospital, Vienna, Austria, 13Hospital Universitario La Fe, Valencia, Spain, 14Paris Descartes University, Paris, France, 15San Francisco Coordinating Center, CPMC Research Institute, and UCSF, San Francisco, CA, 16Leiden University Medical Center, Leiden, Netherlands
Amgen, Inc.
Amiens Hospital
Evaluation of the Impact of Recurrent Ischemic Digital Ulcers on Hand Disability in Patients with Systemic Sclerosis (ECLIPSE). Report of the Cohort At the Time of Inclusion
Luc Mouthon, Hopital Cochin, Paris, France, Patrick Carpentier, CHU Grenoble, Grenoble, France, Catherine Lok, Amiens Hospital, France, Eve Puzenat, Besançon, Besançon, France, Pierre Clerson, Orgametrie, Roubaix, Virginie Gressin, Actelion France, Paris, France and Marie-Aleth Richard, Marseille, Paris, France
Amiens University Hospital
Performances of the 2010 ACR/EULAR Classification Criteria of Rheumatoid Arthritis: Comparison with 1987 ACR Criteria in the Community-Based Vera Cohort
Julia Nicolau Jr.1, Patrick Boumier2, Alain Daragon1, Othman Mejjad1, Jean-François Ménard1, Sophie Pouplin1, Olivier Vittecoq3, Patrice Fardellone2 and Xavier Le Loët Sr.3, 1Rouen University Hospital, Rouen, France, 2Amiens University Hospital, Amiens, France, 3Rouen University Hospital and Inserm U 905, Rouen, France

Takayasu Arteritis: Treatment and Outcome. An American Cohort of 126 Patients
Jean Schmidt1, Tanaz A. Kermani2, A. Kirstin Bacani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1Amiens University Hospital, Amiens, France, 2Mayo Clinic, Rochester, MN

Tumor Necrosis Factor Inhibitors in Patients with Takayasu Arteritis: Experience From a Referral Center with Long-Term Follow-up
Jean Schmidt1, Tanaz A. Kermani2, A. Kirstin Bacani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1Amiens University Hospital, Amiens, France, 2Mayo Clinic, Rochester, MN

Statin Exposure and Risk of Giant Cell Arteritis: A Case Control Study
Jean Schmidt1, Tanaz A. Kermani2, Cynthia S. Crowson2, Eric L. Matteson2 and Kenneth J. Warrington2, 1Amiens University Hospital, Amiens, France, 2Mayo Clinic, Rochester, MN
Analysis Group, Inc.
Economic Burden of Psoriatic Arthritis and Diabetes in Patients with Psoriatic Arthritis in the United States
Annie Guerin1, Genevieve Gauthier1, Robert Day2, Zeba Khan2 and Frank Zhang2, 1Analysis Group, Inc., Montreal, QC, 2Celgene Corporation, Summit,, NJ

Economic Burden of Psoriatic Arthritis and Obesity in Patients with Psoriatic Arthritis in the United States
Frank Zhang1, Annie Guerin2, Dominick Latremouille-Viau2, Robert Day1 and Zeba Khan1, 1Celgene Corporation, Summit,, NJ, 2Analysis Group, Inc., Montreal, QC

Uncontrolled Serum Uric Acid Is Associated with An Increased Risk of Developing Renal Disease In Veterans with Gout
Eswar Krishnan1, Hari Sharma2, Bhavik J. Pandya3, Maryna Marynchenko2, Andrew Yu2, Eric Wu2, Jinan Liu4 and Lizheng Shi4, 1Stanford University, Stanford, CA, 2Analysis Group, Inc., Boston, MA, 3Takeda Pharmaceuticals International, Inc., Deerfield, IL, 4Tulane University, New Orleans, LA

Prevalence of Autoimmune Diseases and Other Comorbidities in Patients with Psoriatic Arthritis in the United States
Frank Zhang1, Annie Guerin2, Genevieve Gauthier2, Robert Day1 and Zeba Khan1, 1Celgene Corporation, Summit,, NJ, 2Analysis Group, Inc., Montreal, QC

Uncontrolled Serum Uric Acid In Veteran Gout Patients Is Associated with a Higher Risk of Diabetes
Bhavik J. Pandya1, Maryna Marynchenko2, Hari Sharma2, Andrew Yu2, Eric Wu2, Lizheng Shi3, Jinan Liu3 and Eswar Krishnan4, 1Takeda Pharmaceuticals International, Inc., Deerfield, IL, 2Analysis Group, Inc., Boston, MA, 3Tulane University, New Orleans, LA, 4Stanford University, Stanford, CA
Anatomopathology, Groupe Hospitalier Pitié-Salpetrière
Immunological Signature Discriminates Active and Inactive Patients with Takayasu Arteritis
David Saadoun1, Benjamin Terrier2, Guillaume Geri3, Wahiba Chaara4, Michelle Rosenzwajg5, Nathalie Costedoat-Chalumeau3, Pierre Fourret6, Lucile Musset3, Adrien Six4, David Klatzmann5 and Patrice Cacoub3, 1Department of Internal Medicine and Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, 2Pitié-Salpêtrière Hospital, Paris, France, 3CHU Pitié-Salpêtrière, Paris, France, 4Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Paris, France, 5Laboratory I3 “Immunology, Immunopathology, Immunotherapy”, UMR CNRS 7211, INSERM U959, Paris, France, 6Anatomopathology, Groupe Hospitalier Pitié-Salpetrière, Paris, France
Anatomy and Cell Biology, Wayne State University School of Medicine
A Novel Role of h2-Calponin in the Development of Anti-GPI Serum-Induced Arthritis
M. Moazzem Hossain1, Qi Quan Huang2, Linda D. Hazlet3, Sharon A. McClellan3, Richard M. Pope2 and J.-P. Jin1, 1Departments of Physiology, Wayne State University School of Medicine, Detroit, MI, 2Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI
Anna Meyer Children's Hospital
Current Evidence of Methotrexate Efficacy in Childhood Chronic Uveitis: A Systematic Review and Meta-Analysis
Gabriele Simonini1, Priyamvada Paudyal2, Gareth T. Jones2, Rolando Cimaz1 and Gary J. Macfarlane2, 1Anna Meyer Children's Hospital, Florence, Italy, 2University of Aberdeen, Aberdeen, United Kingdom

Emperipolesis and Cell Death in NOD2-Related Blau Syndrome and Crohn's Disease   
Carl EI Janssen1, Carlos D. Rose2, A. Naranjo3, Brigitte Bader-Meunier4, Rolando Cimaz5, Miroslav Harjacek6, Pierre Quartier7, Rebecca Ten Cate8, Caroline Thomée9, Isabelle Cleynen1, Tammy M. Martin10, Gert De Hertogh1, Tania Roskams1, Valeer J. Desmet1 and Carine H. Wouters11, 1University Hospital Leuven, Leuven, Belgium, 2duPont Hospital for Children, Wilmington, DE, 3Hospital de G C Dr Negrin, Las Palmas GC, Spain, 4Hôpital Necker, Paris, France, 5Anna Meyer Children's Hospital, Florence, Italy, 6Zagreb, 7IRCCS G. Gaslini, Pediatria II, PRINTO, Paediatric Rheumatology, Genova, Italy, 8PO Box 9600, Leiden, Netherlands, 9Centre Hospitalier, Luxembourg, Luxembourg, 10Oregon Health & Science Univ, Portland, OR, 11Paediatric Rheumatology Internationsl Trials Organization, Leuven, Belgium
Anniston Medical Clinic PC
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BIIB023 (Anti-TWEAK) in Subjects with Rheumatoid Arthritis
Nicolas Wisniacki1, Vishala L. Chindalore2, Christine E. Codding3, Maria W. Greenwald4, Marianne L. Shaw5, Sergey Fitilev6, Olga Ershova7, Xiao Hu8, Timothy S. Zheng9, Lakshmi Amaravadi8, Ray Zhang9 and Linda C. Burkly8, 1Biogen Idec, Maidenhead, United Kingdom, 2Anniston Medical Clinic PC, Anniston, AL, 3Health Research of Oklahoma, Oklahoma City, OK, 4Desert Medical Advances, Palm Desert, CA, 5Duncansville, PA, 6M. Sechenov Moscow Medical Academy, Moscow, Russia, 7Clinical Hospital for Emergency Care, Moscow, Russia, 8Biogen Idec, Cambridge, MA, 9Biogen Idec Inc, Cambridge, MA
Ansar Medical Technologies, Inc
Sympathetic and Parasympathetic Abnormalities in Primary Sjögren’s Syndrome (pSS) Patients Assessed in Outpatients Using Real-Time Digital Autonomic Nervous System (ANS) Monitoring
Nikolay P. Nikolov1, Stanley R. Pillemer1, Vladimir Bakalov2, Lolita Bebris1, Joe Colombo3 and Gabor G. Illei1, 1NIDCR/NIH, Bethesda, MD, 2NIH, Bethesda, MD, 3Ansar Medical Technologies, Inc, Philadelphia, PA
Antrim Area Hospital, Northern Health and Social Care Trust
Does Clinical Examination Underestimate Joint Inflammation In Patients with Psoriatic Arthritis?
Dafna D. Gladman1, Richard J. Cook2, Lihi Eder1, Anupam Wakhlu3, Claire Riddell4, Mikkel Ostergaard5, Arane Thavaneswaran1 and Vinod Chandran1, 1Toronto Western Hospital, University of Toronto, Toronto, ON, 2University of Waterloo, Waterloo, ON, 3CSM Medical University, Lucknow, India, 4Antrim Area Hospital, Northern Health and Social Care Trust, Antrim BT41 2RL, Northern Ireland, Ireland, 5Copenhagen University Hospital at Glostrup, Glostrup, Denmark
AOUP
Damage Accrual in Patients with Systemic Lupus Erythematosus Is Associated with Endothelial Function Detriment: A Prospective Cohort Study
Chiara Tani1, R. Bruno1, Anna d'Ascanio2, Lorenzo Ghiadoni1, Y. Plantinga1, Rossella Neri1, Antonio Tavoni3, Linda Carli1, Stefano Taddei1, Stefano Bombardieri2 and Marta Mosca1, 1University of Pisa, Pisa, Italy, 2Rheumatology Unit, Pisa, Italy, 3AOUP, Pisa, Italy
APHP
Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis
Sébastien Ottaviani1, Yannick Allanore2, Florence Tubach3, Blandine Pasquet3, Olivier Meyer4 and Philippe Dieude5, 1APHP, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3APHP, Hôpital Bichat, Paris, France, 4Hopital Bichat, Paris, France, 5APHP, Hopital Bichat, Paris, France
APHP, Hôpital Bichat
Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis
Sébastien Ottaviani1, Yannick Allanore2, Florence Tubach3, Blandine Pasquet3, Olivier Meyer4 and Philippe Dieude5, 1APHP, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3APHP, Hôpital Bichat, Paris, France, 4Hopital Bichat, Paris, France, 5APHP, Hopital Bichat, Paris, France
APHP, Hopital Bichat
Serum IL-21 Is Increased and Associated with Higher Disease Activity and Higher Serum Levels of Markers of B-Cell Activation in Primary Sjögren's Syndrome
Jacques-Eric Gottenberg1, Ghada Alsaleh1, Corinne Miceli-Richard2, Raphaèle Seror3, Joelle Benessiano4, Valerie Devauchelle-Pensec5, Philippe Dieude6, Jean Jacques Dubost7, Anne-Laure Fauchais8, Vincent Goeb9, Eric Hachulla10, Pierre yves Hatron11, C. Larroche12, Véronique Le Guern13, Jacques Morel14, Aleth Perdriger15, Xavier Puechal16, Stephanie Rist17, Alain Saraux18, Damien Sène19, Jean Sibilia20, Karine Inamo21, Philippe Ravaud22 and Xavier Mariette23, 1Strasbourg University Hospital, Strasbourg, France, 2Hopital Bicêtre, Le Kremlin Bicêtre, France, 3Bicetre university hospital, LE Kremlin-Bicetre, France, 4Rheumatology, Paris Unervisity Hospital BICHAT, France, 5Brest Occidentale university, Brest, France, 6APHP, Hopital Bichat, Paris, France, 7CHU Gabriel Montpied, Clermont-Ferrand, France, 8Hospital, Limoges, France, 9Rheumatology, Rouen Unervisity Hospital, France, France, 10Internal Medicine, Lille CEDEX, France, 11Service de médecine interne, Hôpital Claude Huriez, Université Lille II, Lille, France, Paris, France, 12Hospital University Bobigny, France, 13Cochin Hospital, Paris, France, 14Hopital Lapeyronie, Montpellier, France, 15Hôpital Sud, Rennes, France, 16Le Mans General Hospital, Le Mans, France, 17Hospital University Orléans, France, 18CHU de la Cavale Blanche, Brest Cedex, France, 19Pitie-Salpetriere Hospital, Paris, France, 20Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 21Nihon Univ Hikarigoaka Hosp, Nerima-ku Tokyo, Japan, 22Hopital Hotel Dieu, Paris Descartes University, Paris, France, 23Université Paris-Sud, Le Kremlin Bicetre, France

Body Mass Index Influences the Response to Infliximab in Ankylosing Spondylitis
Sébastien Ottaviani1, Yannick Allanore2, Florence Tubach3, Blandine Pasquet3, Olivier Meyer4 and Philippe Dieude5, 1APHP, Paris, France, 2Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3APHP, Hôpital Bichat, Paris, France, 4Hopital Bichat, Paris, France, 5APHP, Hopital Bichat, Paris, France

Characteristics and Impact of Pain in Systemic Sclerosis: Comparison with Rheumatoid Arthritis
Serge Perrot, Hopital Hotel Dieu, Paris Descartes University, Paris, France, Philippe Dieude, APHP, Hopital Bichat, Paris, France and Yannick Allanore, Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France
ARBITER, Institute of Rheumatology
Efficacy of Different Doses of Rituximab for the Treatment of RA: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LC van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4Copenhagen University Hospital at Glostrup, on behalf of DANBIO, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Lisbon Medical Academic Medical Center on behalf of Rheumatic Diseases Portuguese Register, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain

Seropositivity and Response to RTX: Data From the CERERRA Collaboration
Katerina Chatzidionysiou1, Elisabeth Lie2, Evgeny L. Nasonov3, Galina Lukina3, Merete L. Hetland4, Ulrik Tarp5, Ioan Ancuta6, Karel Pavelka7, Dan C. Nordström8, Cem Gabay9, Helena Canhao10, Matija Tomsic11, Piet LCM Van Riel12, Juan J. Gomez-Reino13, Tore K. Kvien2 and Ronald F. van Vollenhoven1, 1Karolinska Institute, Stockholm, Sweden, 2Diakonhjemmet Hospital, Oslo, Norway, 3ARBITER, Institute of Rheumatology, Moscow, Russia, 4DANBIO, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, 5Aarhus University Hospital, Aarhus, Denmark, 6Cantacuzino Hospital, Bucharest, Romania, 71Institute of Rheumatology, Department of Experimental Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 8ROB-FIN, Helsinki University Central Hospital, Helsinki, Finland, 9for the SCQM registry, University Hospitals of Geneva, Geneva, Switzerland, 10Hosp Santa Maria, Lisbon, Portugal, 11University Medical Centre Ljubjana, Ljubljana, Slovenia, 12Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 13Hospital Clinico Universitario, Santiago, Spain
Arcadia University
Does Physical Performance Mediate the Effect of Knee Osteoarthritis and Risk of Indoor and Outdoor Falls in Older Men and Women?
Uyen Sa D. Nguyen1, Yuqing Zhang1, Tyler J. VanderWeele2, Jingbo Niu1, Robert H. Shmerling3, Douglas P. Kiel4, Suzanne G. Leveille5, Carol A. Oatis6 and Marian T. Hannan7, 1Boston University School of Medicine, Boston, MA, 2Harvard School of Public Health, Boston, MA, 3Beth Israel Deaconess Med Ctr, Boston, MA, 4Hebrew Senior Life/Harvard Medical School, Boston, MA, 5University of Massachusetts-Boston, Boston, MA, 6Arcadia University, Glenside, PA, 7Hebrew SeniorLife & Harvard Med Sch, Boston, MA

Describing the Interventions in Home Care Physical Therapy for Patients Following Total Knee Replacement
Kimberly Nanovic1, Amy Phillips1, Elizabeth Childs1, Patricia D. Franklin2 and Carol A. Oatis1, 1Arcadia University, Glenside, PA, 2Univ of MA Med Schl, Worcester, MA

Architecture et Réactivité de l'ARN, Université de Strasbourg
MiR-20a Regulates Negatively TLR4 Signalling Pathway by Targeting ASK1 in Rheumatoid Synoviocytes
Lucas Philippe1, Ghada Alsaleh1, Sébastien Pfeffer2, Jacques-Eric Gottenberg1, Jean Sibilia1, Dominique Wachsmann1 and Philippe Georgel3, 1EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 2Architecture et Réactivité de l'ARN, Université de Strasbourg, Strasbourg, France, 3Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France

MicroRNA-15a Regulates Etk/BMX Expression and IL-6 Release In Activated Rheumatoid Synoviocytes
Ghada Alsaleh1, Lucas Philippe1, Angélique Pichot1, Sébastien Pfeffer2, Jacques-Eric Gottenberg1, Jean Sibilia1, Philippe Georgel3 and Dominique Wachsmann1, 1EA4438 Laboratoire Physiopathologie des Arthrites, Illkirch-Strasbourg, France, 2Architecture et Réactivité de l'ARN, Université de Strasbourg, Strasbourg, France, 3Laboratoire d'ImmunoGénétique Moléculaire Humaine, Strasbourg, France
Arcispedale S Maria Nuova
The Role of Color-Doppler-Sonography in the Diagnosis of Giant Cell Arteritis Characterized by Adventitial Inflammation of the Temporal Arteries
Francesco Muratore, Luigi Boiardi, Nicolo Pipitone, Alberto Cavazza, Giovanna Restuccia, Giuseppe Germanò, Pierluigi Macchioni, Gianluigi Bajocchi, Maria Grazia Catanoso, Luca Magnani, Fulvia Rossi, Ilaria Chiarolanza, Lucia Dardani, Andrea Caruso, Alessandra Ghinoi and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy

Prednisone Versus Tamoxifen for Idiopathic Retroperitoneal Fibrosis
Augusto Vaglio1, Alessandra Palmisano1, Stefania Ferretti1, Rocco Cobelli1, Luigi Boiardi2, Carlo Buzio1 and Carlo Salvarani2, 1University of Parma, Parma, Italy, 2Arcispedale S Maria Nuova, Reggio Emilia, Italy

Tocilizumab: A Novel Therapy for Patients with Large-Vessel Vasculitis
Maria Grazia Catanoso1, Luca Magnani1, Nicolo Pipitone1, Annibale Versari1, Lucia Dardani1, Lia Pulsatelli2, Riccardo Meliconi3, Luigi Boiardi1 and Carlo Salvarani1, 1Arcispedale S Maria Nuova, Reggio Emilia, Italy, 2Istituto Ortopedico Rizzoli, Bologna, Italy, 3Istituto Ortopedico Rizzoli and University of Bologna, Bologna, Italy

Sensitivity of the New EULAR/ACR Classification Criteria for Polymyalgia Rheumatica in Comparison with the Former Ones: A Single Centre Study. 
Pierluigi Macchioni, Maria Grazia Catanoso, Luigi Boiardi and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy

Does Ultrasonography Guidance Increase the Yeld of Temporal Artery Biopsy in Patients with Giant Cell Arteritis? Preliminary Results From a Single-Blinded Randomized Study
Giuseppe Germanò, Nicolo Pipitone, Luigi Boiardi, Ilaria Chiarolanza, Luca Cimino, Maria Grazia Catanoso, Andrea Caruso and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy

Comparison of CNS Vasculitis in Children and Adults: Is This the Same Disease Entity?
Marinka Twilt1, Tania Cellucci2, Carlo Salvarani3, Gene G. Hunder4 and Susanne M. Benseler1, 1The Hospital for Sick Children, Toronto, ON, 2Hospital for Sick Children, Toronto, ON, 3Arcispedale S Maria Nuova, Reggio Emilia, Italy, 4Mayo Clinic, Rochester, MN

CC Chemokine RECEPTOR 5 POLYMORPHISM  In BEHÇET’S DISEASE
Fabiola Atzeni1, Luigi Boiardi2, Bruno Casali3, Enrico Farnetti3, Piercarlo Sarzi-Puttini1, Nicolo Pipitone2, Ignazio Olivieri4, Fabrizio Cantini5, Fabrizio Salvi6, Renato La Corte7, Giovanni Triolo8, Davide Filippini9, Giuseppe Paolazzi10 and Carlo Salvarani2, 1Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, 2Arcispedale S Maria Nuova, Reggio Emilia, Italy, 3Molecular Biology Laboratory, Arcispedale S. Maria Nuova,, Reggio Emilia, Italy, 4Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, 5Stabilimento Ospedaliero Misericordia, Prato, Italy, 6Dept. of Neurological Sciences, Ospedale Bellaria,, Bologna, Italy, 7Chair of Rheumatology, University of Ferrara,, Ferrara, Italy, 8Rheumatology Unit, University of Palermo, Palermo, Italy, 9Rheumatology Unit, Ospedale Niguarda,, Milan, Italy, 10Ospedale Santa Chiara, Trento
Ardea Biosciences
Identification of Specific Amino Acids in the Uric Acid Transporter URAT1 Required for Uricosuric-Mediated Inhibition
Philip K. Tan, David Hyndman and Jeffrey N. Miner, Ardea Biosciences, San Diego, CA
Ardea Biosciences, Inc.
Efficacy and SAFETY of Lesinurad (RDEA594), A NOVEL Uricosuric Agent, Given In COMBINATION with ALLOPURINOL In ALLOPURINOL-REFRACTORY Gout PATIENTS: PRELIMINARY RESULTS FROM the RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2B Extension STUDY
John Sundy1, Fernando Perez-Ruiz2, Eswar Krishnan3, Vijay Hingorani4, Jody Welp4, Matt Suster4, Kimberly Manhard4, Matt Cravets4, David Hagerty4 and Barry Quart4, 1Duke University Medical Center, Durham, NC, 2Hospital De Cruces, Baracaldo, Spain, 3Stanford University, Stanford, CA, 4Ardea Biosciences, Inc., San Diego, CA

Pharmacokinetics, Efficacy and SAFETY of Lesinurad, A NOVEL URAT1 Inhibitor, In Individuals with Mild to Moderate Renal IMPAIRMENT 
David Hagerty, Brad Kerr, Zangong Shen, Li-tain Yeh, Vijay Hingorani, Matt Cravets, Jody Welp, Jeffrey N. Miner, Kimberly Manhard and Barry Quart, Ardea Biosciences, Inc., San Diego, CA
Arhus University Hospital
Adalimumab Added to Methotrexate and Intra-Articular Glucocorticoid Increases Remission Rates At One Year In Early, DMARD-Naïve Patients with Rheumatoid Arthritis - An Investigator-Initiated Randomized, Controlled, Double-Blinded Study
Kim Hørslev-Petersen1, Merete L. Hetland2, Peter Junker3, Jan Pødenphant4, Torkell Ellingsen5, Palle Ahlqvist6, Hanne M. Lindegaard3, Asta Linauskas7, Annette Schlemmer8, Mette Y. Dam9, Ib Hansen10, Hans Chr Horn6, Anette Jørgensen9, Sophie B. Krintel2, Johnny Raun1, Christian G. Ammitzbøll9, Julia Johansen2, Mikkel Østergaard11 and Kristian Stengaard-Pedersen9, 1University of Southern Denmark, Graasten, Denmark, 2Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3Odense University Hospital, Odense C, Denmark, 4Copenhagen University at Gentofte,, Hellerup, Denmark, 5University Hospital, Silkeborg, Denmark, 6Vejle Hospital,, Vejle, Denmark, 7Vendsyssel Hospital, Hjørring, Denmark, 8Aalborg Hospital, Aalborg, Denmark, 9Arhus University Hospital, Aarhus, Denmark, 10Viborg Hospital, Viborg, Denmark, 11Copenhagen University Hospital at Glostrup, Copenhagen, Denmark
Aristotle University of Thessaloniki
Regulatory and Anti-Inflammatory Effects of MAP Kinase Phosphatase-1 in Inflammation and Arthritis
Riku Korhonen1, Riina Nieminen1, Tuija Turpeinen1, Ville Taimi1, Antonis Goulas2, Andrew R. Clark3 and Eeva Moilanen1, 1University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, 2Aristotle University of Thessaloniki, Greece, 3Imperial College London, London, United Kingdom
Arizona Arthritis Center
Subsequent Therapy of Patients with Biologic Response Modifiers or Disease-Modifying Antirheumatic Drugs After Coccidioidomycosis
Susan Knowles1, Sara Taroumian1, Jeffrey R. Lisse1, James Yanes1, Neil M. Ampel2, Eric P. Gall3, Rafael G. Grau1, Barbara Y. Bode2, Berchman A. Vaz4, John Galgiani5 and Susan E. Hoover1, 1University of Arizona, Tucson, AZ, 2Southern AZ VA Medical Center, Tucson, AZ, 3Arizona Arthritis Center, Tucson, AZ, 4Catalina Pointe Arthritis and Rheumatology, Tucson, AZ, 5Valley Fever Center for Excellence, Tucson, AZ

Arizona Research & Education
Arizona Research Center
A Study of Tanezumab in Adults with Chronic Low Back Pain (NCT00876187)
Alan J. Kivitz1, Joseph Gimbel2, Candace Bramson3, Mary Ann Nemeth3, David Keller4, Mark T. Brown4, Christine R. West5 and Kenneth M. Verburg4, 1Altoona Center for Clinical Research, Duncansville, PA, 2Arizona Research Center, Phoenix, AZ, 3Pfizer, Groton, 4Pfizer, Groton, CT, 5Pfizer, Williamston, MI
Arthritis & Rheum Clinic
Validity and Reliability Problems with Patient Global As a Component of the American College of Rheumatology/European League Against Rheumatism Remission Criteria
Karim R. Masri1, Frederick Wolfe2, Timothy S. Shaver3, Shadi H. Shahouri4, Shirley Y. Wang4, James D. Anderson5 and Ruth E. Busch6, 1Wichita, KS, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Arthritis & Rheum Clinics KS, Wichita, KS, 4Arthritis & Rheum Clinic of KS, Wichita, KS, 5Arthritis & Rheum Clinics KS, Leawood, KS, 6Arthritis & Rheum Clinic, Wichita, KS
Arthritis & Rheum Clinic of KS
Validity and Reliability Problems with Patient Global As a Component of the American College of Rheumatology/European League Against Rheumatism Remission Criteria
Karim R. Masri1, Frederick Wolfe2, Timothy S. Shaver3, Shadi H. Shahouri4, Shirley Y. Wang4, James D. Anderson5 and Ruth E. Busch6, 1Wichita, KS, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Arthritis & Rheum Clinics KS, Wichita, KS, 4Arthritis & Rheum Clinic of KS, Wichita, KS, 5Arthritis & Rheum Clinics KS, Leawood, KS, 6Arthritis & Rheum Clinic, Wichita, KS
Arthritis & Rheum Clinics KS
Validity and Reliability Problems with Patient Global As a Component of the American College of Rheumatology/European League Against Rheumatism Remission Criteria
Karim R. Masri1, Frederick Wolfe2, Timothy S. Shaver3, Shadi H. Shahouri4, Shirley Y. Wang4, James D. Anderson5 and Ruth E. Busch6, 1Wichita, KS, 2National Data Bank for Rheumatic Diseases, Wichita, KS, 3Arthritis & Rheum Clinics KS, Wichita, KS, 4Arthritis & Rheum Clinic of KS, Wichita, KS, 5Arthritis & Rheum Clinics KS, Leawood, KS, 6Arthritis & Rheum Clinic, Wichita, KS
Arthritis & Rheumatic Disease Specialties
Golimumab Use and Sustained Clinical Response in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-Tumor Necrosis Factor Alpha Agents
Josef Smolen1, Jonathan Kay2, Robert Landewe3, Eric L. Matteson4, Norman B. Gaylis5, J. Wollenhaupt6, Frederick T. Murphy7, O. Zamani8, Yiying Zhou9, Elizabeth C. Hsia9 and Mittie K. Doyle9, 1Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 2University of Massachusetts Medical School, Worcester, MA, 3Academic Medical Center, Amsterdam, Netherlands, 4Mayo Clinic, Rochester, MN, 5Arthritis & Rheumatic Disease Specialties, Aventura, FL, 6Eilbeck Hospital, Hamburg, Germany, 7Altoona Ctr for Clinical Research, Duncansville, PA, 8Rheumazentrum Favoriten, Wien, Austria, 9Centocor R&D, a division of Johnson & Johnson Pharmaceutical Research & Development, LLC, Malvern, PA

Arthritis & Rheumatism Assoc
Characterization and Management of Infusion Reactions in Refractory Chronic Gout (RCG) Treated with Pegloticase (PGL)
Herbert Baraf, Arthritis & Rheumatism Assoc, Wheaton, MD, Robert A. Yood, Fallon Clinic, Worcester, MA, John S. Sundy, Duke University Medical Center, Durham, NC, Faith D. Ottery, Savient, East Brunswick, NJ, Zeb D. Horowitz, Celgene Corporation, Basking Ridge, NJ and Michael A. Becker, University of Chicago Medical Center, Chicago, IL


ACR Leadership Town Hall and Business Meeting
David G. Borenstein, Arthritis & Rheumatism Assoc, Washington, DC

Pain: Evaluation and Treatment of Back Pain
David G. Borenstein, Arthritis & Rheumatism Assoc, Washington, DC

Pain: Evaluation and Treatment of Back Pain
David G. Borenstein, Arthritis & Rheumatism Assoc, Washington, DC




Billing, Coding and Report Generation
Herbert Baraf, Arthritis & Rheumatism Assoc, Wheaton, MD





Presidential Address
David G. Borenstein, Arthritis & Rheumatism Assoc, Washington, DC

Arthritis Alliance of Canada
Use of Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis in Quebec, Canada
Jean-Pascal Roussy1, Louis Bessette2, Sasha Bernatsky3, Elham Rahme3, Jean Légaré4 and Jean Lachaine1, 1University of Montreal, Montreal, QC, 2CHUL, Quebec, QC, 3McGill UHC/RVH, Montreal, QC, 4Arthritis Alliance of Canada, Neuville, QC
Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine
Salivary Genomic Biomarkers for Primary Sjögren’s Syndrome : Correlation with Minor Salivary Gland Lymphocyte Focus Score and Serum Interleukin-17, 21, 23 Level
Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4 and Ji-Yoon Kim5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Dongsan Medical Center, Keimyung University, School of medicine, Daegu, South Korea

A Serological Proteome Approach for Screening of Autoantigens From Korean Rheumatoid Arthritis Patients
Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4, Yong-Hak Kim5, Yeonkyung Park5 and Mina Choi5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Catholic univeristy of Daegu, School of Medicine, Daegu, South Korea
Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine
Salivary Genomic Biomarkers for Primary Sjögren’s Syndrome : Correlation with Minor Salivary Gland Lymphocyte Focus Score and Serum Interleukin-17, 21, 23 Level
Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4 and Ji-Yoon Kim5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Dongsan Medical Center, Keimyung University, School of medicine, Daegu, South Korea

A Serological Proteome Approach for Screening of Autoantigens From Korean Rheumatoid Arthritis Patients
Sung-Hoon Park1, Ji Hun Kim1, Seong-Kyu Kim2, Jung-Yoon Choe3, Sang-Hyon Kim4, Yong-Hak Kim5, Yeonkyung Park5 and Mina Choi5, 1Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegu, South Korea, 2Arthritis and Autoimmunity Research Center, Catholic University of Daegu School of Medicine, Daegue, South Korea, 3Arthritis and Autoimmunity Research Center, Catholic university of Daegu, School of mediine, Daegu, 4Dongsan Medical Center, Keimyung University, Daegu, South Korea, 5Catholic univeristy of Daegu, School of Medicine, Daegu, South Korea
Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation
Evidence for Epistatic Gene-Gene Interactions in Systemic Lupus Erythematosus
Travis Hughes1, Adam Adler1, Jennifer A. Kelly1, Kenneth Kaufman2, Adrienne Williams3, Carl D. Langefeld4, Elizabeth Brown for PROFILE5, Elena Sanchez1, Javier Martin6, Luis M. Vila7, Gary S. Gilkeson8, Patrick M. Gaffney9, Kathy L. Moser9, J.T. Merrill1, Judith A. James10, Timothy J. Vyse11, Marta E. Alarcon-Riquelme12, John B. Harley13, Bruce C. Richardson14 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Wake Forest University, Winston-Salem, 4Wake Forest University Health Sciences, Winston-Salem, NC, 5Univ of Alabama at Birmingham, Birmingham, AL, Birmingham, AL, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7University of PuertoRico Medical Sciences Campus, San Juan, PR, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 12Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 13Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14University of Michigan, Ann Arbor, MI

Sex-Specific Genetic Architecture of Systemic Lupus Erythematosus
Travis Hughes1, Adam Adler1, J.T. Merrill1, Jennifer A. Kelly1, Kenneth Kaufman2, Adrienne Williams3, Carl D. Langefeld4, Gary S. Gilkeson5, Elena Sanchez1, Javier Martin6, Elizabeth E. Brown for PROFILE7, Patrick M. Gaffney8, Kathy L. Moser8, Tomothy J. Vyse9, Marta E. Alarcon-Riquelme10, Judith A. James11, Robert H. Scofield12, John B. Harley13, Bruce C. Richardson14 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Wake Forest University, Winston-Salem, 4Wake Forest University Health Sciences, Winston-Salem, NC, 5Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7University of Alabama at Birmingham, Birmingham, AL, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9King's College London, Guy's Hospital, London, United Kingdom, 10Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 11Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 12Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 13Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14University of Michigan, Ann Arbor, MI

A High-Density Genome-Wide Association Study by the Sjögren’s Genetics Network Identifies Five Novel Susceptibility Loci for Primary Sjögren’s Syndrome and Confirms Association with MHC, IRF5, and BLK
Christopher J. Lessard1, John A. Ice1, Indra Adrianto1, Jennifer A. Kelly1, Roland Jonsson2, Gabor G. Illei3, Maureen Rischmueller4, Gunnel Nordmark5, Xavier Mariette6, Corinne Miceli-Richard6, Marie Wahren Herlenius7, Torsten Witte8, Michael T. Brennan9, Roald Omdal10, Timothy J. Vyse11, James A. Lessard12, Wan-Fai Ng13, Nelson L. Rhodus14, Barbara M. Segal15, R. Hal Scofield1, Benjamin A. Rybicki for ACCESS16, Juan-Manuel Anaya17, John B. Harley18, Courtney G. Montgomery1 and Kathy L. Moser19, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Bergen, Bergen, Norway, 3NIDCR/ NIH #10 1N110, Bethesda, MD, 4Queen Elizabeth Hospital, Adelaide, Australia, 5Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6Bicêtre University Hospital, Le Kremlin Bicêtre, France, 7Karolinska Institute, Stockholm, Sweden, 8Hannover Medical School, Hanover, Germany, 9Carolinas Medical Center, Charlotte, NC, 10Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 11Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 12Valley Bone & Joint Clinic, Grand Forks, ND, 13Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle, England, 14University of Minnesota, Minneapolis, MN, 15Hennepin County Medical Center, Minneapolis, MN, 16Henry Ford Hospital, Detroit, MI, 17Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 18Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Phenotypic Associations of Genetic Susceptibility Loci In Systemic Lupus Erythematosus
Elena Sanchez1, Ajay Nadig1, Bruce C. Richardson2, Barry I. Freedman3, Kenneth Kaufman4, Timothy B. Niewold5, Diane L. Kamen6, Gary S. Gilkeson7, Carl D. Langefeld3, Robert P. Kimberly8, J.T. Merrill1, Juan-Manuel Anaya9, Judith A. James10, Bernardo Pons-Estel11, Javier Martin12, Sang-Cheol Bae13, Kathy L. Moser14, Tomothy J. Vyse15, Lindsey A. Criswell16, Patrick M. Gaffney14, Betty P. Tsao17, Chaim O. Jacob18, John B. Harley19, Marta E. Alarcon-Riquelme on behalf of BIOLUPUS and GENLES20 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Michigan, Ann Arbor, MI, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 5University of Chicago, Chicago, IL, 6Medical University of SC, Charleston, SC, 7Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 8University of Alabama at Birmingham, Birmingham, AL, 9Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Rosario, Argentina, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 14Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 15King's College London, Guy's Hospital, London, United Kingdom, 16University of California San Francisco, San Francisco, CA, 17UCLA School of Medicine, Los Angeles, CA, 18Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 19Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 20Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK

Genetic Associations with Serologic Autoimmunity in a Large Multi-Ancestral Systemic Lupus Erythematosus Cohort
Silvia Kariuki1, Beverly S. Franek1, Akaash A. Kumar1, Marissa Kumabe1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly11, Javier Martin12, Joan T. Merrill13, Bernardo Pons-Estel14, Betty P. Tsao15, Timothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Kathy L. Moser18, Patrick M. Gaffney18, Andrew D. Skol1 and Timothy B. Niewold1, 1University of Chicago, Chicago, IL, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11University of Alabama at Birmingham, Birmingham, AL, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 17Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Association of a Functional Variant in TLR7 with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Multiple Ancestries
Yun Deng1, Jian Zhao1, Wenfeng Tan1, Kenneth M. Kaufman2, Elizabeth E. Brown3, Jeffrey C. Edberg4, Diane L. Kamen5, Gary S. Gilkeson6, Chaim O. Jacob7, Robert H. Scofield8, Robert P. Kimberly on behalf of PROFILE investigators4, Carl D. Langefeld9, Marta E. Alarcόn-Riquelme on behalf of the BIOLUPUS and GENLES10, John B. Harley11, Timothy J. Vyse12, Patrick M. Gaffney13, Kathy L. Moser13, Judith A. James14, Ji-Yih Chen15, Ted R. Mikuls16, Nancy A. Shadick17, Michael E. Weinblatt17, S. Louis Bridges Jr.18, Harold E. Paulus1 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Medical University of SC, Charleston, SC, 6Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 10Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 15Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taipei, Taiwan, 16Omaha VA and University of Nebraska, Omaha, NE, 17Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 18Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

A Single Risk Haplotype in the Region of UBE2L3 Is Associated with Systemic Lupus Erythematosus in Multiple Ethnic Populations
Shaofeng Wang1, Indra Adrianto1, Graham B. Wiley1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly on behalf of PROFILE investigators11, Javier Martin12, Joan T. Merrill1, Timothy B. Niewold13, Bernardo Pons-Estel14, Betty P. Tsao15, Tomothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Edward Wakeland18, Kathy L. Moser19, Courtney G. Montgomery1 and Patrick M. Gaffney19, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation; Center for Genomics and Oncological Research, Oklahoma City; Granada, Spain, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13University of Chicago, Chicago, IL, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16King's College London, Guy's Hospital, London, United Kingdom, 17Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Univ of Texas SW Med Ctr, Dallas, TX, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

A Functional Haplotype in the Region of TNIP1 Is Associated with Systemic Lupus Erythematosus in Multiple Populations
Indra Adrianto1, Graham B. Wiley1, Shaofeng Wang1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES networks4, Sang-Cheol Bae5, Elizabeth E. Brown for PROFILE6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly6, Javier Martin11, Joan T. Merrill1, Timothy B. Niewold12, Betty P. Tsao13, Timothy J. Vyse14, Carl D. Langefeld7, John B. Harley15, Edward K. Wakeland16, Kathy L. Moser17, Courtney G. Montgomery1 and Patrick M. Gaffney17, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 12University of Chicago, Chicago, IL, 13David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 14Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 15Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 16Univ of Texas SW Med Ctr, Dallas, TX, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

SLE-Risk Alleles of SNPs in the NMNAT2/SMG7 Region Are Associated with Lower mRNA Levels of SMG7
Jian Zhao1, Daisuke Sakurai1, Yun Deng1, Andrea L. Sestak2, Carl D. Langefeld3, Kenneth M. Kaufman4, Jennifer A. Kelly5, Patrick M. Gaffney6, Kathy L. Moser6, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network7, John B. Harley8, Sang-Cheol Bae9, Timothy J. Vyse10, Chaim O. Jacob11, Robert P. Kimberly on behalf of PROFILE investigators12, Lindsey A. Criswell13, Judith A. James14, Gary S. Gilkeson15, Juan-Manuel Anaya16, Deh-Ming Chang17, Yeong W. Song18, Jennifer M. Grossman19, Bevra H. Hahn19, Rita M. Cantor20 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4US Department of Veterans Affairs Medical Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 9Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 10Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 11Keck School of Medicine University of Southern California, Los Angeles, CA, 12University of Alabama Birmingham, Birmingham, AL, 13Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, University of California San Francisco, San Francisco, CA, 14Department of Medicine, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 16Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 17National Defense Medical Center, Taipei, 18Seoul National University, Seoul, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA

Fine Mapping of Xq28: Both MECP2/IRAK1 and NAA10/RENBP Contribute to Risk for SLE in Multiple Ancestral Groups
Kenneth M. Kaufman1, Jennifer A. Kelly2, Travis Hughes2, Adam Adler2, Elena Sanchez2, Joshua O. Ojwang2, Carl D. Langefeld3, Julie T. Ziegler3, Judith A. James4, Elizabeth E. Brown5, Robert P. Kimberly6, Jeffrey C. Edberg7, Lindsey A. Criswell8, Deh-Ming Chang9, Gary S. Gilkeson10, Timothy B. Niewold11, Sang-Cheol Bae12, Marta E. Alarcón-Riquelme13, Chaim O. Jacob14, Kathy L. Moser15, Patrick M. Gaffney15, John B. Harley16, Amr H. Sawalha2 and Betty P. Tsao17, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 5Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6University of Alabama at Birmingham, Birmingham, AL, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of California San Francisco, San Francisco, CA, 9National Defense Medical Center, Taipei, 10Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 11University of Chicago, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 14Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 17David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA

Triple X Syndrome (47,XXX) Increases the Risk and Accelerates the Onset of Systemic Lupus Erythematosus and Sjögren's Syndrome: Support for a Gene-Dose Effect From the X Chromosome
Skyler P. Dillon1, Lydia Kao1, Kenneth M. Kaufman2, John A. Ice2, Roald Omdal3, Xavier Mariette4, Torsten Witte5, Gabor G. Illei6, Maureen Rischmueller7, Gunnel Nordmark8, Roland Jonsson9, Marie Wahren Herlenius10, Timothy J. Vyse11, Michael T. Brennan12, Benjamin A. Rybicki13, Wan-Fai Ng14, Barbara M. Segal15, Nelson L. Rhodus16, Joan T. Merrill2, Courtney G. Montgomery2, Christopher J. Lessard2, John B. Harley17, Kathy L. Moser18, Patrick M. Gaffney18 and R. Hal Scofield2, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 4Université Paris-Sud, Le Kremlin Bicetre, France, 5Hannover Medical School, Hanover, Germany, 6NIDCR/ NIH #10 1N110, Bethesda, MD, 7Queen Elizabeth Hospital, Adelaide, Australia, 8Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 9University of Bergen, Bergen, Norway, 10CMM L8204 Karolinska Hosp, Stockholm, Sweden, 11Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 12Carolinas Medical Center, Charlotte, NC, 13Henry Ford Health System, Detroit, MI, 14Newcastle University, Newcastle upon Tyne, United Kingdom, 15Hennepin County Medical Center, Minneapolis, MN, 16University of Minnesota, Minneapolis, MN, 17Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Large-Scale, High-Density Genotyping Performed by the Sjögren’s Genetics Network Using the ImmunoChip Identifies PRKRA as a Novel Sjögren's Syndrome Susceptibility Locus and Confirms Associations with IRF5, BLK and MHC
Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, Jennifer A. Kelly1, Roland Jonsson2, Gabor G. Illei3, Maureen Rischmueller4, Gunnel Nordmark5, Xavier Mariette6, Corinne Miceli-Richard6, Marie Wahren Herlenius7, Torsten Witte8, Michael T. Brennan9, Roald Omdal10, Patrick M. Gaffney11, James A. Lessard12, Wan-Fai Ng13, Nelson L. Rhodus14, Barbara M. Segal15, R. Hal Scofield1, Judith A. James16, Juan-Manuel Anaya17, John B. Harley18, Courtney Montgomery1 and Kathy L. Moser11, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Bergen, Bergen, Norway, 3NIDCR/ NIH #10 1N110, Bethesda, MD, 4Queen Elizabeth Hospital, Adelaide, Australia, 5Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, 6Bicêtre University Hospital, Le Kremlin Bicêtre, France, 7Karolinska Institute, Stockholm, Sweden, 8Hannover Medical School, Hanover, Germany, 9Carolinas Medical Center, Charlotte, NC, 10Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Valley Bone & Joint Clinic, Grand Forks, ND, 13Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle, England, 14University of Minnesota, Minneapolis, MN, 15Hennepin County Medical Center, Minneapolis, MN, 16Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 17Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 18Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH

Early Systemic Lupus Erythematosus Specific Antigens Predict Disease Characteristics
Jessica J. Hale1, Jennifer A. Kelly1, Chee Paul Lin1, Stuart B. Glenn1, Jourdan Anderson1, Patrick M. Gaffney2, Kathy L. Moser2, John B. Harley3, Judith A. James4 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK

Poly (ADP-Ribose) Polymerase 1 and Special AT-Rich Sequence Binding Protein 1 Bind to the TT>A System Lupus Erythematosus Associated Regulatory Downstream of TNFAIP3
Feng Wen1, Michael Kinter1, Joel Guthridge1, Mary Beth Humphrey2 and Patrick M. Gaffney3, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Large Scale Analysis of Serum Tumor Necrosis Factor Alpha Levels in Systemic Lupus Erythematosus
Corinna E. Weckerle1, Dorothy Imbuka1, Beverly S. Franek1, Jennifer A. Kelly2, Marissa Kumabe1, Kathy L. Moser3, Judith A. James4, John B. Harley5 and Timothy B. Niewold1, 1University of Chicago, Chicago, IL, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 5Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH

Altered Soluble Mediators of Inflammation At Baseline in Individuals Who Subsequently Transition to Systemic Lupus Erythematosus:  Early Studies From the Lupus Autoimmunity in Relatives (LAUREL) Study
Melissa E. Munroe1, Joel M. Guthridge1, Diane L. Kamen2, Jill M. Norris3, Kathy L. Moser1, Timothy B. Niewold4, Gary S. Gilkeson5, David R. Karp6, Michael H. Weisman7, Mariko L. Ishimori8, Daniel J. Wallace9, John B. Harley10 and Judith A. James11, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Medical University of SC, Charleston, SC, 3University of Colorado Denver, Aurora, CO, 4University of Chicago, Chicago, IL, 5Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 6UT Southwestern Medical Center, Dallas, TX, 7Cedars-Sinai Medical Center, Los Angeles, CA, 8Cedars Sinai Medical Ctr, Los Angeles, CA, 9Cedars-Sinai/UCLA, Los Angeles, CA, 10Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 11Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK

Genome-Wide Association Study of African Americans Implicates Multiple Lung and Inflammatory Disease-Associated Loci in Sarcoidosis Susceptibility
Indra Adrianto1, Chee Paul Lin1, Jessica J. Hale1, Albert M. Levin2, Indrani Datta2, Ryan Parker1, Adam Adler1, Jennifer A. Kelly1, Kenneth M. Kaufman3, Christopher J. Lessard1, Kathy L. Moser4, Michael C. Iannuzzi5, Benjamin A. Rybicki2 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Henry Ford Health System, Detroit, MI, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5SUNY Upstate Medical University, Syracuse, NY

A Large-Scale, Multi-Racial Replication Study Identifies Novel Systemic Lupus Erythematosus Susceptibility Loci At IRF8, TMEM39A, and IKZF3/ZPBP2
Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, Jennifer A. Kelly1, He Li1, Graham B. Wiley1, Astrid Rasmussen1, Marta E. Alarcon-Riquelme2, Juan-Manuel Anaya3, Sang-Cheol Bae4, Elizabeth E. Brown for PROFILE5, Chaim O. Jacob6, Judith A. James7, Javier Martin8, Timothy B. Niewold9, Bernardo Pons-Estel10, Betty P. Tsao11, Timothy J. Vyse12, John B. Harley13, Edward Wakeland14, Kenneth M. Kaufman15, Courtney Montgomery1, Carl D. Langefeld16, Patrick M. Gaffney17 and Kathy L. Moser17, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 5University of Alabama at Birmingham, Birmingham, AL, 6Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 7Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 8Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 9University of Chicago, Chicago, IL, 10Rosario, Argentina, 11UCLA School of Medicine, Los Angeles, CA, 12Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 13Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14Univ of Texas SW Med Ctr, Dallas, TX, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 16Wake Forest University Health Sciences, Winston-Salem, NC, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Identification of Novel Genetic Susceptibility Loci In African-American lupus patients Using a Candidate Gene Association Study
Elena Sanchez1, Mary E. Comeau2, Barry I. Freedman2, Jennifer A. Kelly1, Kenneth Kaufman3, Carl D. Langefeld2, Elizabeth E. Brown for PROFILE4, Robert P. Kimberly4, Jeffrey C. Edberg5, Rosalind Ramsey-Goldman6, M. Petri7, John D. Reveille8, Luis M. Vila9, J.T. Merrill1, Betty P. Tsao10, Diane L. Kamen11, Gary S. Gilkeson12, Judith A. James13, Tomothy J. Vyse14, Patrick M. Gaffney15, Chaim O. Jacob16, Timothy B. Niewold17, Bruce C. Richardson18, John B. Harley19, Marta E. Alarcon-Riquelme20 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Wake Forest University Health Sciences, Winston-Salem, NC, 3Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 4University of Alabama at Birmingham, Birmingham, AL, 5Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 6Northwestern University, Chicago, IL, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8University of Texas Health Science Center at Houston, Houston, TX, 9University of PuertoRico Medical Sciences Campus, San Juan, PR, 10UCLA School of Medicine, Los Angeles, CA, 11Medical University of SC, Charleston, SC, 12Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 13Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 14King's College London, Guy's Hospital, London, United Kingdom, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 17University of Chicago, Chicago, IL, 18University of Michigan, Ann Arbor, MI, 19Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 20Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK

Risk Alleles of SLE Associated IL10 SNPs Conferred Differential Binding to Transcription Factors
Daisuke Sakurai1, Jian Zhao1, Yun Deng1, Kenneth Kaufman2, Jennifer A. Kelly3, Robert P. Kimberly on behalf of PROFILE investigators4, Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ5, John B. Harley6, Sang-Cheol Bae7, Chaim O. Jacob8, Timothy J. Vyse9, Timothy B. Niewold10, Patrick M. Gaffney11, Kathy L. Moser11, Judith A. James12, Gary S. Gilkeson13, Diane L. Kamen14, Carl D. Langefeld15, Deh-Ming Chang16, Yeong Wook Song17, Chack-Yung Yu18, Jennifer M. Grossman19, Rita M. Cantor20, Bevra H. Hahn19 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Oklahoma Medical Research Foundation; Center for Genomics and Oncological Research, Oklahoma City; Granada, Spain, OK, 6Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 8Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 9Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 10University of Chicago, Chicago, IL, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 13Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 14Medical University of SC, Charleston, SC, 15Wake Forest University Health Sciences, Winston-Salem, NC, 16National Defense Medical Center, Taipei, 17Seoul National University College of Medicine, Seoul, South Korea, 187Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 19UCLA David Geffen School of Medicine, Los Angeles, CA, 20University of California Los Angeles, Los Angeles, CA
Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center
Genetic Associations with Serologic Autoimmunity in a Large Multi-Ancestral Systemic Lupus Erythematosus Cohort
Silvia Kariuki1, Beverly S. Franek1, Akaash A. Kumar1, Marissa Kumabe1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly11, Javier Martin12, Joan T. Merrill13, Bernardo Pons-Estel14, Betty P. Tsao15, Timothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Kathy L. Moser18, Patrick M. Gaffney18, Andrew D. Skol1 and Timothy B. Niewold1, 1University of Chicago, Chicago, IL, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11University of Alabama at Birmingham, Birmingham, AL, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 17Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Association of a Functional Variant in TLR7 with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Multiple Ancestries
Yun Deng1, Jian Zhao1, Wenfeng Tan1, Kenneth M. Kaufman2, Elizabeth E. Brown3, Jeffrey C. Edberg4, Diane L. Kamen5, Gary S. Gilkeson6, Chaim O. Jacob7, Robert H. Scofield8, Robert P. Kimberly on behalf of PROFILE investigators4, Carl D. Langefeld9, Marta E. Alarcόn-Riquelme on behalf of the BIOLUPUS and GENLES10, John B. Harley11, Timothy J. Vyse12, Patrick M. Gaffney13, Kathy L. Moser13, Judith A. James14, Ji-Yih Chen15, Ted R. Mikuls16, Nancy A. Shadick17, Michael E. Weinblatt17, S. Louis Bridges Jr.18, Harold E. Paulus1 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Medical University of SC, Charleston, SC, 6Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 10Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 15Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taipei, Taiwan, 16Omaha VA and University of Nebraska, Omaha, NE, 17Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 18Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

A Single Risk Haplotype in the Region of UBE2L3 Is Associated with Systemic Lupus Erythematosus in Multiple Ethnic Populations
Shaofeng Wang1, Indra Adrianto1, Graham B. Wiley1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme on behalf of the BIOLUPUS and GENLES networ4, Sang-Cheol Bae5, Elizabeth E. Brown6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly on behalf of PROFILE investigators11, Javier Martin12, Joan T. Merrill1, Timothy B. Niewold13, Bernardo Pons-Estel14, Betty P. Tsao15, Tomothy J. Vyse16, Carl D. Langefeld7, John B. Harley17, Edward Wakeland18, Kathy L. Moser19, Courtney G. Montgomery1 and Patrick M. Gaffney19, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation; Center for Genomics and Oncological Research, Oklahoma City; Granada, Spain, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 12Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 13University of Chicago, Chicago, IL, 14Sanatorio Parque, Rosario, Argentina, 15David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 16King's College London, Guy's Hospital, London, United Kingdom, 17Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 18Univ of Texas SW Med Ctr, Dallas, TX, 19Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

A Functional Haplotype in the Region of TNIP1 Is Associated with Systemic Lupus Erythematosus in Multiple Populations
Indra Adrianto1, Graham B. Wiley1, Shaofeng Wang1, Kenneth M. Kaufman2, Juan-Manuel Anaya3, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES networks4, Sang-Cheol Bae5, Elizabeth E. Brown for PROFILE6, Barry I. Freedman7, Gary S. Gilkeson8, Chaim O. Jacob9, Judith A. James10, Robert P. Kimberly6, Javier Martin11, Joan T. Merrill1, Timothy B. Niewold12, Betty P. Tsao13, Timothy J. Vyse14, Carl D. Langefeld7, John B. Harley15, Edward K. Wakeland16, Kathy L. Moser17, Courtney G. Montgomery1 and Patrick M. Gaffney17, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, Oklahoma City, OK, 5Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 6University of Alabama at Birmingham, Birmingham, AL, 7Wake Forest School of Medicine, Winston-Salem, NC, 8Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 9Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 10Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 11Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 12University of Chicago, Chicago, IL, 13David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 14Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 15Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 16Univ of Texas SW Med Ctr, Dallas, TX, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Fine Mapping of Xq28: Both MECP2/IRAK1 and NAA10/RENBP Contribute to Risk for SLE in Multiple Ancestral Groups
Kenneth M. Kaufman1, Jennifer A. Kelly2, Travis Hughes2, Adam Adler2, Elena Sanchez2, Joshua O. Ojwang2, Carl D. Langefeld3, Julie T. Ziegler3, Judith A. James4, Elizabeth E. Brown5, Robert P. Kimberly6, Jeffrey C. Edberg7, Lindsey A. Criswell8, Deh-Ming Chang9, Gary S. Gilkeson10, Timothy B. Niewold11, Sang-Cheol Bae12, Marta E. Alarcón-Riquelme13, Chaim O. Jacob14, Kathy L. Moser15, Patrick M. Gaffney15, John B. Harley16, Amr H. Sawalha2 and Betty P. Tsao17, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Wake Forest University Health Sciences, Winston-Salem, NC, 4Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 5Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 6University of Alabama at Birmingham, Birmingham, AL, 7Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 8University of California San Francisco, San Francisco, CA, 9National Defense Medical Center, Taipei, 10Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 11University of Chicago, Chicago, IL, 12Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 13Oklahoma Medical Research Foundation and Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain, on behalf of the BIOLUPUS and GENLES networks, Oklahoma City, OK, 14Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 16Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 17David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA

Genome-Wide Association Study of African Americans Implicates Multiple Lung and Inflammatory Disease-Associated Loci in Sarcoidosis Susceptibility
Indra Adrianto1, Chee Paul Lin1, Jessica J. Hale1, Albert M. Levin2, Indrani Datta2, Ryan Parker1, Adam Adler1, Jennifer A. Kelly1, Kenneth M. Kaufman3, Christopher J. Lessard1, Kathy L. Moser4, Michael C. Iannuzzi5, Benjamin A. Rybicki2 and Courtney G. Montgomery1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Henry Ford Health System, Detroit, MI, 3Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 4Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 5SUNY Upstate Medical University, Syracuse, NY

A Large-Scale, Multi-Racial Replication Study Identifies Novel Systemic Lupus Erythematosus Susceptibility Loci At IRF8, TMEM39A, and IKZF3/ZPBP2
Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, Jennifer A. Kelly1, He Li1, Graham B. Wiley1, Astrid Rasmussen1, Marta E. Alarcon-Riquelme2, Juan-Manuel Anaya3, Sang-Cheol Bae4, Elizabeth E. Brown for PROFILE5, Chaim O. Jacob6, Judith A. James7, Javier Martin8, Timothy B. Niewold9, Bernardo Pons-Estel10, Betty P. Tsao11, Timothy J. Vyse12, John B. Harley13, Edward Wakeland14, Kenneth M. Kaufman15, Courtney Montgomery1, Carl D. Langefeld16, Patrick M. Gaffney17 and Kathy L. Moser17, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 3Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 4Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 5University of Alabama at Birmingham, Birmingham, AL, 6Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 7Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 8Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 9University of Chicago, Chicago, IL, 10Rosario, Argentina, 11UCLA School of Medicine, Los Angeles, CA, 12Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 13Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14Univ of Texas SW Med Ctr, Dallas, TX, 15Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 16Wake Forest University Health Sciences, Winston-Salem, NC, 17Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center
Sex-Specific Genetic Architecture of Systemic Lupus Erythematosus
Travis Hughes1, Adam Adler1, J.T. Merrill1, Jennifer A. Kelly1, Kenneth Kaufman2, Adrienne Williams3, Carl D. Langefeld4, Gary S. Gilkeson5, Elena Sanchez1, Javier Martin6, Elizabeth E. Brown for PROFILE7, Patrick M. Gaffney8, Kathy L. Moser8, Tomothy J. Vyse9, Marta E. Alarcon-Riquelme10, Judith A. James11, Robert H. Scofield12, John B. Harley13, Bruce C. Richardson14 and Amr H. Sawalha1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Wake Forest University, Winston-Salem, 4Wake Forest University Health Sciences, Winston-Salem, NC, 5Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 6Instituto de Parasitologia y Biomedicina Lopez-Neyra (CSIC), Granada, Spain, 7University of Alabama at Birmingham, Birmingham, AL, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 9King's College London, Guy's Hospital, London, United Kingdom, 10Oklahoma Medical Research Foundation, Center for Genomics and Oncological Research Pfizer-University of Granada-Junta de Andalucia, Oklahoma City, OK, 11Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 12Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 13Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 14University of Michigan, Ann Arbor, MI

Gene Expression Profiling in a Cohort of 275 European American Sjögren's Syndrome Patients and Controls
Jennifer A. Kelly1, Christopher J. Lessard1, Indra Adrianto1, John A. Ice1, He Li1, Stuart B. Glenn1, Kimberly Hefner2, Evan Glenn Vista3, Donald U. Stone4, Raj Gopalakrishnan5, Glen D. Houston4, David M. Lewis4, Michael Rohrer5, Pamela Hughes5, John B. Harley6, Courtney G. Montgomery1, James Chodosh7, James A. Lessard8, Juan-Manuel Anaya9, Barbara M. Segal10, Nelson L. Rhodus5, Lida Radfar4, M. Bart Frank1, Robert H. Scofield11 and Kathy L. Moser1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Hefner Eye Care and Optical Center, Oklahoma City, OK, 3University of Santo Tomas, Taguig City, Philippines, 4University of Oklahoma Health Sciences Center, Oklahoma City, OK, 5University of Minnesota, Minneapolis, MN, 6Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7Harvard Clinical and Translational Science Center, Boston, MA, 8Valley Bone & Joint Clinic, Grand Forks, ND, 9Universidad del Rosario-Corporacion para Investigaciones Biologicas, Bogota, Colombia, 10Univ of Minnesota, Minneapolis, MN, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Association of a Functional Variant in TLR7 with Systemic Lupus Erythematosus and Rheumatoid Arthritis in Multiple Ancestries
Yun Deng1, Jian Zhao1, Wenfeng Tan1, Kenneth M. Kaufman2, Elizabeth E. Brown3, Jeffrey C. Edberg4, Diane L. Kamen5, Gary S. Gilkeson6, Chaim O. Jacob7, Robert H. Scofield8, Robert P. Kimberly on behalf of PROFILE investigators4, Carl D. Langefeld9, Marta E. Alarcόn-Riquelme on behalf of the BIOLUPUS and GENLES10, John B. Harley11, Timothy J. Vyse12, Patrick M. Gaffney13, Kathy L. Moser13, Judith A. James14, Ji-Yih Chen15, Ted R. Mikuls16, Nancy A. Shadick17, Michael E. Weinblatt17, S. Louis Bridges Jr.18, Harold E. Paulus1 and Betty P. Tsao1, 1David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation and US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 3Department of Medicine and Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 4Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 5Medical University of SC, Charleston, SC, 6Division of Rheumatologyand Immunology, Medical University of South Carolina, Charleston, SC, 7Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, 8Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, US Department of Veterans Affairs Medical Center and Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 9Department of Biostatistical Sciences, Wake Forest University Health Sciences, Winston-Salem, NC, 10Center for Genomics and Oncological Research, Pfizer-University of Granada-Junta de Andalucia, Granada, Spain and Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 11Cincinnati Children's Hospital Medical Center and the US Department of Veterans Affairs Medical Center, Cincinnati, OH, 12Divisions of Genetics and Molecular Medicine and Immunology, King's College London, London, United Kingdom, 13Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 14Oklahoma Medical Research Foundation and Oklahoma University Health Sciences Center, Oklahoma City, OK, 15Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital, Taipei, Taiwan, 16Omaha VA and University of Nebraska, Omaha, NE, 17Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 18Marguerite Jones Harbert-Gene V. Ball, MD Professor of Medicine, and Director, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Arthritis Associates
The Oral S1P Lyase Inhibitor LX3305 (LX2931) Demonstrates Favorable Safety and Potential Clinical Benefit at 12-Weeks in a Phase 2 Proof-of-Concept Trial in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Therapy
Roy M. Fleischmann1, Jeffrey E. Poiley2, Rumen Stoilov3, Vibeke Strand4, Joel Freiman5, Tamas Oravecz5, Arthur Sands5, Brian Zambrowicz5 and Lexicon Pharmaceuticals RA Clinical Development6, 1University of Texas Southwestern Medical Center and Metroplex Clinical Research Center, Dallas, TX, 2Arthritis Associates, Orlando, FL, 3University Multiprofile Hospital for Active Treatment (UMHAT) St. Ivan Rilski EAD, Sofia, Bulgaria, 4Stanford University, Palo Alto, CA, 5Lexicon Pharmaceuticals, Inc., The Woodlands, TX, 6The Woodlands, TX
Arthritis Associates PLLC
Symptomatic Subcutaneous Anti-Tumor Necrosis Factor-Treated Rheumatoid Arthritis Patients Improve Following An Active Switch to Golimumab: An Initial 14 Week Assessment
J. Eugene Huffstutter1, Rebecca Bolce2, Shelly P. Kafka3, Lawrence H. Brent4, Jim Wang5, Raphael J. DeHoratius2, Trev Sprabery2 and Dennis Decktor2, 1Arthritis Associates PLLC, Hixson, TN, 2Janssen Services, LLC, Horsham, PA, 3Mountain State Rheumatology, Clarksburg, WV, 4Albert Einstein Med Ctr, Philadelphia, PA, 5Johnson & Johnson Pharmaceutical Research and Development, LLC, Belle Mead
Arthritis Center Inc.
Musculoskeletal Ultrasonography: Basic
Gurjit S. Kaeley, MBBS, MRCP; Ponte Vedra Beach, FL and Janak R. Goyal, MD; Arthritis Center Inc., Perth Amboy, NJ
Arthritis Center of Nebraska
Subcutaneous (SC) Abatacept (ABA) Versus Intravenous (IV) ABA in Patients (pts) with Rheumatoid Arthritis: Long-Term Data From the ACQUIRE (Abatacept Comparison of Sub[QU]cutaneous versus Intravenous in Inadequate Responders to MethotrexatE) Trial
Mark C. Genovese1, Arturo Covarrubias Cobos2, Gustavo Leon3, Eduardo F. Mysler4, Mauro W. Keiserman5, Robert M. Valente6, Peter T. Nash7, J. Abraham Simon Campos8, Wieslawa Porawska9, Jane H. Box10, Clarence W. Legerton III11, Evgeny L. Nasonov12, Patrick Durez13, Ramesh Pappu14, Ingrid Delaet14, Julie Teng14 and Rieke Alten15, 1Stanford University Medical Center, Palo Alto, CA, 2Calle Maiz No 49, Mexico, Mexico, 3Instituto De Ginecologia Y Reproduccion, Lima, Peru, 4OMI, Buenos Aires, Argentina, 5Pontiphycial Catholic Univ, Porto Alegre, Brazil, 6Arthritis Center of Nebraska, Lincoln, NE, 7University of Queensland, Brisbane, Australia, 8Centro De Especialidades Médicas, Merida, Yucatan, 97000, Mexico, 9Poznañski Oœrodek Medyczny ‘Novamed', Poznañ, Poland, 10Box Arthritis & Rheumatology of the Carolinas, Charlotte, NC, 11LowCountry Rheumatology, Charleston, SC, 12Institue of Rheumatology, Moscow, 13Université Catholique de Louvain, Brussels, Belgium, 14Bristol-Myers Squibb, Princeton, NJ, 15Schlosspark-Klinik, Berlin, Germany
Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia
Organization of Care Delivery for People with Arthritis: Models and Processes
A. M. Davis, Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Rehabilitation Science and Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, C. Cott, Health Care and Outcomes Research, Toronto Western Research Institute; Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, L. Li, Arthritis Centre of Canada and Department of Physical Therapy, University of British Columbia, Vancouver, BC, M. Landry, Departments of Physical Therapy and Rehabilitation Science, University of Toronto, Toronto, ON, A. Jones, Departments of Physical Therapy and School of Public Health, University of Alberta, Edmonton, AB, R. Wong, Health Care and Outcomes Research, Toronto Western Research Institute, Toronto, ON, C. Frank, Alberta Bone and Joint Institute and Department of Surgery, University of Calgary, Calgary, AB, L. Bergeron, Canadian Arthritis Patient Alliance, Ottawa, ON, R. Birtwhistle, Centre for Studies in Primary Care and Family Medicine and Community Health and Epidemiology, Queen's University, Kingston, ON and E. M. Badley, Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON
Arthritis Centre Twente, Medisch Spectrum Twente and University Twente
What Is A Realistic Treatment Target in Rheumatoid Arthritis: Remission or Minimal Disease Activity?
Yvonne M.R. de Punder1, Jaap Fransen1, Wietske Kievit1, Pieternella Houtman2, Henk Visser3, Mart A.F.J. van de Laar4 and Piet LC van Riel1, 1Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 2Medical Centre Leeuwarden, Leeuwarden, Netherlands, 3Alysis Care Group, Arnhem, Netherlands, 4Arthritis Centre Twente, Medisch Spectrum Twente and University Twente, Enschede, Netherlands
Arthritis Clinic
One Year Efficacy and Safety Results of a Phase II Trial of Secukinumab in Patients with Rheumatoid Arthritis
Mark C. Genovese1, Patrick Durez2, Hanno B. Richards3, Jerzy Supronik4, Eva Dokoupilova5, Jacob A. Aelion6, Sang-Heon Lee7, Christine E. Codding8, Herbert Kellner9, Takashi Ikawa10, Sophie Hugot3, Gregory Ligozio11 and Shephard Mpofu3, 1Stanford University, Palo Alto, CA, 2Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, 3Novartis Pharma AG, Basel, Switzerland, 4NZOZ Centrum Medyczne Artur Racewicz, Bialystok, Poland, 5Medical Plus s.r.o, Uherske Hradiste, Czech Republic, 6Arthritis Clinic, Jackson, TN, 7Konkuk University Medical Center, Seoul, South Korea, 8Health Research of Oklahoma, Oklahoma City, OK, 9Centre for Inflammatory Joint Diseases, Munich, Germany, 10Kobe - Konan Yamate Clinic, Kobe, Japan, 11Novartis Pharmaceuticals Corporation, East Hanover, NJ
Arthritis Foundation
Improving Doctor-Patient Communication Through Let's Talk RA
Arlene Vinci, Emily L. Creek and Cindy McDaniel, Arthritis Foundation, Atlanta, GA

Internet-Based Patient Registry and Biospecimen Collection: One Year Experience of the Arthritis Internet Registry
Kaleb Michaud1, Kimberly Harp1, Rebecca Schumacher1, Stanley J. Naides2, William F. Patten2, Beth Axtell3 and Robert M. Plenge4, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Quest Diagnostics Nichols Inst, San Juan Capistrano, CA, 3Arthritis Foundation, Atlanta, GA, 4Brigham and Women's Hospital, Boston, MA

Health Care Transition Improvement Utilizing Learning Collaborative and the New Six Core Transition Elements
Patience H. White1, Peggy McManus2, Jeanne McAllister3 and Carl Cooley3, 1Arthritis Foundation, Washington, DC, 2National Alliance to Advance Adolescent Health, Washington, DC, 3Center for Medical Home Improvement, Concord, NH
Arthritis Research Centre
Can American College of Rheumatology Criteria for Rheumatoid Arthritis Be Assessed Using Self-Report Data? - Comparison of Self-Reported Data with Chart Review
Jack Chang1, Pam Rogers1 and Diane Lacaille2, 1Arthritis Research Centre, Vancouver, BC, 2Arthritis Research Centre; University of British Columbia, Vancouver, BC

Comparison of the 1987 American College of Rheumatology Criteria and the 2010 American College of Rheumatology/European League Against Rheumatism Criteria in Patients with Established Rheumatoid Arthritis
Iman Hemmati, University of British Columbia, Vancouver, BC, Maria Victoria Goycochea-Robbles, Regional Hospital No 1 IMSS, Mexico City, Mexico, Eric C. Sayre, Arthritis Research Centre, Vancouver, BC and Diane Lacaille, Arthritis Research Centre; University of British Columbia, Vancouver, BC

Disease Modifying Anti-Rheumatic Drugs Compliance Study
Kateryna Vostretsova1, Pam Rogers1, Darby JS Thompson2 and Diane Lacaille3, 1Arthritis Research Centre, Vancouver, BC, 2Simon Fraser University, Vancouver, BC, 3Arthritis Research Centre; University of British Columbia, Vancouver, BC
Arthritis Research Centre of Canada
High Resolution Peripheral Quantitative Computed Tomography Bone Health Outcomes in the Metacarpal Head and Ultra-Ultra Distal Radius: A Precision Study Using Novel Scan Acquisition and Custom Semi-Automatic Contour and Evaluation Protocols
Lynne M. Feehan1, Helen R. Buie2, Eric C. Sayre3, Steve K. Boyd2, Heather A. McKay4 and Linda C. Li1, 1Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, 2University of Calgary, Calgary, AB, 3Arthritis Research Centre of Canada, Vancouver, BC, 4University of British Columbia, Vancouver, BC

Ambivalent Attitudes, Accessing Information and Decision-Making: An Interview Study of Medication Use in Early Rheumatoid Arthritis (RA)
Anne F. Townsend1, Paul M. Adam2, Catherine L. Backman3, Linda C. Li3 and ERAHSE Team4, 1Arthritis Research Centre of Canada, Vancouver, BC, 2Mary Pack Arthritis Centre, Vancouver, BC, 3University of British Columbia, Vancouver, BC, 4Vancouver & Toronto

Development and Usability Testing of ANSWER: A Web-Based Methotrexate Decision Aid for Patients with Rheumatoid Arthritis
Linda C. Li1, Paul M. Adam2, Anne F. Townsend3, Diane Lacaille3, Charlene Yousefi3, Shawn Turnau1, Dawn Stacey4, Jessie McGowan5, Peter Tugwell6, Catherine L. Backman1 and ANSWER Team7, 1University of British Columbia, Vancouver, BC, 2Mary Pack Arthritis Centre, Vancouver, BC, 3Arthritis Research Centre of Canada, Vancouver, BC, 4University of Ottawa, Ottawa, ON, 5Universtiy of Ottawa, Ottawa, ON, 6Institute of Population Hlth, Ottawa, ON, 7Vancouver & Ottawa

The Association Between Lifelong Joint Force From Physical Activity, Local Joint Factors and Knee Osteoarthritis
Charles R. Ratzlaff1, Mieke Koehoorn1, Jolanda Cibere2 and Jacek A. Kopec3, 1University of British Columbia, Vancouver, BC, 2Arthritis Research Ctr of CA, Vancouver, BC, 3Arthritis Research Centre of Canada, Vancouver, BC

Obesity and the Risk of Psoriatic Arthritis in the General Population
Yanyan Zhu1, Hyon K. Choi1, Yuqing Zhang1, Lindsay Wall-Burns2, Alexis Ogdie3, Joel Gelfand4 and Thorvardur Love5, 1Boston University School of Medicine, Boston, MA, 2Arthritis Research Centre of Canada, Vancouver, BC, 3University of Pennsylvania, Philadelphia, PA, 4University of Pennsylvania., Philadelphia, PA, 5Landspitali University Hospital, Reykjavík, Iceland

Statins and Risk of Acute Myocardial Infarction in Patients with RheumatoidArthritis: A Population-Based Study 
Mary De Vera1, Diane Lacaille1, Michal Abrahamowicz2, Jacek A. Kopec1 and Hyon K. Choi3, 1Arthritis Research Centre of Canada, Vancouver, BC, 2McGill UHC/RVH, Montreal, QC, 3Boston University School of Medicine, Boston, MA
Arthritis Research Centre of Canada and University of British Columbia
High Resolution Peripheral Quantitative Computed Tomography Bone Health Outcomes in the Metacarpal Head and Ultra-Ultra Distal Radius: A Precision Study Using Novel Scan Acquisition and Custom Semi-Automatic Contour and Evaluation Protocols
Lynne M. Feehan1, Helen R. Buie2, Eric C. Sayre3, Steve K. Boyd2, Heather A. McKay4 and Linda C. Li1, 1Arthritis Research Centre of Canada and University of British Columbia, Vancouver, BC, 2University of Calgary, Calgary, AB, 3Arthritis Research Centre of Canada, Vancouver, BC, 4University of British Columbia, Vancouver, BC
Arthritis Research Centre of Canada/University of British Columbia
Adult Prevalence of Systemic Autoimmune Rheumatic Diseases (SARDs) in British Columbia, Canada
J. Antonio Avina-Zubieta1, Eric C. Sayre1, Sasha Bernatsky2, Allen J. Lehman1, Kamran Shojania1, John Esdaile3 and Diane Lacaille1, 1Arthritis Research Centre of Canada/University of British Columbia, Vancouver, BC, 2McGill UHC/RVH, Montreal, QC, 3University of Calgary, Calgary, AB
Arthritis Research Centre; University of British Columbia
Can American College of Rheumatology Criteria for Rheumatoid Arthritis Be Assessed Using Self-Report Data? - Comparison of Self-Reported Data with Chart Review
Jack Chang1, Pam Rogers1 and Diane Lacaille2, 1Arthritis Research Centre, Vancouver, BC, 2Arthritis Research Centre; University of British Columbia, Vancouver, BC

Comparison of the 1987 American College of Rheumatology Criteria and the 2010 American College of Rheumatology/European League Against Rheumatism Criteria in Patients with Established Rheumatoid Arthritis
Iman Hemmati, University of British Columbia, Vancouver, BC, Maria Victoria Goycochea-Robbles, Regional Hospital No 1 IMSS, Mexico City, Mexico, Eric C. Sayre, Arthritis Research Centre, Vancouver, BC and Diane Lacaille, Arthritis Research Centre; University of British Columbia, Vancouver, BC

Use of Bisphosphonates for the Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatoid Arthritis — a Population Based Study
Diane Lacaille1, Mushfiqur Rahman1 and John Esdaile2, 1Arthritis Research Centre; University of British Columbia, Vancouver, BC, 2University of Calgary, Calgary, AB

Disease Modifying Anti-Rheumatic Drugs Compliance Study
Kateryna Vostretsova1, Pam Rogers1, Darby JS Thompson2 and Diane Lacaille3, 1Arthritis Research Centre, Vancouver, BC, 2Simon Fraser University, Vancouver, BC, 3Arthritis Research Centre; University of British Columbia, Vancouver, BC
Arthritis Research Ctr Canada
The Accuracy of Identifying Kidney Disease in Administrative Databases for Rheumatic Disease Research - A Systematic Review of Validation Studies
Bindee Kuriya, University of Toronto, Toronto, ON, Ziv Harel, Division of Nehprology, University of Toronto, Toronto and Diane Lacaille, Arthritis Research Ctr Canada, Vancouver, BC

A Systematic Review of Validation Studies of Administrative Data Used to Identify Infections
Claire Barber, Mount Sinai Hospital, Toronto, ON, Diane V. Lacaille, Arthritis Research Ctr Canada, Vancouver, BC, Joan E. Wither, Toronto Western Research Institute, University Health Network, Toronto, ON and Paul R. Fortin, Toronto Western Hospital and University of Toronto, Toronto, ON

Case Study
Diane V. Lacaille, Arthritis Research Ctr Canada, Vancouver, BC
Arthritis Research Ctr of CA
The Association Between Lifelong Joint Force From Physical Activity, Local Joint Factors and Knee Osteoarthritis
Charles R. Ratzlaff1, Mieke Koehoorn1, Jolanda Cibere2 and Jacek A. Kopec3, 1University of British Columbia, Vancouver, BC, 2Arthritis Research Ctr of CA, Vancouver, BC, 3Arthritis Research Centre of Canada, Vancouver, BC
Arthritis Research Ctr; University of British Columbia
Consensus Statements Concerning the Use of Administrative Data in Rheumatology Research and Surveillance
Diane Lacaille, Arthritis Research Ctr; University of British Columbia, Vancouver, BC, Lisa Lix, University of Saskatchewan, Saskatoon, SK, Sasha Bernatsky, McGill UHC/RVH, Montreal, QC, Siobhan O'Donnell, Public Health Agency of Canada, Ottawa, ON, Claire Bombardier, Institute for Work & Health, Toronto, ON and Administrative Data Rheumatology Research & Surveillance
Arthritis Research Group, Queen's University
Clinical and Ultrasound Outcomes of Ultrasound-Guided Ankle Injection In Juvenile Idiopathic Arthritis; An Analysis of Current Clinical Practice
Eimear Savage1, Laura Pascoli1 and Madeleine Rooney2, 1Belfast Hospitals Trust, Musgrave Park Hospital, Belfast BT9 7JB, Northern Ireland, 2Arthritis Research Group, Queen's University, Belfast, United Kingdom

Cytokine Expression Array Analysis Segregates Oligoarticular Juvenile Idiopathic Arthritis Patients At Risk of Disease Extension
Sorcha Finnegan, Madeleine Rooney and David S. Gibson, Arthritis Research Group, Queen's University, Belfast, United Kingdom

Ultrasound Assessment of Erosive hand arthritis In Systemic Lupus Erythematosus
Elisabeth M.A Ball, Musgrave Park Hospital/Queens' University, Belfast, United Kingdom, Madeleine Rooney, Arthritis Research Group, Queen's University, Belfast, United Kingdom and Aubrey Bell, Musgrave Park Hospital/Queens' University, Belfast, Ireland
Arthritis Research UK
An International Collaboration for the Genetic Fine Mapping of 8,000 Rheumatoid Arthritis Cases and 12,000 Controls Refines Associations to Known Loci, Indicates Multiple Independent Affects and Reveals Novel Associations
Stephen Eyre1, John Bowes2, Anne Barton3, Soumya Raychaudhuri4, Christopher Amos5, Dorothee Diogo4, Annette T. Lee6, Lars Klareskog7, Leonid Padyukov8, Eli A. Stahl4, Peter K. Gregersen9, Robert M. Plenge4 and Jane Worthington1, 1University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 4Brigham and Women's Hospital, Boston, MA, 5Houston, TX, 6Feinstein Institute Med Rsch, Manhasset, NY, 7Karolinska Institutet, Stockholm, Sweden, 8Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 9Feinstein Institute Medical Reschearch, Manhasset, NY

Fine-Mapping of Autoimmune Susceptibility Loci Using Immunochip Identifies Novel Susceptibility Loci for Psoriatic Arthritis
John Bowes1, Pauline Ho2, Eleanor Korendowych3, Neil J. McHugh3, Helena Marzo-Ortega4, Jonathon Packham5, Ian N. Bruce1 and Anne Barton1, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK, Manchester, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4University of Leeds, Leeds, United Kingdom, 5Haywood Hospital, Stoke on Trent, United Kingdom
Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester
Investigation of Caucasian Rheumatoid Arthritis Susceptibility Loci in African Patients with the Same Disease
Sebastien Viatte1, Edward Flynn1, Mark Lunt1, Joanne Barnes1, Madeleine Singwe-Ngandeu2, Sylvette Bas3, Anne Barton1 and Cem Gabay3, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Unit of Rheumatology, Department of Internal Medicine, School of Medicine, University of Yaoundé, Yaoundé, Cameroon, 3Division of Rheumatology, University Hospitals of Geneva, 26 Avenue Beau-Séjour, 1211 Geneva 14, Switzerland

Investigation of the Interaction Between Smoking and TRAF1/C5 on Radiological Severity of Inflammatory Polyarthritis
Lily M. Wheeler, Sebastien Viatte, Suzanne Verstappen, Deborah P. Symmons, Jane Worthington and Anne Barton, Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom

An International Collaboration for the Genetic Fine Mapping of 8,000 Rheumatoid Arthritis Cases and 12,000 Controls Refines Associations to Known Loci, Indicates Multiple Independent Affects and Reveals Novel Associations
Stephen Eyre1, John Bowes2, Anne Barton3, Soumya Raychaudhuri4, Christopher Amos5, Dorothee Diogo4, Annette T. Lee6, Lars Klareskog7, Leonid Padyukov8, Eli A. Stahl4, Peter K. Gregersen9, Robert M. Plenge4 and Jane Worthington1, 1University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK, Manchester, United Kingdom, 3Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 4Brigham and Women's Hospital, Boston, MA, 5Houston, TX, 6Feinstein Institute Med Rsch, Manhasset, NY, 7Karolinska Institutet, Stockholm, Sweden, 8Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 9Feinstein Institute Medical Reschearch, Manhasset, NY

Fine-Mapping of Autoimmune Susceptibility Loci Using Immunochip Identifies Novel Susceptibility Loci for Psoriatic Arthritis
John Bowes1, Pauline Ho2, Eleanor Korendowych3, Neil J. McHugh3, Helena Marzo-Ortega4, Jonathon Packham5, Ian N. Bruce1 and Anne Barton1, 1Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK, Manchester, United Kingdom, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4University of Leeds, Leeds, United Kingdom, 5Haywood Hospital, Stoke on Trent, United Kingdom
Arthritis Research UK Epidemiology Unit, The University of Manchester
Anti Tumour Necrosis Factor Therapy Is Associated with Reduced Mortality From Ruptured Abdominal Aortic Aneurysm: Results From the British Society for Rheumatology Biologics Register
Audrey SL Low1, James B. Galloway1, Louise K. Mercer1, Rebecca Davies1, Mark Lunt1, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium1, Kimme L. Hyrich1, William G. Dixon1, Deborah PM Symmons1 and On behalf of the BSRBR2, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2British Society for Rheumatology, London, United Kingdom

The Association Between Clinical and Lifestyle Factors and the Development of Inflammatory Polyarthritis and Rheumatoid Arthritis. Results From the European Prospective Investigation of Cancer (Norfolk) Study and the Norfolk Arthritis Register
Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Diane K. Bunn3, Mark Lunt1, Nick Warehan2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce4, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3University of East Anglia, Norwich, United Kingdom, 4A, Manchester, United Kingdom

Higher Fruit and Fructose Consumption Is Associated with a Reduced Risk of Inflammatory Polyarthritis and Rheumatoid Arthritis in Men. Results From the European Prospective Investigation of Cancer (Norfolk) and the Norfolk Arthritis Register
Manjari Lahiri1, Catharine Morgan1, Robert N. Luben2, Marleen Lentjes3, Diane K. Bunn4, Mark Lunt1, Nick Wareham2, Suzanne M.M. Verstappen1, Deborah P. M. Symmons1, Kay-Tee Khaw2 and Ian N. Bruce5, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3Cambridge, United Kingdom, 4University of East Anglia, Norwich, United Kingdom, 5A, Manchester, United Kingdom

Immediate and Delayed Impact of Oral Glucocorticoid Therapy On Risk of Serious Infection In Patients with Rheumatoid Arthritis: A Nested Case-Control Analysis Using a Weighted Cumulative Dose Model
William G. Dixon1, Michal Abrahamowicz2, Marie-Eve Beauchamp2, David W. Ray3, Sasha Bernatsky4, Samy Suissa5 and Marie-Pierre Sylvestre6, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2McGill University, Montreal, QC, 3The University of Manchester, Manchester, United Kingdom, 4McGill UHC/RVH, Montreal, QC, 5Royal Victoria Hosp, McGill Un, Montreal, 6University of Montreal, Montreal, QC

Opportunistic Infections in Patients Exposed to Anti-Tumour Necrosis Factor Therapy: Results From the British Society for Rheumatology Biologics Register
James B. Galloway1, Audrey SL Low1, Louise K. Mercer1, William G. Dixon1, Andrew Ustianowski2, Mark Lunt1, Kath D. Watson1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium3, Kimme L. Hyrich1, Deborah PM Symmons1 and . on behalf of the BSRBR1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Manchester, Manchester, United Kingdom, 3British Society for Rheumatology, London, United Kingdom

The Risk of Solid Cancer in Patients Receiving Anti-Tumour Necrosis Factor Therapy for Rheumatoid Arthritis for up to 5 Years: Results From the British Society for Rheumatology Biologics Register
Louise K. Mercer1, James B. Galloway1, Audrey SL Low1, Kath D. Watson1, Mark Lunt1, William G. Dixon1, British Society for Rheumatology Biologics Register (BSRBR) control centre consortium1, Deborah PM Symmons1, Kimme L. Hyrich1 and On behalf of the BSRBR2, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2British Society for Rheumatology, London, United Kingdom

NT-Pro-BNP Levels Are Associated with Increased All Cause and Cardiovascular Mortality in Early Inflammatory Polyarthritis Independent of Disease Severity and Autoantibody Status- Results From the Norfolk Arthritis Register (NOAR)
Hoda Mirjafari1, Suzanne Verstappen1, Manjari Lahiri1, Paul Welsh2, Diane K. Bunn3, Tarnya Marshall3, Mark Lunt1, Naveed Sattar2, Deborah P. M. Symmons1 and Ian N. Bruce1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 2University of Glasgow, Glasgow, United Kingdom, 3Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom

Cardioprotective Effects of Disease-modifying Anti-rheumatic Drugs
William G. Dixon, Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom
Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre
Older Age, Male Gender, Current Smoking and Worse Disease Activity Are Predictors of Respiratory Disease Mortality in Patients with Inflammatory Polyarthritis: Results From the Norfolk Arthritis Register
Suzanne MM Verstappen1, Mark Lunt1, Diane K. Bunn2, Tarnya Marshall3 and Deborah PM Symmons1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 2Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, 3Norfolk and Norwich University Hospitals Trust, Norwich, UK, Norwich, United Kingdom, Norwich, United Kingdom

Comparison of Respiratory Function in Patients with Inflammatory Polyarthritis and the General Population in the United Kingdom
Suzanne MM Verstappen1, Mark Lunt1, Robert N. Luben2, Jackie Chipping3, Nick Wareham2, Kay-Tee Khaw2, Ian N. Bruce1 and Deborah PM Symmons1, 1Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 2University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 3Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom
Arthritis Research UK Epidemiology Unit, University of Manchester
Predictors of Disability in Children with Inflammatory Arthritis, Two and Three Years After First Presentation to Paediatric Rheumatology. Results From the Childhood Arthritis Prospective Study (CAPS)
Roberto Carrasco1, Joanna Cobb1, Eileen M. Baildam2, Helen Foster3, Janet Gardner-Medwin4, Alice Chieng5, Lucy R. Wedderburn6, Joyce Davidson7, Kimme L. Hyrich1, CAPS Study8 and Wendy Thomson1, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Paediatric Rheumatology International Trials Organization, Genoa, Italy, 3Newcastle Hospitals NHS Trust, Newcastle, United Kingdom, 4Royal Hospital for Sick Children, Yorkhill Hospital, University of Glasgow, Glasgow, United Kingdom, 5Manchester Children's Hospital, Manchester, United Kingdom, 6University College London (UCL), London, United Kingdom, 7Greater Glasgow and Clyde Health Board and Royal Hospital for Sick Children, Glasgow, United Kingdom, 8Manchester

Investigating children's beliefs about Juvenile Arthritis: A Study Using Cognitive Interviewing
Daniela Ghio1, Wendy Thomson2, Eileen M. Baildam3, Kimme Hyrich2, Michael W. Beresford4, Carol Lydon5, Olivia Lloyd4, Gavin Cleary4, Liza J. McCann6, Childhood Arthritis Prospective Study (CAPS)7, Fiona Ulph1 and Lis Cordingley8, 1School of Psychological Sciences, University of Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Paediatric Rheumatology International Trials Organization, Genoa, Italy, 4Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 5Alder Hey, Liverpool, United Kingdom, 6Alder Hey Children's NHS Foundation Hospital, Liverpool, United Kingdom, 7Manchester, United Kingdom, 8School of Community Based Medicine, University of Manchester, Manchester, United Kingdom

Impact of Rituximab On the Quality of Life and Physical Function of Patients with Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
Moetaza M. Soliman1, Kimme L. Hyrich2, Mark Lunt2, Kath D. Watson2, Deborah PM Symmons2 and Darren M. Ashcroft1, 1School of Pharmacy and Pharmaceutical sciences, University of Manchester, Manchester, United Kingdom, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

Mortality and Cause of Death In Young Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: Results From the British Society for Rheumatology Biologics Register
Malack Alachkar, Kath D. Watson, Kimme L. Hyrich and Deborah PM Symmons, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom

Analysis of the Immunochip in a Large Cohort of Oligo- and Polyarthritis Juvenile Idiopathic Arthritis Cases Confirms Previous and Identifies Novel Associations
Joanna Cobb1, Anne Hinks1, John Bowes1, Marc Sudman2, Miranda C. Marion3, Mehdi Keddache4, Lucy R. Wedderburn5, Johannes Peter Haas6, David N. Glass2, Carl D. Langefeld3, Wendy Thomson1 and Susan D. Thompson2, 1Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 2Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Wake Forest School of Medicine, Winston-Salem, NC, 4Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 5University College London (UCL), London, United Kingdom, 6German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany

Registries/Cohorts that Have Made a Difference in Rheumatology
Jeffrey D. Greenberg, New York University School of Medicine, New York, NY, Kimme L. Hyrich, Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, Thomas A. Medsger, Univ of Pittsburgh, Pittsburgh, PA, Laura E. Schanberg, Duke University Medical Center, Durham, NC and Frederick Wolfe, National Data Bank for Rheumatic Diseases, Wichita, KS
Arthritis/Osteoporosis Med Ctr
Safety and Efficacy of Abatacept in Eight Rheumatoid Arthritis Patients with Chronic Hepatitis B
Paul S. Kim, University of California, Irvine, Orange, CA, Gerald Y. Ho, Arthritis/Osteoporosis Med Ctr, La Palma, CA, Pamela E. Prete, Long Beach VA Med Ctr, Long Beach, CA and Daniel E. Furst, UCLA, Los Angeles, CA
Arthrogen B.V
Inhibition of Murine Collagen-Induced Arthritis by Overexpression of Glucocorticoid-Induced Leucine Zipper Locally in the Joints Using a Gene Therapy Approach
Devi Ngo1, Elaine Beaulieu1, Scott Loiler2, Margriet Vervoordeldonk3 and Eric Morand1, 1Monash University, Melbourne, Australia, 2Arthrogen B.V, Amsterdan, Netherlands, 3Arthrogen B.V, AMC/University of Amsterdam, Amsterdan, Netherlands

Safety and Biodistribution of An Adeno-Associated Virus Vector, AAV5 hIFN beta (ART-I02), Delivered Via Intra-Articular Injection to Rhesus Monkeys with Collagen-Induced Arthritis
Caroline J. Aalbers1, L. Bevaart1, K. de Cortie1, M.P.M. Vierboom2, J.F. Wright3, Paul P. Tak4 and Margriet Vervoordeldonk5, 1Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, 2Biomedical Primate Research Centre, Rijswijk, Netherlands, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam The Netherlands, Amsterdam, Netherlands, 5Arthrogen B.V, Amsterdan, Netherlands
Arthrogen B.V, AMC/University of Amsterdam
Inhibition of Murine Collagen-Induced Arthritis by Overexpression of Glucocorticoid-Induced Leucine Zipper Locally in the Joints Using a Gene Therapy Approach
Devi Ngo1, Elaine Beaulieu1, Scott Loiler2, Margriet Vervoordeldonk3 and Eric Morand1, 1Monash University, Melbourne, Australia, 2Arthrogen B.V, Amsterdan, Netherlands, 3Arthrogen B.V, AMC/University of Amsterdam, Amsterdan, Netherlands
ArthroVision Inc.
Change in Knee Cartilage Volume and Incident Meniscal Extrusion As Predictors of Change in Joint Space Width of the Tibiofemoral Joint: 5 Year Longitudinal Study
Joanna Hall1, Laura Laslett1, Johanne M. Pelletier2, Jean Pierre Pelletier2, François Abram3, Chang-Hai Ding4, Flavia Cicuttini5 and Graeme Jones1, 1University of Tasmania, Hobart, Australia, 2Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 3ArthroVision Inc., Montreal, QC, 4University of Tasmania & Monash University, Hobart, Australia, 5Monash University, Central and Eastern Clinical School, Melbourne, Australia

Similar Reliability of DESS and TSE Magnetic Resonance Imaging Sequences in the Assessment of Bone Marrow Lesions in Knee Osteoarthritis Patients: Data From the Osteoarthritis Initiative Cohort
Jean-Pierre Raynauld1, Lukas M. Wildi1, François Abram2, Thomas Moser3, Manon Girard2, Johanne Martel-Pelletier1 and Jean Pierre Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 2ArthroVision Inc., Montreal, QC, 3Department of Radiology, University of Montreal Hospital Centre (CHUM), Notre-Dame Hospital, Montreal, QC
Asheville Arthritis Ctr
Educational Efficacy and Durability of Knowledge Gained From a Module on Gout
Bernadette C. Siaton1, John S. Sundy1, Sanjay Garg2, Christopher G. Meyer3 and Lisa G. Criscione-Schreiber1, 1Duke University Medical Center, Durham, NC, 2Center for Arthritis and Rheumatism, Fayetteville, NC, 3Asheville Arthritis Ctr, Asheville, NC
Asklepios Clinic Sankt Augustin
Long-Term Safety of Etanercept Compared to Methotrexate and Combinations in Children with Juvenile Idiopathic Arthritis – Data of the German BIKER-Registry
Gerd Horneff1, Stephanie Bischof1 and German BIKER Registry collaborative group2, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Sankt Augustin

Effects of Switching From Etanercept to Adalimumab in Juvenile Idiopathic Arthritis
Gerd Horneff, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, Ivan Foeldvari, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, Gerd Ganser, Sankt Josef Stift, Sendenhorst, Germany, Johannes Peter Haas, Childrens Hospital, Erlangen, Germany, Kirsten Minden, Charite, Berlin, Germany and Hans-Iko Huppertz, Krinikum Bremen-Mitte, Bremen, Germany

Double Blind, Placebo-Controlled Trial with Adalimumab for Treatment of Juvenile Ankylosing Spondylitis (jAS)
Gerd Horneff1, Sigrid Fitter1, Hans-Iko Huppertz2, Ivan Foeldvari3, Jasmin B. Kuemmerle-Deschner4, Rolf M. Kuester5, Nikolay Tzaribachev6, Angelika Thon7, Michael Borte8, Gerd Ganser9, Ralf Trauzeddel10 and Kirsten Minden11, 1Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, 2Krinikum Bremen-Mitte, Bremen, Germany, 3Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, 4University Hospital Tuebingen, Tuebingen, Germany, 5Rheumaklinik Bad Bramstedt, Bad Bramstedt, Germany, 6Center for Rheumatic Diseases, Bad Bramstedt, Germany, 7Kinderklinik der Medizinischen Hochschule Hannover, Hannover, Germany, 8Sankt Georg Clinics, Leeipzig, Germany, 9Sankt Josef Stift, Sendenhorst, Germany, 10Helios Clinics, Berlin, Germany, 11Charite, Berlin, Germany
Asklepios Klinikum Bad Abbach
Sensitivity to Change of the 7-Joint Ultrasound (US7) Score Among Patients with Different Musculoskeletal Diseases Under Twelve Months of Therapy
Tina M. Backhaus, Berlin, Germany, Sarah Ohrndorf, Charité –University Medicine Berlin,, Berlin, Germany, Herbert Kellner, Centre for Inflammatory Joint Diseases, Munich, Germany, Johannes Strunk, Cologne, Germany, Wolfgang Hartung, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, Horst Sattler, Klinikum Ludwigshafen, Ludwigshafen, Germany, Christof Iking-Konert, University Hospital Hamburg Eppendorf, Hamburg, Germany, Gerd R. Burmester, Charité - Universitätsmedizin Berlin, Berlin, Germany, Wolfgang A. Schmidt, Med Ctr Rheumatol Berlin Buch, Berlin, Germany and Marina Backhaus, Charite University Hospital, Berlin, Germany

Introduction of a New Ultrasound Score for Large Joints: One Year Experience in Daily Rheumatologic Practice
Wolfgang Hartung1, Herbert Kellner2, Johannes Strunk3, Wolfgang A. Schmidt4, Boris P. Ehrenstein1, Horst Sattler5, Marina Backhaus6 and Martin Fleck1, 1Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, 2Centre for Inflammatory Joint Diseases, Munich, Germany, 3Cologne, Germany, 4Med Ctr Rheumatol Berlin Buch, Berlin, Germany, 5Klinikum Ludwigshafen, Ludwigshafen, Germany, 6Charite University Hospital, Berlin, Germany

Dexamethasone Reduces Staphylococcus Aureus-Induced Production of Inflammatory Cytokines and Matrix Metalloproteases in Primary Human Chondrocytes and Synovial Fibroblasts
Frank Hanses1, Irina Fink1, Susanne Graessel1, Bernd Salzberger1 and Martin Fleck2, 1University Hospital Regensburg, Regensburg, Germany, 2Asklepios Klinikum Bad Abbach, Bad Abbach, Germany
Assistant Professor of Internal Medicine
Dyslipidemia in Patients with Seronegative Spondyloarthropathies
Charalampos Papagoras1, Theodora E. Markatseli1, Ioanna Saougou1, Haralampos J. Milionis2 and Alexandros A. Drosos3, 1Fellow in Rheumatology, Ioannina, Greece, 2Assistant Professor of Internal Medicine, Ioannina, Greece, 3Professor of Medicine/Rheumatology, Ioannina, Greece
Associate Professor of Nuclear Medicine
Myocardial Involvement in Systemic Sclerosis As Assessed by Ultrasonography and Scintigraphic Perfusion Imaging
Niki Tsifetaki, Registrar in Rheumatology, Ioannina, Greece, Charalampos Papagoras, Fellow in Rheumatology, Ioannina, Greece, Kersten Achenbach, Cardiologist, Ioannina, Greece, Athanasia Georgiou, Fellow in Nuclear Medicine, Ioannina, Greece, Spyridon Tsiouris, Registrar of Nuclear Medicine, Greece, Andreas Fotopoulos, Associate Professor of Nuclear Medicine, Greece and Alexandros A. Drosos, Professor of Medicine/Rheumatology, Ioannina, Greece
Associazione per la Difesa degli Psoriasici
Patient-Perceived Impact of Psoriatic Arthritis Is Due to Pain and Fatigue, but Also to Psychological Aspects- the Psa Impact of Disease Study
Laure Gossec1, Maarten de Wit2, Andra Balanescu3, Peter V. Balint4, Gabor Békés4, Juergen Braun5, Juan D. Canete6, Laurence Carton7, Alina Dinte8, Kurt L. De Vlam9, Turid Heiberg10, Philip Helliwell11, Umut Kalyoncu12, Uta Kiltz13, Thomas Luger14, Mara Maccarone15, Ronan H. Mullan16, Dennis O'Sullivan16, Kati Otsa17, Andrew Parkinson18, Anselm Sanchez Lombarte6, Rossana Scrivo19, Josef Smolen20, Tanja A. Stamm21 and Tore K. Kvien22, 1Cochin Hospital, Paris, France, 2Dutch Arthritis Patient League, Amersfoort, Netherlands, 3University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, 4National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 5Ruhr-University Bochum, Herne, Germany, 6Hospital Clinic, Barcelona, Spain, 7Cochin Hospital and Association Française de Lutte Anti-Rhumatismale, Paris, France, 8“Sf. Maria” Hospital, Bucharest, Romania, 9University Hospital, Leuven, Belgium, 10Ullevaal Univ Hospital, Oslo, Norway, 11NIHR-Leeds Biomedical Research Unit and Leeds Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom, 12Hacettepe University Faculty of Medicine, Ankara, Turkey, 13Rheumazentrum Ruhrgebiet, Herne, Germany, 14University Hospital Münster, Münster, Germany, 15Associazione per la Difesa degli Psoriasici, Rome, Italy, 16St Vincent's University Hospital, Dublin, Ireland, 17Tallinn Central Hospital, Tallinn, Estonia, 18University of Leeds, Leeds, United Kingdom, 19Reumatologia - Sapienza Università di Roma, Rome, Italy, 20Medical University of Vienna and Hietzing Hospital, Vienna, Austria, 21Medical University of Vienna, Vienna, Austria, 22Diakonhjemmet Hospital, Oslo, Norway
Astellas Pharma Inc.
A Calcineurin Inhibitor FK506 Suppresses Joint Destruction in Patients with Early Rheumatoid Arthritis and Low Disease Activity
Yoshiya Tanaka1, Shinichi Kawai2, Tsutomu Takeuchi3, Kazuhiko Yamamoto4, Shinya Tani5, Toshiyuki Okada5 and Nobuyuki Miyasaka6, 1University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan, 2Toho Uni Sch of Med, Tokyo, Japan, 3Keio University School of Medicine, Tokyo, Japan, 4Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Tokyo, Japan, 5Astellas Pharma Inc., Tokyo, Japan, 6Tokyo Medical and Dental University, Tokyo, Japan

Anti-Inflammatory Profile of AS2444697, A Novel Interleukin-1 Receptor-Associated Kinase-4 Inhibitor
Junko Imanishi, Takeshi Ishikawa, Emiko Imamura, Hidekazu Mizuhara, Haruna Iwaoka, Ball Evelyn, Hiroshi Inami, Tsuyoshi Mizutani, Junko Watanabe, Hiroyuki Usuda, Shinya Nagashima, Tomonori Ito, Toru Kontani, Yasuaki Shimizu and Seitaro Mutoh, Astellas Pharma Inc., Tsukuba, Japan

5-HT2C Receptor Agonists Attenuate Muscle Pain in a Rat Model of Fibromyalgia
Shinichi Ogino, Mina Tsukamoto, Yukinori Nagakura, Tomonari Watabiki, Yasuaki Shimizu and Hiroyuki Ito, Astellas Pharma Inc., Tsukuba, Japan
Astra-Zeneca
Clinical Outcome in Early Undifferentiated Arthritis Is Best Predicted by a Combination of Baseline Clinical Features and Serum Biomarkers
Carol A. Hitchon1, Gilles Boire2, Michael Centola3, Andrew Lloyd4, Richard Kay4 and Hani S. El-Gabalawy1, 1University of Manitoba, Winnipeg, MB, 2CHUS - Sherbrooke University, Sherbrooke, QC, 3Oklahoma Medical Research Fdn, Oklahoma City, OK, 4Astra-Zeneca, Cheshire, United Kingdom
AstraZeneca
Effects of the Oral SYK Inhibitor, Fostamatinib (R788), on Health-Related Quality of Life in a Phase II Study of Active Rheumatoid Arthritis
Michael E. Weinblatt1, Arthur Kavanaugh2, Mark C. Genovese3, David A. Jones4, Theresa K. Musser5, Elliott B. Grossbard5 and Daniel B. Magilavy5, 1Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2University of California San Diego, San Diego, CA, 3Stanford University, Palo Alto, CA, 4AstraZeneca, Macclesfield, United Kingdom, 5Rigel Pharmaceuticals, South San Francisco, CA

Longer-Term Safety of Fostamatinib (R788) in Patients with Rheumatoid Arthritis – Analysis of Clinical Trial Data From up to 2 Years of Exposure
Arthur Kavanaugh1, Michael E. Weinblatt2, Mark C. Genovese3, Theresa K. Musser4, Elliott B. Grossbard4, Daniel B. Magilavy4, Sally Hollis5, Eveline Wesby van-Sway5 and David Millson5, 1University of California San Diego, San Diego, CA, 2Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 3Stanford University, Palo Alto, CA, 4Rigel Pharmaceuticals, South San Francisco, CA, 5AstraZeneca, Macclesfield, United Kingdom
Athens University, Medical School
Myocardial Ischemia in Asymptomatic Patients with Rheumatoid Arthritis: A Comparative Study with Diabetes Mellitus
A. Karanasos1, I. Felekos1, C. Aggeli1, E. Zampeli1, A. Protogerou1, C. Stefanadis1, G. Kitas2, K. Toutouzas1 and PP Sfikakis1, 1Athens University, Medical School, Athens, Greece, 2The Dudley Group of Hospitals NHS Foundation Trust, Dudley, and Arthritis Research Campaign Epidemiology Unit, University of Manchester, UK, Manchester, United Kingdom
Attikon Hospital, Athens
A novel mutation in the PSTPIP1 gene is Associated with An Autoinflammatory disease distinct From classical Pyogenic Arthritis, Pyoderma Gangrenosum and Acne Syndrome
Dirk Holzinger1, Judith Austermann1, Peter Lohse2, Ivona Aksentijevich3, Steven Holland4, Marco Gattorno5, Carlos Rodríguez-Gallego6, S. Fessatou7, Bertrand Isidor8, S. Tokio9, Jon Bernstein10, Barry Sampson11, Cord Sunderkoetter12, Dirk Foell13 and Johannes Roth13, 1University Muenster, Muenster, Germany, 2University Munich, Munich, Germany, 3National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 4National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 5G. Gaslini Institute, Genova, Italy, 6Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain, 7Attikon Hospital, Athens, Greece, 8Centre Hospitalo-Universitaire, Nantes, France, 9Nagoya City University, Tokyo, Japan, 10Stanford University Medical Center, CA, 11Charing Cross Hospital, London, United Kingdom, 12Muenster, Germany, 13University of Muenster, Muenster, Germany
Augurex Life Sciences Corp
Serum 14-3-3η: A Rheumatoid Arthritis Biomarker
Walter P. Maksymowych, University of Alberta, Edmonton, AB, Robert Landewe, Academic Medical Center, Amsterdam, Netherlands, Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Paul-Peter Tak, Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands and Anthony Marotta, Augurex Life Sciences Corp, North Vancouver, BC

Extracellular 14-3-3η: An Early RA Pathogenic Factor
Anthony Marotta, Augurex Life Sciences Corp, North Vancouver, BC, Vivian Bykerk, Brigham and Women's Hospital, Boston, MA, Katherine A. Siminovitch, Mount Sinai Hospital, Toronto, ON, Maarten Boers, VU University Medical Center, Amsterdam, Netherlands, Robert Landewe, Academic Medical Center, Amsterdam, Netherlands, Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, Paul-Peter Tak, Professor of Medicine/ Director, Division of Clinical Immunology and Rheumatology, Amsterdam, Netherlands, M. C. Genovese, Stanford University Medical Center, Palo Alto, CA, Michael E. Weinblatt, Department of Medicine, Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA and Walter P. Maksymowych, University of Alberta, Edmonton, AB

14-3-3η, a Novel Mediator Upregulated by TNFα, Reflects Clinical Response to Anti-TNFα Therapy
Walter P. Maksymowych, University of Alberta, Edmonton, AB and Anthony Marotta, Augurex Life Sciences Corp, North Vancouver, BC

Extracellular 14-3-3η: A Novel Mediator of Inflammation Associated with Selective Activation of Intracellular Pathways
Anthony Marotta1, Yuan Gui1, Aziz Ghahary2, Ruhangiz Kilani2 and Walter P. Maksymowych3, 1Augurex Life Sciences Corp, North Vancouver, BC, 2University of British Columbia, Vancover, BC, 3University of Alberta, Edmonton, AB
Augusta Krankenanstalten
The Degree of Spinal Inflammation Is Similar in Patients with Axial Spondyloarthritis Who Report High or Low Levels of Disease Activity – a Cohort Study
Uta Kiltz1, Xenofon Baraliakos1, Pantelis Karakostas1, Manfred Igelmann2, Ludwig H. Kalthoff3, Claudia Klink4, Dietmar MJ Krause4, Elmar Schmitz-Bortz5, Martina Floerecke1, Matthias Bollow6 and Juergen Braun1, 1Ruhr-University Bochum, Herne, Germany, 2Private Rheumatology office, Bochum, Germany, 3Private rheumatology office, Herne, Germany, 4Private rheumatology office, Gladbeck, Germany, 5Private rheumatology office, Hattingen, Germany, 6Augusta Krankenanstalten, Bochum, Germany

Patients with Non-Radiographic Axial Spondyloarthritis Differ From Patients with Ankylosing Spondylitis in Several aspects– Results of a Cross-Sectional Cohort Study
Uta Kiltz1, Xenofon Baraliakos2, Pantelis Karakostas2, Manfred Igelmann3, Ludwig H. Kalthoff4, Claudia Klink5, Dietmar MJ Krause6, Elmar Schmitz-Bortz7, Martina Floerecke2, Matthias Bollow8 and Juergen Braun2, 1Rheumazentrum Ruhrgebiet, Herne, Germany, 2Ruhr-University Bochum, Herne, Germany, 3Private Rheumatology office, Bochum, Germany, 4Private rheumatology office, Herne, Germany, 5Private rheumatology office, Gladbeck, Germany, 6Gladbeck, Germany, 7Private rheumatology office, Hattingen, Germany, 8Augusta Krankenanstalten, Bochum, Germany
Aurora Health Care Oshkosh
Prognostic and Diagnostic Significance of Autoantibodies to Citrullinated Proteins (ACPA) in Patients with a Scleroderma-Rheumatoid Arthritis (SSc-RA) Overlap Syndrome
Makoto Soejima1, Zhou Zhijie2, Donald M. Jones1, Danielle Goudeau1, Christine L. Amity1, Lynne M. Frydrych1, Robyn T. Domsic1, Aarat M. Patel1, Larry W. Moreland3, David M. Lee4, Thomas A. Medsger1 and Marc C. Levesque1, 1Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 2Aurora Health Care Oshkosh, Oshkosh, WI, 3University of Pittsburgh, Pittsburgh, PA, 4Brigham and Womens Hospital, Boston, MA
Austin and Repatriation Medical Centre, University of Melbourne
Denosumab Decreases Cortical Porosity in Postmenopausal Women with Low Bone Mineral Density
C. Libanati1, S. K. Boyd2, K. K. Nishiyama2, R. M. Zebaze3, D. A. Hanley2, J. R. Zanchetta4, Thierry Thomas5, S. Boutroy6, C. E. Bogado4, M. Austin1 and E. Seeman7, 1Amgen Inc., Thousand Oaks, CA, 2University of Calgary, Calgary, AB, 3University of Melbourne, Melbourne, Australia, 4Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 5INSERM U1059 and University Hospital, Saint-Étienne, France, 6INSERM U831 and Université de Lyon, Lyon, France, 7Austin and Repatriation Medical Centre, University of Melbourne, Melbourne, Australia
Austin Health
Burden of Delay to Diagnosis of Ankylosing Spondylitis
Sarah E. Grigg, Belinda J. Martin, Russell R. Buchanan and Lionel Schachna, Austin Health, Melbourne, Australia
Austrian Agency for Health and Food Safety (AGES)
EMEA Guidelines for Biosimilars
Andrea Laslop, Austrian Agency for Health and Food Safety (AGES), Vienna, Austria
Avila Therapeutics
Translational Medicine of a Selective Inhibitor of Btk in Rheumatic Diseases: Pharmacology and Early Clinical Development
Erica Evans, Richland Tester, Sharon Aslanian, Prasoon Chaturvedi, Russell Karp, Matt Labenski, Hormoz Mazdiyasni, Mariana Nacht, Michael Sheets, Kathryn Stiede, Steve Witowski, Heather Lounsbury, Russ Petter, Juswinder Singh and William Westlin, Avila Therapeutics, Waltham, MA
Axio Research, LLC
Successful Tapering of Glucocorticoids (GC) in Rheumatoid Arthritis Patients-Results From the Consortium of Rheumatology Researchers of North America Registry
Thasia G. Woodworth, Leading Edge Clinical Research, Stuart, FL, Elizabeth Thomas, Axio Research, LLC, Seattle, WA, Jeffrey D. Greenberg, New York University School of Medicine, New York, NY and Daniel E. Furst, UCLA, Los Angeles, CA
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z